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Acronyms (arrange by alphabetical order) 
 
ABPM,   Ambulatory blood pressure monitoring. 
ACE   Angiotensin  I converting enzyme. 
ACEi,   Angiotensin  I converting enzyme inhibitors. 
ACR,   Albumin creatinine ratio. 
ADAM23,  A disintegrin and metalloprotease domain 23.  
ADAM7,   Disintegrin and metalloproteinase domain-containing protein 7 precursor gene. 
ADD1,   Alpha adducin gene. 
ADIPOQ,  Adiponectin precursor. 
ADLR1,   Aldose reductase gene. 
ADRBR2,  Beta adrenergic receptor type 2 gene.  
AGE,   Advanced glycation end products. 
AGT,   Angiotensinogen. 
ANKAR,  Ankyrin and armadillo repeat-containing protein gene. 
ANP,   Atrial natriuretic peptide. 
Apo E,   Apolipoprotein E. 
apt,   Affymetrix power tool. 
AQP1   Aquaporin 1 gene. 
ARBs,   Angiotensin II receptor blockers. 
ARBs,   Angiotensin II receptor blockers. 
ASNSD1,  Asparagine synthetase domain-containing protein 1 gene.  
AT1R, AGTR1  Angiotensin II type 1 receptor gene.  
AUC,   Area under curve. 
Bcl-2,   B-cell leukaemia/lymphoma 2 gene. 
BMI,   Body mass index. 
BNC2,   Basonuclin gene. 
BONF,   Bonferroni correction test.. 
BP,   Blood pressure. 
BRLMM,  Bayesian robust linear model with Mahalanobis distance classifier.  
BSA,   Body surface area. 
C12orf59,  Chromosome 12 open reading frame 59 gene.  
CC,   Creatinine clearance. 
CDH8,   Cadherin-8 precursor. 
CDH5,   Cadherin-5 precursor. 
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CDH11,   Cadherin 11 precursor gene. 
CDKN2A,  Cyclin-dependent kinase inhibitor 2A. 
CDKN2B,  Cyclin-dependent kinase inhibitor 2B 
CETP,   Cholesterol ester transfer protein precursor. 
CG,    Candidate genes. 
Chr,   Chromosome. 
CKD,   Chronic kidney disease 
CNDP1,   Carnosine dipeptidase 1 gene. 
CNV,   Copy number variation. 
COL4A1  Collagen type 4 Alpha 1 gene.  
CRF,   Chronic renal failure. 
CRP,   C reactive protein. 
CV,    Cardiovascular. 
CXCL12,  Chemokine (C-X-C motif) ligand 12 gene.  
CYP11B2,   Aldosterone synthase gene.  
DBP,   Diastolic blood pressure. 
DF,   Degree freedom. 
DM,   Dynamic model. 
DM2,   Type 2 diabetes mellitus. 
DN,   Diabetic nephropathy. 
DNA,   Deoxyribonucleic acid. 
DSP,   Discordant sib-pairs. 
EDTA,   Ethylenediaminetetraacetic acid. 
eGFR,   Estimated GFR. 
ELMO1,   Engulfment and cell motility 1 gene. 
ELMO3,   Engulfment and cell motility protein 3. 
EM,   Expectation maximization algorithm. 
eNOS,   Endothelial nitric oxide synthase. 
ENPP1,    Ectonucleotide pyrophosphatase phosphodiesterase 1 gene. 
EPDR1,   Ependymin related protein 1 gene. 
EPHA5,   Ephrin-A5 precursor gene. 
ESRD,   End stage renal disease.  
FBAT,    Family based association test. 
FDR,   False discovery rate. 
FSGS,   Focal and segmental glomerulosclerosis. 
Acronyms 
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GCOS,   GeneChip Operating Software. 
GEE ,   Generalized estimating equations. 
GFR,    Glomerular  filtrate rate. 
GLEPP1,  Glomerular epithelial protein 1.  
GLM,   Generalized linear model. 
GRR,   Genotypes relative risk. 
GTYPE,   GeneChip Genotyping Analysis Software. 
GWAS,   Genome wide association studies. 
HDL,   High density lipoprotein. 
hNPY,   Human neuropeptide Y. 
HOMA,   Homeostatic model assessment index. 
HTN,   Essential hypertension. 
HWE,   Hardy-Weinberg equilibrium. 
I/D,   Insertion-Deletion polymorphism. 
IBD,   Identity by descent. 
IBS,   Identity by state. 
IFNA,   Interferon alpha precursor. 
IFNB1,   Interferon beta precursor.  
IFNW1,   Interferon omega-1 precursor. 
IFNγ,   Interferon gamma 
IGF1R,   Insulin growth factor 1 receptor. 
IGF2BP2,  Insulin-like growth factor 2 mRNA-binding protein 2. 
IL-1,   Interleukin 1 
IL-6,   Interleukin 6. 
IL-8,   Interleukin 8. 
IL-33,   Interleukin 33.  
IMPAD1,  Inositol monophosphatase domain containing 1 gene.  
IMT,    Intima media thickness. 
IP-10,   Interferon-gamma-inducible protein. 
KLRC2,   NKG2-C type II integral membrane protein gene. 
KLRC3,   NKG2-E type II integral membrane protein gene. 
KLRC4,   NKG2-F type II integral membrane protein gene. 
KLRD1,   Natural killer cells antigen CD94 gene. 
KLRK1,   Killer cell lectin-like receptor subfamily K member 1 gene. 
KSR2,   Kinase suppressor of Ras 2. 
LA,    Linkage analysis. 
Acronyms 
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LD,   Linkage disequilibrium. 
LDL,   Low density lipoprotein. 
LOD,   Logarithmic of odds score. 
LOX1,   Oxidized low-density lipoprotein receptor 1. 
LPL,   Lipoprotein lipase. 
LR,   Logistic regression. 
LVM,   Left ventricular mass. 
MAF,   Minor allele frequency. 
MALD,   Mapping by admixture linkage disequilibrium. 
MCF2L2,  MCF2 cell line derived transforming sequence-like 2 gene.  
MCTP2,   Multiple C2 and transmembrane domain-containing protein 2 gene. 
MCP-1,   Monocyte chemoattractant protein-1.  
MDRD,   Modification of diet in renal disease. 
MIP-1δ,   Macrophage inflammatory protein-1delta.  
MLS   Maximum likelihood score.  
MnSOD,  Manganese superoxide dismutase.  
MSR1,   Macrophage acetylated LDL receptor I and II gene.  
MTHFS,   Methenyltetrahydrofolate synthetase.  
MYH9,    Non-muscle myosin heavy chain 9 gene.  
NADPH,   Nicotiamide-adenin dinucleotid phosphate.   
NCALD,   Neurocalcin D gene.   
NRP1,   Neuropilin 1 gene.  
OGGT   Oral glucose tolerance test.  
OLR1,   Oxidized low-density lipoprotein receptor 1 gene.  
OR,   Odds ratio.  
ORMDL1,  ORM1-like1.   
OSA,   Ordered subsets analysis.  
OSGLPL1,  O-sialoglycoprotein endopeptidase-like 1 gene.   
PAI-I1   Plasminogen activator inhibitor type 1. 
PCDH9,   Protocadherin  9. 
PCDH10,  Protocadherin-10 precursor. 
PCDH18,  Protocadherin-18 precursor. 
PK-C,   Protein kinase C. 
PLEKHH2,   Pleckstrin homology domain containing, family H gene.  
PON-1,   Paraoxonase 1. 
PON-2,   Paraoxonase 2. 
Acronyms 
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PTPRO,   Protein tyrosine phosphatase receptor type O. 
PVT1,   Plasmocytoma variant translocation gene. 
QC,   Quality control 
Q-Q,   Quantile-Quantile. 
QTL,   Quantitative trait loci. 
RAAS,   Renin angiotensin aldosterone system. 
RAGE,   Receptor of the advanced glycation end products. 
REEP1,   Receptor Expression-Enhancing Protein 1. 
RFC5,   Replication factor C subunit 5. 
RFLP,   Restriction fragment length polymorphism. 
RI,   Renal insufficiency. 
SBP,    Systolic blood pressure. 
SD,   Standard deviation  
SFRP4,   Secreted frizzled-related protein 4 precursor gene.  
SLC12A3,  Solute carrier family 12, member 3 gene.   
SLC40A1,  Solute carrier family 40 member 1.  
SLE,   Systemic lupus erythemathosus.  
SNP,   Single nucleotide polymorphisms.  
SNS,   Sympathetic nervous system. 
TAOK3,   Serine/threonine-protein kinase TAO3.  
TDT,   Transmission disequilibrium test.  
TGF-B,   Transforming growth factor beta.  
TGFBR1,  TGF-B receptor type 1 gene   
TGFBR2,  TGF-B receptor type 2 gene.   
TNF-α    Tumor necrosis factor alpha.  
TRPC1,  Transient receptor potential cation channel subfamily C, member 1 gene. 
TXNDC3,  Thioredoxin domain-containing protein 3 gene.   
U6,   U6 spliceosomal RNA gene.  
U8,   U8 small nucleolar RNA  gene.  
UAE,    Urinary albumin excretion.  
UTE,   Urinary transferrin excretion. 
VEGF,   Vascular endothelial growth factor. 
WSB2,   WD repeat and SOCS box-containing protein 2. 
WWOX,  WW domain containing oxidoreductase gene.
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Genetic glossary 
Additive genetic model - In a disease association study, if the risk conferred by an allele is increased r -fold for 
heterozygotes and 2r -fold for homozygotes, this corresponds to additive model. These data are best analyzed using 
Armitage trend test for genotype frequencies or by logistic regression in which the genotypes are represented as ( -1), 0, 
(+1). This genotype -based association test does not require the locus to be in Hardy -Weinberg equilibrium. In the case 
of an association with heterozygosity, the additive model test may be statistically non -significant despite the presence of 
an association. Thus, a non -significant additive model test does not rule out an association. It has been pointed out that 
genes do not generally act in a simple additive manner but through complex networks involving gene -gene and gene -
environment interactions 
 
Admixture mapping (mapping by admixture linkage disequilibrium -MALD) - An association -based approach to 
localizing disease -causing variants that differ in frequency between two historically separated populations by a whole -
genome scan. Fundamental to the use of admixture mapping is the knowledge that the disease of interest exhibits 
frequency differences across the two populations because of genetic differences. 
 
Affected sibpair (ASP) method - A linkage study design that tests for excess sharing of marker alleles identical by 
descent in affected -affected sibpairs. This method is often described as a nonparametric and model -free alternative to 
the parametric LOD score method.  
 
Allele - If the DNA sequence at a given locus (often a gene or a marker) varies between different chromosomes in the  
population, each different version is an allele. If there are two alleles at a given locus, the allele that is less common in 
the population is the minor allele.  
 
Association  - Comparison of the chance that people who have a particular genetic variation in their DNA have a 
particular characteristic (trait), symptom, or disease with the chance that people who do not have the particular genetic 
variation have the particular characteristic, symptom, or disease. 
 
Candidate gene - . A gene known to be located in the region of interest whose product has biochemical or other 
properties suggesting that it may prove to be the disease gene being sought. 
 
Candidate gene approach - This approach involves assessing the association between a particular allele (or set of 
alleles) of a gene that may be involved in the disease ( i . e . , a candidate gene) and the disease itself. In other words, 
this type of association study tries to answer the question, “ Is one allele of a candidate gene more frequently seen in 
subjects with the disease than in subjects without the disease?”. 
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Case -control study: A design preferred over cohort studies for relatively rare diseases in which cases with a disease or 
exposure are compared with controls randomly selected from the same study base. This design yields odds ratio (as 
opposed to relative risk from cohort studies) as the measure of the strength of association. 
 
Centimorgan - 1 centimorgan (cM) corresponds to a region within which a crossover is expected once every 100 
meioses. This implies a 1% chance of a single crossover at a single meiosis, and because the probability of a double 
crossover is exceedingly small (about 0·01%), this also corresponds to a chance of roughly 1% of recombination at each 
meiosis. 
 
Chromosome  - One of the threadlike "packages" of genes and other DNA in the nucleus of a cell.  Humans have 23 
pairs of chromosomes, 46 in all: 44 autosomes (or non -sex chromosomes) and two sex chromosomes. Each parent 
contributes one chromosome to each pair, so children get half of their chromosomes from their mothers and half from 
their fathers.  
 
Cohort study: A longitudinal follow -up study which begins with a group of people who do not have the trait of interest at 
the outset but a proportion of which will develop during the follow -up. The outcome is modeled for the explanatory 
variables to obtain the relative risk. Cohort studies may be historical or prospective. 
 
Complex disease - The term complex trait/disease refers to any phenotype that does not exhibit classic Mendelian 
inheritance attributable to a single gene; although they may exhibit familial tendencies (familial clustering, concordance 
among relatives). The contrast between Mendelian diseases and complex diseases involves more than just a clear or 
unclear mode of inheritance. Other hallmarks of complex diseases include known or suspected environmental risk 
factors; seasonal, birth order, and cohort effects; late or variable age of onset; and variable disease progression. 
 
Dominant allele -  An allele that masks an alternative allele when both are present (in heterozygous form). Homozygous 
dominant and heterozygous genotypes contribute the same to the phenotype. Most common autosomal dominant 
diseases are due to mutations in transcription factor genes 
 
Dominant model - A genetic association analysis mode that examines association with a dominant allele. The 
comparison groups are wild -type homozygous genotypes vs allele positivity (combining heterozygotes and 
homozygotes for the variant). 
 
EM algorithm - A method for calculating maximum likelihood estimates with incomplete data. E (expectation) -step 
computes the expected values for missing data and M (maximization) -step computes the maximum likelihood estimates 
assuming complete data. It was first used in genetics (Ceppellini R et al, 1955) to estimate allele frequency for 
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phenotype data when genotypes are not fully observable (this requires the assumption of HWE and calculation of 
expected genotypes from phenotype frequencies) 
 
Exon  - A segment of a gene that is represented in the mature RNA product. Individual exons typically include protein -
coding sequences. 
 
Gene  - the functional and physical unit of heredity passed from parent to offspring. Genes are pieces of DNA, and many 
genes contain the information for making a specific protein. 
 
Gene family  - A group of genes having similar DNA sequence evolved from a single ancestral gene. These genes may 
or may not be located in the same region of a chromosome. 
 
Genetic marker  - a segment of DNA with a known physical location on a chromosome and a discernible inheritance 
pattern. A marker can be a gene, or it can be a section of DNA with no known function. DNA segments that lie near each 
other on a chromosome tend to be inherited together.  Therefore, markers often are used as indirect ways of tracking the 
inheritance pattern of a gene that has not yet been identified, but whose approximate location is known. 
 
Genetic variation (variant)  - differences (or variants) in DNA sequences that are found by comparing the genomes of 
different individuals and can be used as genetic markers to track inheritance patterns in families. 
 
Genome  - all the DNA contained in an organism or a cell, which includes the chromosomes within the nucleus and the 
DNA in organelles called mitochondria. 
 
Genomic control  - One method to adjust for population stratification bias in case -control association studies is to use a 
'genomic control markers' panel. The panel consists of 20 -50 polymorphic markers unlinked to the loci of interest. The 
information obtained from unlinked markers may be used in a variety of ways (genomic control, structured association, 
latent -class approach). The adjustments requires some statistical manipulation, which can be handled using a variety of 
statistical approaches. 
 
Genotype  - all or part of the genetic make -up of an individual or group, including variation at a particular genetic marker 
or gene. 
 
Genotype -environment (GxE) interaction  - This term refers to both the modification of genetic risk factors by 
environmental risk and protective factors, and the role of specific genetic risk factors in determining individual differences 
in vulnerability to environmental risk factors. When GxE interaction is present, a specific environmental change 
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influences the outcome in different ways depending on the genotype. This requires inclusion of a multiplicative 
interaction term into the statistical model. 
 
Genotype relative risk (GRR)  - The risk of disease for one genotype at a locus versus another. It is usually assessed 
as having one copy of the allele of interest (Aa) vs having none (AA), which is GRR1; and having two copies of the allele 
(aa) vs having none, which is GRR2. In simple statistical analysis this is achieved by using dummy variables for each 
genotype, selecting the genotype AA as referent and obtaining odds ratios for other genotypes Aa and aa. Most of the 
time, what is presented is actually genotype odds ratio. 
Genotyping  - the process whereby the genotype(s) of an individual or many individuals is (are) determined from a DNA 
sample(s) in the laboratory.  Typically, DNA samples are obtained by drawing a small amount of blood or by collecting 
cheek cells. 
GWAS (Genome -wide Association Studies)  - research studies that involve scanning markers (genotypes) across the 
complete set of DNA, or genomes, of many people to find genetic variations associated with a particular disease. 
 
Hardy -Weinberg equilibrium (HWE) - In an infinitely large population, gene and genotype frequencies remain stable 
as long as there is no selection, mutation, or migration. For a bi -allelic locus where the gene frequencies are p and q: 
p2+2pq+q2 = 1. HWE should be assessed in controls in a case -control study and any deviation from HWE should alert 
for genotyping errors (Gomes, 1999; Lewis, 2002). Relying only on HWE tests to detect genotyping errors is not 
recommended as this is a low power test (Leal, 2005). 
 
Haplotype - A series of alleles at linked loci along a single chromosome. 
 
Haplotype blocks - A chromosomal region with high linkage disequilibrium and low haplotype diversity. Probably 
flanked by recombinational hotspots, haplotype blocks are shorter in African populations (average 11kb) than in other 
populations (average 22kb) (Gabriel, 2002). Haplotype block lengths correlate with recombinational rate (Greenwood, 
2004) but most haplotype -block boundaries do not occur at hotspots (Wall, 2003). All pairs of polymorphisms within a 
block are expected to show high linkage disequilibrium. Haplotype blocks are useful in association studies and a 
representative set of haplotype tagging SNPs can be used instead of the whole set of polymorphisms within a block 
(Zhang, 2004). Haploview is the most popular software for haplotype block analysis. 
 
Haplotype relative risk (HRR) method - This method uses non -inherited parental haplotypes of affected persons as 
the control group and thus eliminates the potential problems of using unrelated individuals as controls in case -control 
association studies. Haplotyping is not necessary to use this method; it can be used for allelic associations. 
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Heritability - Fraction of the total phenotypic variation in a population that is caused by genetic differences between 
individuals: genetic variance / total variance. The genetic variance is the part of the total variance that is caused by allelic 
variations at whatever loci influence the trait. The total variance is the amount of variation in phenotype in a defined 
population. It only applies to a population on which observations are made and cannot be extended to other populations 
that have different allele frequencies or environments. Therefore, it cannot be used to explain differences between 
populations. 
 
High -throughput genotyping - Simultaneous genotyping of large numbers of samples. Most machines can run 4x96 
(384) samples simultaneously (SNP typing, real -time PCR, sequencing) with a queuing system that would allow 
automatic continuation of the typing. A number of companies perform SNP high -throughput genotyping 
 
Identity by descent (IBD) - Alleles that trace back to a shared ancestor. For sibs, refers to inheritance of the same allele 
from a given parent.  
 
Identical -by -state (IBS) - Two alleles (from the same or different individuals) are identical -by -state if they are of the 
same type. 
 
Intron - Non -coding DNA that separates neighboring exons in a gene. 
 
Linkage analysis - Strategy for gene mapping by testing for linkage between markers and phenotypes using families. In 
classic linkage analysis the transmission model is fixed (possibly with parameter values obtained from segregation 
analysis) and the likelihoods (LOD scores) of the disease and marker data are compared under the null hypothesis of no 
linkage and the alternative hypothesis of linkage. Non -parametric linkage analysis avoids fixing an explicit mode of 
inheritance of the disease. 
 
Linkage disequilibrium - A condition in which alleles at two loci or genes are found together in a population at a greater 
frequency than that predicted simply by the product of their individual allele frequencies. Alleles at markers near disease 
causing genes tend to be in linkage disequilibrium in the affected individuals. This is particularly the case in isolated, 
homogeneous populations, in which it can be assumed that most affected individuals carry the same mutation.  
 
Locus - A locus is a unique chromosomal location defining the position of an individual gene or DNA sequence. In 
genetic linkage studies, the term can also refer to a region involving one or more genes, perhaps including noncoding 
parts of the DNA. 
 
LOD score - A statistical estimate, obtained in linkage analysis, which indicates whether alleles at two loci are inherited 
together more often than expected and are thus likely to be placed near each other on a chromosome. A LOD score is 
Genetic glossary 
 
  XXI 
the ratio of two probabilities: (1) the probability of the observed inheritance of a trait (usually a disease) and alleles at a 
marker in a pedigree if they were linked given a inheritance model for the trait and a recombination probability between 
marker and disease, and (2) the probability of the observed inheritance of a trait and marker in a pedigree under the 
assumption that they are not linked. A LOD score is the logarithm of the ratio of those two probabilities. LOD scores can 
be added across pedigrees, and are usually taken to indicate significant linkage if they are above three. The 
recombination fraction that gives the highest LOD score from a marker of known genomic location can be used to map a 
gene. 
 
Microarray -  A novel method of studying large numbers of genes simultaneously by automating and miniaturising a 
hybridisation detection system. The method uses a robot to precisely apply tiny droplets containing DNA to glass slides. 
The labelled probes are allowed to bind to complementary DNA strands on the slides. The slides are put into a scanning 
microscope that can measure the brightness of each fluorescente dot; brightness reveals how much of a specific DNA 
fragment is present. 
 
Microsatellite - Microsatellites consist of multiple repeats of a short sequence (typically 2–8 bp) such as: CACACA . . . . 
The alleles of a microsatellite are differentiated by the number of repeats they involve (eg, CA12 would denote 12 CA 
repeats in a row). 
 
Misclassification - Errors in the classification of individuals by phenotype, exposures or genotype that can lead to errors 
in results. The probability of misclassification can be the same across all groups in a study (nondifferential) or vary 
among groups (differential).  
 
mRNA (messenger RNA) - RNA transcribed from genes undergoes posttranscriptional processing and the resultant 
mature mRNA is used as the template for the translation process that results in synthesis of a protein. 
 
Multivariable analysis - As opposed to univariable analysis, statistical analysis performed in the presence of more than 
one explanatory variable to determine the relative contributions of each is (or should be) called multivariable analysis (in 
practice, however, it is called univariate and multivariate analysis more frequently). It is a method to simultaneously 
assess contributions of multiple variables or adjust for the effects of known confounders. 
 
Permutation Test - A statistical approach to examine statistical significance of associations based on Monte Carlo 
methods that accounts for multiple comparisons issue 
 
Phase - Denotes the haplotypic configuration of linked loci. The diplotype U1U3–V1V2 is consistent with two possible 
phases: (1) U1–V1 on one chromosome and on one chromosome and U3–V1 on the other. If a child receives U1–V1 on 
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a paternally derived chromosome from a father with diplotype U1U3–V1V2 it either implies that the father was in phase 
(1) and no recombination has occurred, or he was in phase (2) and there has been recombination. 
 
Phenotype  - the observable traits or characteristics of an individual such as hair color, weight, or the presence or 
absence of a disease. Phenotypic traits are not necessarily genetic. 
 
Polymerase Chain Reaction (PCR) - A procedure for obtaining a large number of copies of a particular segment of 
DNA. The principle depends on the requirement by DNA polymerase of a primer with a 3’ end to which nucleotides can 
be added. Two such synthetic primers define a segment that is replicated in a thermal cycle of denaturation, reannealing 
(reformation of complementary primer - DNA structure), and replication. Each cycle, which takes two to three minutes, 
doubles the amount of DNA between the primer boundaries. Thirty cycles would yield 230 copies. PCR has made it 
possible to characterize extremely small amounts of DNA. 
 
Polymorphism - Implies genetic variation at a designated locus. A locus that is polymorphic has at least two alternative 
alleles.  Unfortunately, polymorphism has alternative, more specific definitions (none universally accepted), an important 
example being “the existence of two or more genetic variants (alleles, other sequence variants, chromosomal structure 
variants) at significant frequencies in the population. 
 
Population stratification - An example of 'confounding by ethnicity' in which the co -existence of different disease rates 
and allele frequencies within population sub -sections leads to a spurious association at the population level. Differing 
allele frequencies in ethnically different strata in a single population may lead to a spurious association or 'mask' an 
association by artificially modifying allele frequencies in cases and controls when there is no real association (for this to 
happen, the subpopulations should differ not only in allele frequencies but also in baseline risk to the disease being 
studied) (Mark, 1996; Altshuler, 1998). Confounding, cryptic relatedness (which increases overdispersion of the test 
statistics and leads to inflation of significance levels overall) and selection bias are potential consequences of population 
stratification (Thomas, 2005). It is notable that the consequences of population structure on association outcomes 
increases with sample size, i.e., larger sample size is not a remedy for this issue and may make it worse (Marchini, 
2004). Case -control association studies can still be conducted by using genomic controls (Devlin, 1999; Pritchard, 1999) 
even when population stratification is present.  
 
Publication bias - Editors and authors tend to publish articles containing positive findings as opposed to negative result 
papers. This results in a belief that there is a consistent association while this may not be the case. Plots of relative risks 
by study may be used to check publication bias in meta -analyses. If publication bias is operating, one would expect that, 
of published studies, the larger ones report the smaller effects, as small positive trials are more likely to be published 
than negative ones. 
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Quantile -Quantile plot (Q -Q plot) - In a GWAS, the Q -Q plot is used to assess the number and magnitude of 
observed associations compared with the expectations under no association. The nature of deviations from the identity 
line provide clues whether the observed associations are true associations or may be due to population stratification or 
cryptic relatedness or something else. 
 
Quantitative character - A character displaying a 'continuous' phenotypic range rather than discrete classes; characters 
measured rather than counted such as metabolic activity, height, length, width, arm span, body fat content, growth rate, 
milk production, blood pressure. The genetic variation underlying a continuous character distribution may be the result of 
segregation at a single genetic locus or more frequently, at numerous interacting loci which produce a cumulative effect 
on the phenotype (with contributions from the environment). A gene affecting a quantitative character is a quantitative 
trait locus, or QTL (should be seen as a continuous trait locus). 
 
R project for statistical computing - R is a language and environment for statistical computing and graphics which can 
be seen as a different implementation of the S language. R and a comprehensive set of programs written for a variety of 
statistical analysis are all available as Free Software. 
 
Recessive - A trait that is not expressed in heterozygotes (i.e., that can only be expressed in the homozygotes). Most 
common recessive disease genes are those encoding metabolic enzymes. 
 
Recessive model - A genetic association analysis mode that examines association with a recessive allele. The 
comparison groups are variant homozygous genotypes vs the rest (combining heterozygotes for the variant and 
homozygotes for the wild -type allele). 
 
Restriction Fragment Length Polymorphism (RFLP) - Genetic variation at the site where a restriction enzyme cuts a 
piece of DNA. Such variations affect the ability of the restriction enzyme to cut, and therefore, produce different fragment 
sizes. Most RFLPs are single base pair changes in the 4–6 bp target sequence of the restriction enzyme. Vice versa, 
many single nucleotide polymorphisms (SNPs) are RFLPs and can be detected with this technique. 
 
Single nucleotide polymorphism (SNP) - A DNA variant that represents variation in a single base. A common SNP 
can be defined as a locus at which two SNP alleles are present, both at a frequency of 1% or more. Across the human 
genome there could be 10 million common SNPs. 
 
Susceptibility gene - A gene that is neither necessary nor sufficient to cause a disease but increases the risk of its 
development. These low -penetrance genes would be detected by association studies but would show no evidence for 
linkage with the disease. 
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Tag SNP - It is a representative single nucleotide polymorphism (SNP) in a region of the genome with high linkage 
disequilibrium (the non -random association of alleles at two or more loci). It is possible to identify genetic variation 
without genotyping every SNP in a chromosomal region. Tag SNPs are useful in whole -genome SNP association 
studies in which hundreds of thousands of SNPs across the entire genome are genotyped. 
 
Trait - Some characteristic of, for instance, a human, that may or may not have a genetic component. 
 
Transmission disequilibrium test (TDT) - A family -based study to compare the proportion of alleles transmitted (or 
inherited) from a heterozygous parent to a disease -affected child. Any significant deviation from 0.50 in transmission 
ratio implies an association. 
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1. BACKGROUND 
Cardiovascular diseases and essential hypertension are the leading causes of mortality and 
morbidity in developed countries including Spain (http://www.isciii.es/htdocs/centros/epidemiologia/ 
epi_enfcardiovasculares.jsp). 
Lifestyle modifications continue being the main strategy in order to prevent them. However it is 
important to know more about the complex physiopathology of this kind of diseases for both, the 
development of new effective drugs and the identification of those subjects prone to manifest the 
disease or related traits who would need a more aggressive treatment. Undoubtedly, genetic 
factors play an important role in their origin. From the initial studies in candidate gene we have 
gone to the study of functional pathways in order to have a wide vision of the complex 
physiopathology of the cardiovascular diseases. Subtle modifications in several genes, 
environmental factors and the interaction between all of them may be the responsible for the 
development of complex diseases1 .  Therefore the study of genetic polymorphisms is an important 
tool to try to unravel the genetic susceptibility of the cardiovascular diseases with complex 
heritability patterns2. Nowadays the development of new microarrays, which are able to interrogate 
hundreds of thousands of single nucleotide polymorphisms (SNPs), and powerful tools for the 
analysis of the huge amount of data obtained with them, have given us the possibility of study the  
whole genome (http://www.affymetrix.com/products/application/clinical_research.affx).
Current knowledge about microalbuminuria 
 
 4 
2. CURRENT KNOWLEDGE ABOUT MICROALBUMINURIA 
2.1. Definition and clinical relevance 
There are large amount of information for microalbuminuria as a prognostic marker for 
cardiovascular and/or renal risk in diabetic and non-diabetic subjects3-13. Although determinants 
of subtle increases in urinary albumin excretion (UAE) and its progression remain poorly 
understood, microalbuminuria assessment is now recommended in a risk stratification strategy 
for hypertension management14, 15. Moreover, the potential of microalbuminuria as an 
intermediate endpoint during antihypertensive treatment is still unclear.  
Microalbuminuria is defined as UAE from 30-300 mg/24 hour or equivalent amounts using timed-
overnight or spot urine samples. The definition comes from studies which have established its 
value as a marker of risk to develop nephropathy in diabetic subjects. When the potential 
prognostic value of microalbuminuria on cardiovascular disease was being assessed in both 
diabetic and non-diabetic populations, the threshold value pointing to an increment of risk was 
largely below the UAE value of 30 mg/24 hour regardless of the population studied16 . Dammsgard5  
in an elderly population demonstrated that subjects with timed-overnight UAE >7.5 mg/min had a 
higher mortality rate than those with lower values. Borch-Johnsen8  in a population-based cohort of 
2,085 consecutive subjects, the relative risk of ischemic heart disease associated with an spot 
urine albumin/creatinine ratio of only >0.65 mg/mmol, was 2.3 when adjusted for other risk factors, 
Likewise, Jager in the Hoorn study9 , a population-based cohort aged 50 to 75 years followed 
prospectively for 5 years, albumin/creatinine ratio >2.0 mg/mmol in a spot urine was associated 
with a 4-fold increase in cardiovascular mortality and about an 2-fold increase in all-cause 
mortality. Furthermore, in a cohort of postmenopausal women living in Utrech10 , the cardiovascular 
age-adjusted mortality rate for hypertensive women who were in the highest quintile of UAE was 
4.3 times greater than that observed in women without detectable UAE. The highest quintile 
corresponded to an albumin/creatinine ratio >2.41 mg/mmol. Finally, in the cohort of subjects 
included in the HOPE study11 , compared with the lowest quartile of albumin/creatinine ratio the 
relative risk of the primary end point in the fourth quartile, defined as albumin/creatinine ratio >1.62 
mg/mmol, was 1.97. 
Klausen et a17  have delved deeply at this point, not only in looking for a threshold for risk, but also 
in calculating risk along a wide range of UAE. They have observed that hypertensives with a timed-
overnight UAE above 5 mg/min have an increased risk for total mortality and coronary heart 
disease. The risk of coronary heart disease and mortality significantly increases 70% and 50% 
respectively when the UAE is between 5 to 10 mg/min, and 100% for both when the UAE is higher 
10 mg/min. In their study, this increment of risk is independent of the factors which are known to 
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influence the presence of microalbuminuria: age, blood pressure levels, smoking, body mass 
index, diabetes, creatinine clearance or total or HDL-cholesterol. Even though UAE was only 
measured once, it was done in timed overnight samples which are among the most reproducible. 
Two recently published studies have also shed light on our knowledge of microalbuminuria in 
hypertension populations and how it can be managed18 . In one study by our group, subjects with 
an initial UAE level in the high normal range, from 15-29 mg/24hour, have an increased risk of 
progressing towards microalbuminuria. The development of microalbuminuria is linked to 
insufficient BP control and to a progressive increment of glucose values. Thus, appropriate 
intervention may reduce the progressive increment of UAE. Ibsen et al19 in the LIFE study find that 
baseline and in-treatment levels of albuminuria are powerful predictors for subsequent 
cardiovascular morbidity and mortality. Reduction in albuminuria during treatment translates into a 
reduction in cardiovascular events. Although the units by which UAE have been expressed differ 
among the three studies, the 5 mg/min from Klausen17 is close to the 15 mg/24 hour from our study 
in which there was an increased risk for UAE to increase over time, and to the 1 mg/mmol of 
creatinine in a morning urine spot corresponding to the second strata of risk in the Ibsen study19. 
Until studies specifically designed to answer whether or not UAE may be used as an intermediate 
endpoint to monitor the success of a reduction in cardiovascular and renal risk are available such 
in diabetes20 , how can this new information influence daily clinical practice?. The three studies 
pointed to monitoring of albuminuria as an integrated part of the management of hypertension.   
In both diabetic and non-diabetic subjects, the continuous relationship between UAE and 
cardiovascular (CV) risk raises the question of the value of UAE where there is a substantial 
increment of risk and, consequently, where intervention is justified. Furthermore, what should be 
the UAE goal during intervention?. Defining the risk of microalbuminuria at an early stage, such as 
at the threshold established in the Klausen study, would be adequate for guiding therapies aimed 
to preventing progression of UAE. If albuminuria is not decreased by a patient’s current 
antihypertensive and/or other treatment, further intervention directed toward blood pressure control 
and other modifiable risks should be considered. 
Finally, Klausen et al propose in the title of their article “a new definition of microalbuminuria in 
hypertensive subjects”. The use of the term microalbuminuria as defined by different values 
according to the disease considered, eg, diabetes or hypertension, diseases which are closely 
linked to each other may be misleading. The use of UAE, avoiding categorization with a given 
threshold, should be encouraged. 
The assessment of subtle increases in UAE is a powerful way to identify those at risk for multiple 
cardiovascular risk factor intervention. Changes in UAE seem to run in parallel to cardiovascular 
risk, and prompt intervention to avoid the progressive increment of UAE may result in better 
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protection against hypertension-induced morbidity and mortality. Although some pieces of 
information remain to be found, UAE has come of age in the arena of hypertension. 
The next table summarizes the current criteria to define microalbuminuria according to urine 
samples. 
 
Table 2. 1. Criteria to define microalbuminuria according to urine samples. 
 Urine Sample 
 
Units Spot Timed-
overnight 
24 hour 
mg/24 hour   30-299 
 
mg/min  20-199  
 
mg/mmol Cr 3-29   
 
mg/mg Cr 30-299   
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2.2. Physiopathology of microalbuminuria 
Whether UAE in hypertension is mainly from glomerular or tubular origin has been studied by 
searching simultaneous urinary excretion of albumin and enzymes present in tubular cells, mainly 
beta-2-microglobulin and n-acetyl-glucosaminidase, which move to urine when tubular dysfunction 
is present. As suggested by the finding of normal urinary excretion of beta-2-microglobulin in 
normoalbuminurics and microalbuminurics with essential hypertension21 , microalbuminuria in 
essential hypertensive patients is probably the consequence of an increased transglomerular 
passage of albumin rather than the result of a decrease in the proximal tubule reabsorption of 
albumin. 
Increased transglomerular passage of albumin, derived from the glomerular structures in essential 
hypertensive patients, may result from hemodynamic-mediated mechanisms and/or functional or 
structural impairment of the glomerular barrier. 
 
2.2.1. Hyperfiltration 
Hyperfiltration and an increased filtration fraction have been regarded as the forerunners of 
haemodynamic abnormalities that may lead to the development of renal damage in primary 
hypertension. The presence of hyperfiltration has been considered an early sign of organ damage, 
and an association between an increased glomerular filtration rate (GFR) and microalbuminuria 
has been reported by several authors22, 23 . There have been conflicting results, however, on the 
possible role of hyperfiltration and reports of either, increased24 , unchanged25, or decreased26  
creatinine clearance (CC) have been reported in microalbuminuric hypertensives. Minram did not 
find differences in basal GFR, effective plasma flow and filtration fraction between essential 
hypertensive patients with or without microalbuminuria25 . Furthermore, this author observed that in 
a group of normal-weight, essential hypertensive subjects with hyperfiltration, urinary albumin 
excretion was similar to that observed in a group with normofiltration27 . Probably the discrepancies 
found in these studies have reflected the unpredictable mix of functional and structural alterations 
leading to microalbuminuria in hypertensive patients. 
Hyperfiltration, which increases glomerular pressure, is probably mediated by progressive loss of 
functioning nephrons and/or from abnormal transmission of systemic hypertension to the 
glomerulus through a disturbance in glomerular auto-regulation. Systemic blood pressure 
elevations are usually accompanied by increases in pre-glomerular vascular resistance preventing 
the increased systemic blood pressure from being transmitted to the glomeruli. The increased 
glomerular pressure would contribute to increase UAE, glomerular injury and progression of 
chronic renal failure (CRF). From clinical studies, we are now aware that alterations for constricting 
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afferent arterioles are present in subsets of hypertensive subjects, such as blacks, CRF, diabetics 
and the elderly. The prevalence of microalbuminuria in these subgroups, that have the highest risk 
of developing renal insufficiency, was higher than that observed in essential hypertensives. Thus, 
glomerular hypertension contributes to the appearance of microalbuminuria and could be a marker 
of risk for developing renal insufficiency among patients with essential hypertension. 
 
2.2.2. Glomerular basal membrane abnormalities 
Presence of glomerular basal membrane abnormalities as the main mechanism underlying 
the presence of microalbuminuria in hypertension has been suggested by several authors. Other 
studies, however, did not support this point of view. Urinary transferrin excretion (UTE), a more 
anionic and higher size molecule than the albumin molecule, was studied simultaneously to the 
UAE in hypertension. In contrast to observations in diabetic subjects, in which a correlation 
between UTE and UAE was present28 , no relationship between UTE and UAE was observed in 
hypertensives, and the impact of blood pressure changes in UTE was negligible29 . 
 
2.2.3. Endothelial dysfunction 
Microalbuminuria reflect the kidney expression of a more generalized state of endothelial 
dysfunction 30 . Higher levels of circulating von Willebrand factor antigen, a glycoprotein released in 
greater concentrations when endothelial cells are damaged, were found in microalbuminuric 
compared to well-matched normoalbuminuric patients with essential hypertension. A direct 
correlation between von Willebrand factor antigen and albumin excretion rate was described, 
supporting the hypothesis that albuminuria reflects systemic dysfunction of the vascular 
endothelium26. 
 
2.2.4. Nephrosclerosis 
Nephrosclerosis needs to be mentioned when abnormal UAE in essential hypertension is the 
issue. Glomerular and vascular structural alterations coexist with altered functional mechanisms 
particularly in the more severe cases and in those with long-standing disease, but in most patients 
with primary hypertension and microalbuminuria no specific pathologic kidney changes can be 
found31 . Studies of the natural history of nephrosclerosis in essential hypertension are lacking, due 
to the limitation of carrying out renal biopsies on these patients. Data from experimental rat 
models, such as streptozotocin-induced diabetes and 5/6 renal ablation, induces albuminuria early 
after injury which progresses throughout the observation period. Micropunture studies performed 
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during the initial post-injury phase, in a normotensive state, showed the presence of hyperfiltration, 
and an increase in intraglomerular capillary pressure resulting from preferential dilatation of the 
afferent glomerular arteriole. Later, glomerular hypertension induces a progressive nephron loss. 
Proteinuria appears from the beginning supporting the role of hyperfiltration in the increment of 
urinary albumin excretion. Moreover, the use of micropuncture techniques has shown that 
albuminuria originates from intact glomeruli rather than damaged ones32 . Whether an increase in 
the transglomerular passage of albumin is a cause or a consequence of glomerulosclerosis 
remains a subject of debate. 
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2.3. Factors related to microalbuminuria 
Factors related to the presence of microalbuminuria in essential hypertension have been 
analyzed in cross-sectional studies, but follow-up studies are rare7, 33-35. From these studies it 
seems that the significance of microalbuminuria in essential hypertension is much broader than 
expected, and several factors may influence the presence of microalbuminuria. An overview of 
these is presented in the following sections. 
2.3.1. Cross-sectional studies 
During the last decade, cross-sectional studies have tried to analyze what the determinants 
of microalbuminuria in essential hypertension are. Although there are several determinants 
which appear important in all the studies, others depend on the selection of the study population 
and on the interest of the authors vis a vis specific factors. Subsequently, microalbuminuria has 
been related to blood pressure  (BP) values36-39  and to hyperinsulinemia as an expression of 
insulin resistance40, 41.   
2.3.1.1. Blood pressure values 
Blood pressure is the main determinant of microalbuminuria in both diabetics as well as in 
non-diabetics. A positive relationship between blood pressure levels obtained in the office and 
UAE in hypertensives was observed in several studies36-39 . The impact of BP values on the 
presence of microalbuminuria has been further reinforced by data coming from studies using 24-
hour ambulatory BP monitoring (ABPM). Ambulatory blood pressure values showed a stronger 
association with UAE than office blood pressure measurements did42-44 . In one study by our 
group, conducted on patients with essential hypertension, significant differences in blood 
pressure were found between microalbuminuric patients and normoalbuminurics44 . The 
differences were maintained throughout the 24-hour data collection period, reflecting that 
ambulatory blood pressure measurements were better predictors than casual measurements 
were for the presence of microalbuminuria. 
A blunted physiological nocturnal BP fall, and then the persistence of elevated BP during night, 
were also associated with high UAE rates44 . Providing further evidence of the importance of 
blood pressure during night, patients with a lower day/night ratio had higher UAE even when 
controlling for daytime blood pressure. This observation could be interpreted as high blood 
pressure maintained over time leading to an increase in UAE. 
Blood pressure leads to endothelial dysfunction resulting in an increase in the permeability of 
macromolecules and the glomerular capilar wall does not escape this impact. The higher the 
blood pressure the higher the endothelial dysfunction. In addition, persistence of high BP levels 
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during the night-time implies that during the recumbent position there is a reduced activity of the 
mediators controlling pre-glomerular tone, mainly sympathetic and renin-angiotensin activities. 
The presence of conditions that impair, and thereby reduce, pre-glomerular tone permit further 
and easier transmission of high pressure into the glomeruli which trigger mechanisms increasing 
the UAE45. 
2.3.1.2. Insulin resistance and hyperinsulinemia 
Hypertensive subjects with microalbuminuria have shown higher values for fasting insulin 
and/or insulin after glucose challenge40, 41, and hyperinsulinemia has been related to 
microalbuminuria both in hypertensive subjects as well as in non-diabetic normotensives. In one 
study by our group41 , we found higher values for both fasting insulin and area-under the curve 
(AUC) of insulin during an oral glucose-tolerance test (OGTT) in the microalbuminuric group 
when these factors were compared to those of the normoalbuminuric one. 
Hyperinsulinemia is probably an expression of insulin resistance, and a higher degree of 
peripheral resistance to insulin, estimated by euglucemic-clamp, has been described in 
microalbuminuric patients with non-insulin dependent diabetes mellitus46, 47 or hypertension48. 
The link between hyperinsulinemia and microalbuminuria seems to be recognized in several 
studies, and microalbuminuria has been included as a component of the metabolic syndrome. 
Insulin may lead to the increase in UAE enhancing the endothelial permeability of albumin in the 
kidney. In healthy subjects, an increase in the transcapillary escape rate of albumin produced by 
insulin infusion has been described49 . Whether a direct effect of insulin in the endothelial 
permeability of albumin is present or not, other factors, such as the impact on concurrent factors 
such as glomerular hemodinamics, salt balance, and/or overactivity of angiotensin II and 
sympathetic nervous system, might also contribute to the proalbuminuric effect of insulin. 
2.3.1.3. Salt-sensitivity 
Some observations have linked salt-sensitivity to microalbuminuria in essential 
hypertension40, 50, and salt-sensitivity may be a prevalent state among microalbuminuric 
hypertensives. Salt-sensitive hypertensive subjects manifest complex abnormalities: an 
exaggerated BP response to noradrenaline and angiotensine II, reduction in urinary kallikrein 
excretion, decreased insulin sensitivity, and renal hemodynamic derangement51. In salt-sensitive 
hypertensive patients, even small increases in dietary salt may have potentially detrimental 
effects on glomerular hemodynamics and proteinuria52 . The corollary is that the presence of 
more UAE in salt-sensitive patients could be interpreted as a marker of greater renal damage, 
and potentially as a prognostic indicator of the future progression of the renal disease. Indeed, a 
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modest salt reduction may be helpful by reducing the risk of adverse renal hemodynamic 
changes in the subjects who display microalbuminuria. 
 
2.3.1.4. Overactivity of the Renin-Angiotensin System 
The hypothesis that microalbuminuria can be a marker of more severe renal ischemia and 
activated renin system was supported by the study of Erley and cols53 , who found higher 
postcaptopril plasma renin activity in young patients with essential hypertension who had 
albuminuria than in those without. Moreover, an increased albumin excretion rate in essential 
hypertensive patients with DD genotype of the I/D  polymorphism of the angiotensin converting 
enzyme (ACE) has been described54 . This genotype is characterized by high serum levels of ACE 
and possibly of angiotensin II, both at circulating and tissue levels. 
 
2.3.1.5. Inflammation 
The impact of low-grade inflammation in the UAE has been analyzed in several studies55 . 
Although both C-reactive protein (CRP), a marker of low-grade inflammation in the vascular wall, 
and microalbuminuria cluster frequently, the positive relationship between serum C-reactive protein 
and microalbuminuria emerges mainly in subjects in absence of other major cardiovascular risk 
factors such as hypertension and/or diabetes 56, 57. In essential hypertension, however, levels of 
CRP modulate the relation between blood pressure and UAE, and for a given BP value the higher 
CRP the higher UAE 58. A potential explanation for these observations is that low-grade 
inflammation is not a strong determinant of microalbuminuria, but inflammation can booster the 
impact of other strongest factors such as high blood pressure levels. 
 
2.3.2. Follow-up studies 
Long-term studies of microalbuminuria in essential hypertension are rare7, 33-35, and 
information about the contribution of factors other than BP reduction in the changes of UAE 
overtime are scarce. Again in these studies the potential risk factors are similar to those which 
were analyzed in cross-sectional studies, although others deserve attention. 
 
2.3.2.1. Blood pressure and glucose values 
Blood pressure role has been analyzed prospectively, mainly in patients with diabetes. The 
normotensive arm of the ABCD study in Type 2 diabetes has demonstrated that patients with an 
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intensive diastolic BP control program, 128/75 mmHg, had a lower risk of developing 
microalbuminuria than those with a moderate therapy, 137/81 mmHg did59. Furthermore, a 
progressive increase in systolic BP during sleep has been related to the development of 
microalbuminuria in normotensive Type 1 diabetics60. 
In patients with essential hypertension, several studies demonstrated that by reducing BP values 
the UAE decreases significantly, mainly when the BP reduction was large enough. In other 
cases, when the BP reduction is small, antihypertensive drugs blocking the activity of the renin-
angiotensin system seem to be more beneficial than in the other antihypertensive groups61. All of 
these studies have focused on the BP changes and not on other potential changes. 
Our group conducted a prospective study to assess factors related to the occurrence of 
microalbuminuria during the follow-up of a group of never previously treated young adults with 
essential hypertension35 . The main factor influencing the occurrence of microalbuminuria during 
antihypertensive treatment was the slope of systolic blood pressure. Thus, BP needs to be 
lowered as much as possible in order to prevent occurrence of microalbuminuria. 
Besides the impact of SBP overtime in the risk of developing microalbuminuria, a trend in 
increasing glucose values was also a determinant of risk, which was independent of the BP 
values18, 35. 
2.3.2.2.  Baseline urinary albumin excretion 
The importance of the baseline level of UAE on the risk of developing microalbuminuria has 
been analyzed in two follow-up studies of non-diabetic essential hypertensives. Agewall et al62  
studied 213 patients without microalbuminuria after a three-year follow-up, controlled biannually, 
using the level of UAE from a single measurement of overnight UAE. This study observed that 
patients who developed microalbuminuria had higher UAE at baseline compared with those who 
remained normoalbuminurics. Probably, the increase in baseline UAE is, at least in part, an 
expression of cardiovascular factors and end-organ damage even in values below the threshold 
to define microalbuminuria. Redon et al35 studied 187 normoalbuminuric subjects in whom 
baseline UAE was one of the determinants for the risk of developing microalbuminuria. 
The following table summarizes those factors associated to the prevalence (cross-sectional 
studies) or the incidence (follow-up studies) of microalbuminuria in essential hypertension. 
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Table 2. 2 . Factors associated to the prevalence or the incidence of microalbuminuria in essential 
hypertension. 
Variable Prevalence Incidence 
Baseline UAE NA +++ 
BP values +++ +++ 
Glucose values + ++ 
Hyperinsulinemia +++ NA 
Genetics + + 
Body weight + + 
Smoking + NA 
     NA: not available 
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2.4. Natural history of microalbuminuria in hypertension 
Considering information available, we can hypothesize and graphically represent the natural 
history of microalbuminuria in hypertension (Figure 2.1). 
 
Figure 2. 1. Natural history of microalbuminuria in hypertension. 
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In hypertensive subjects microalbuminuria may be the consequence of a double product, time of 
hypertension per blood pressure values. If the patient has insulin-resistance, microalbuminuria 
can be present even when the double product of time and pressure is small. By contrast 
subjects without insulin-resistance need a long time and/or high blood pressure values to 
develop microalbuminuria. At the top of these scenarios, the development of 
nefroangiosclerosis, less prevalent in non-insulin resistance, adds a new component to the risk 
of having microalbuminuria. 
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2.5. Effects of therapy in microalbuminuria 
 
2.5.1. Short term effects 
A substantial decrease in microalbuminuria as a result of the effective control of hypertension is 
suggested by the correlation between blood pressure levels and microalbuminuria. Lowering blood 
pressure with antihypertensive medication reduces albuminuria in diabetes63  and in primary 
hypertension61  according to several studies. The reduction has been observed when using agents 
as diverse as angiotensin-converting enzyme inhibitors (ACEi), angiotensin II-receptor blockers 
(ARBs), betablockers, calcium channel blockers or a combination therapy. Questions have arisen 
over whether antihypertensive agents differ with respect to their action on microalbuminuria, and 
whether hypertensive patients do not reduce or whether they even increase UAE despite blood 
pressure control. 
At the same level of achieved BP, antihypertensive drugs blocking the activity of the renin-
angiotensin system, both angiotensin converting enzyme inhibitors (ACEi) and angiotensin II 
receptor antagonists, seem to be more beneficial than the other antihypertensive groups61, 63. The 
ACEi and angiotensin II blocking-receptors (ARBs) have additional beneficial effects on 
microalbuminuria, independent of BP reduction, since they reduce the biological actions of 
angiotensin II. It has been implicated in the progression of renal failure in diabetic and non-diabetic 
nephropathy, by up-regulating the expression of growth factors and cytokines such as transforming 
growth factor-beta1, tumor necrosis factor-alpha (TNF-α), osteopontin, vascular cell adhesion 
molecule1, nuclear factor-kappa, platelet-derived growth factor, fibroblast growth factor and insulin-
like growth factor64, 65. ACEi and ARBs reduce the increased levels of some of these growth factors 
and cytokines65. 
Some research, however, has reported discordant results. Erley and coworkers66 , who used 
felodipine, doxazosin, ramipril and atenolol noted a similar lowering of blood pressure and a 
decrease of UAE. Discrepancies between studies like of Erley´s one and others may be explained 
by the initial blood pressure values, the extent of blood pressure fall during treatment and the 
presence of factors other than BP which determine UAE, glucose metabolism abnormalities and 
salt intake.  
The beneficial effects of the antihypertensive agents on microalbuminuria are proportional to BP 
reduction. The higher the initial blood pressure the greater the UAE reduction. If a large enough BP 
reduction is achieved, differences among the antihypertensive drug classes diminish.  
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Glucose metabolism derangement induces microalbuminuria even though BP values are “quasi” 
normal since hyperfiltration and basal membrane alterations have been described as a 
consequence of hyperglycemia. Despite lowering BP, no change or only a minimal reduction in 
UAE occurs. 
Dietary salt intake is a missed factor in the majority of the studies. Salt influences UAE through its 
impact on the activity of the renin-angiotensin system and on BP values. There is a high 
prevalence of salt-sensitive subjects in the subset of hypertensives who are microalbuminuric, and 
changes in salt-intake significantly modify BP, glomerular hemodynamics and consequently, 
UAE52. Until more information is available, patients with microalbuminuria should be encouraged to 
moderate their salt intake. 
The regression of UAE has been observed shortly after BP reduction, favouring the hypothesis 
that the regression comes from a reduction of albumin filtration in the glomerulus as a 
consequence of a lower intraglomerular pressure. Hypertensive patients with persistent 
microalbuminuria under short, intensive antihypertensive therapy, however, show a statistically 
significant higher prevalence of hypertensive retinopathy and, therefore, microalbuminuria can 
be considered an indicator of general microvascular damage in essential hypertension67.  
In summary, the heterogeneity in the UAE changes during antihypertensive treatment may be 
related to the different factors involved in the presence of microalbuminuria and/or to the 
presence of structural end-organ damage. Short-term UAE reduction with antihypertensive 
treatment depends on initial BP, extent of BP reduction, antihypertensive class, factors other 
than BP and structural abnormalities established in the glomerulus. 
 
2.5.2. Long term effects 
Long-term studies of microalbuminuria in essential hypertension are rare 7, 19, 34, 35 , and 
information about the contribution of factors other than BP reduction in the changes of UAE over 
time is scarce. The information available comes from studies in which changes in UAE over time 
were presented as a whole or separately for subjects with or without response to treatment. 
In the LIFE study68 , yearly examination of UAE has performed in a cohort of essential 
hypertensives with left ventricular hypertrophy and the median changes in albuminuria across 5 
years of follow-up has reported. At each year the decrease in albuminuria is more pronounced for 
losartan-based as compared with atenolol-based treatment68 . At the first and second year of 
follow-up, a 33% reduction was seen for losartan as compared with 25% for atenolol. By observing 
the reported data, the initial reduction is progressively attenuated over time. After the initial 
reduction, which is greater for losartan as compared to atenolol, the trend toward the initial levels 
seems to be similar for both groups of treatment68 . This means that in hypertensive subjects as a 
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whole, UAE increases progressively despite the antihypertensive treatment. Whether or not this is 
the result of calculating the average of UAE from subjects increasing and decreasing it is not 
offered by the authors. Another potential explanation for the observation in the LIFE study is that 
the BP achieved during treatment, 144/84 mmHg, is too high to protect against the increment in 
UAE.  
The Prevention of Renal and Vascular End-Stage Disease Intervention Trial (PREVEND-IT)69 
cohort of approximately 800 otherwise healthy subjects with high levels of urinary albumin have 
selected out of the PREVEND general population cohort. They have randomized to receive the 
ACEi fosinopril 20 mg/d or placebo, and pravastatin 40 mg/d or placebo, for 4 years. After 3 
months, albuminuria levels have significantly reduced by approximately 30% in patients assigned 
to fosinopril as compared with placebo, and the reduced levels have sustained at the 4-year follow-
up. 
Studies showing individual changes provide more useful information when trying to understand the 
evolution of UAE under antihypertensive treatment. In one study18 , from 245 normoalbuminuric 
hypertensives, representative of a middle-aged population with mild hypertension, in thirty subjects 
(12.2%), UAE increases to the microalbuminuric range, from 13.1±7.7 to 44.2±18.2 mg/24 hours, 
(p<0.001) after a mean follow-up of 29.9 months with a conversion rate of 2.5/100 patients/year. 
Two hundred and fifteen subjects (87.8%) do not develop microalbuminuria after a mean follow-up 
of 61.7 months. In these patients, UAE do not increase even within the normoalbuminuric range 
(from 9.4±6.2 to 9.0±9.7 mg/24 hrs). Subjects who remained normoalbuminurics over time, maintain 
stable levels in sharp contrast with those who become microalbuminurics in which a progressive 
increase occurs. 
In this study 18, in initially normoalbuminuric hypertensive subjects the persistence of higher than 
normal SBP precedes the development of microalbuminuria. Additionally, an upward trend in fasting 
glucose values seems to be present in those subjects who develop microalbuminuria. Thus, the 
potential for developing microalbuminuria appears very low in subjects who achieve strict normal 
blood pressure, or in those who maintain stable fasting glucose values. 
The role of blood pressure on the evolution of microalbuminuria has been analyzed prospectively, 
mainly in patients with diabetes. The normotensive arm of the ABCD study in Type 2 diabetes has 
demonstrated that patients with an intensive diastolic BP control program, 128/75 mmHg have a 
lower risk of developing microalbuminuria than did those with a moderate therapy, 137/81 mmHg59. 
Furthermore, a progressive increase in systolic BP during sleep has been related to the 
development of microalbuminuria in normotensive Type 1 diabetics60 . A significant increase of 2.2 
times in the risk to develop microalbuminuria for SBP > 139 mmHg over the subjects with SBP 
<130 mmHg, is observed in one study performed in essential hypertension subjects18 . 
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Besides the impact of SBP over time in the risk of developing microalbuminuria, a trend in 
increasing glucose values is also a determinant of risk which is independent of the BP values. The 
risk of developing microalbuminuria is sharply increased in patients with a positive slope of 
glucose plasma levels. This seems to reflect that the patients in the study prone to developing 
microalbuminuria are at an early stage of carbohydrate metabolism abnormality. The upward trend 
in glucose levels in those hypertensives who become microalbuminurics is in agreement with data 
coming from The Framingham Offspring Study70  in which 24-year time-integrated fasting glucose 
levels are strongly associated with the risk of developing microalbuminuria in the general 
population. The increased risk is not limited to diabetic levels of fasting glucose, and subtle 
elevations in apparently normal levels also increases the risk, suggesting that the increased risk 
occurs in a graded fashion across the spectrum of glucose tolerance71 .  A significant increase in 
the risk of 2.2 times to develop microalbuminuria for a positive trend in fasting glucose as 
compared to those with a neutral or negative trend have been observed independent of baseline 
UAE and SBP values. 
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3. GENETIC BASES OF MICROALBUMINURIA AND 
RELATED TRAITS  
 
3.1. Overview 
Microalbuminuria has become a marker of risk not only for renal, but also for 
cardiovascular disease in diabetes, hypertension (HTN) and in the general population. In 
hypertension, microalbuminuria has been associated with a clustering of cardiovascular risk 
factors. Moreover, changes in microalbuminuria over time seem to have prognostic 
implications. Therefore, microalbuminuria assessment is now recommended for the 
stratification of risk of patients with HTN 4-13. Although microalbuminuria reflects systemic 
endothelial dysfunction26, 30, it is also a marker of renal damage that can antedate the 
development of proteinuria20, 23, 31 , an unequivocal sign of established nephropathy. 
Factors related to the development of microalbuminuria have been extensively analyzed in 
cross-sectional and follow-up studies over the last several years. Blood pressure levels, 
hyperglucemia, hyperinsulinemia and insulin resistance  are probably the main factors36-39. 
Other factors such as  obesity72 and smoking73 have also been implicated in the risk of 
developing microalbuminuria. The role of genetic factors has been considered to be based 
both on epidemiological, as well as on animal studies74, 75. Familial clustering of renal disease 
76, 77
 and racial differences in risk for end-stage renal disease 78-80 81 have been recognized. 
Likewise, a susceptibility loci for renal disease and UAE has been identified in rats82.  
In the following pages of this doctoral thesis, a systematic review summarizing the current 
knowledge of the genetics of microalbuminuria and related traits in essential hypertension is 
presented. 
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3.2. Evidence supporting the influence of genetic factors for renal traits 
The first line of evidence is the genetic epidemiological studies. These kinds of studies 
demonstrate that there is a strong familiar clustering for renal disease and microalbuminuria 
not only in type 1 and type 2 diabetes but also in HTN. In this way, it has been demonstrated 
that relatives of patients with type 2 diabetes ( DM2) are prone to develop microalbuminuria 
even if they were not diabetics themselves and this microalbuminuria can finally drive to the 
end stage renal disease (ESRD)76, 77.  Also the ESRD itself have a strong family clustering in 
diabetes and HTN77, 83. 
Another piece of evidence are the huge differences existing between ethnics regarding to the 
prevalence of renal damage.  There is some ethnics which are in high risk of develop diabetic 
or hypertensive ESRD such as Afro-Americans or Hispano-Americans78-80. It is not clear if that 
differences between ethnics are due to environmental factors such as different lifestyle or 
inequalities in the availability of the treatments or to different genetic backgrounds81. 
Finally we have several studies performed in animals which strongly support the presence of 
susceptibility loci for renal disease. In mice, several quantitative trait loci (QTL) have been 
linked with renal traits including UAE82. Moreover, since 2005 it is available an internet tool to 
compare humans and mice quantitative trait loci related with renal traits 
(http://pga.jax.org/qtl/kidneyqtltable.htm).  For UAE, in hypertensive rats, there are QTL on 
chromosomes 2 and 3 which correspond with human QTL for albumin creatinine ratio (ACR) 
on chromosomes 3 and 20 according to one linkage study in type 2 diabetics Pima Indians 84. 
Besides those linkage studies, knockout mice models also demonstrate the relevance of 
several candidate genes, such as endothelial nitric oxide synthase (eNOS), in renal damage 
and UAE  85, 86.  
Taking into account all of these facts, it is clear that genetic plays an important role in 
microalbuminuria, but what are the genes or variants involved remains unclear.   
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3.3. Elucidating the genetic susceptibility of microalbuminuria and renal traits 
Candidate gene (CG), linkage analysis (LA) and genome wide analysis (GWAS) has been 
used to unravel genetic variants of susceptibility to microalbuminuria and renal damage in 
essential hypertension. Although detailed analysis of the advantages and the limitations of 
each of the methods used is out of the scope of the present doctoral thesis, some key aspects 
need to be acknowledged.  
Candidate genes strategy, which tries to simplify the study of complex diseases by selecting of 
a small set of genes and then studying the associations of polymorphisms with the problem 
trait, has the strength of the biological plausibility. Additional functional in vitro studies and 
knockout mice models of the polymorphisms detected can help to assess the relevance of the 
association. This is the case of the polymorphisms of eNOS and of angiotensin II type 1 
receptor (ATR1) genes,  which have been associated with nephroangioesclerosis87 and UAE  
85, 86
. Candidate gene studies take advantage of the detailed data base of gene SNPs, the 
HapMap project (http://www.hapmap.org/) and of haplotype construction by creating stronger 
markers. Epistatic interaction with other physiologically related genes is used to detect 
interactions between different components on the same metabolic pathway or on related ones. 
Linkage studies within families evaluate the coincident inheritance of polymorphic genetic 
markers across the genome among family members with the disease status. Heritability, 
susceptible loci and potential candidate genes associated with a particular disease are 
obtained and have successfully been used in animal models of renal damage. Linkage of 
urinary albumin excretion with two QTL on chromosomes 2 and 3 have been described, and 
this linkage has been replicated in type 2 diabetic Pima Indians 84. In general, linkage strategy 
has been useful for oligo or monogenic disease, but it has failed in complex diseases which 
must be produced by the interaction of multiple variants of low risk.  
The most recent approach is the genome wide association studies (GWAS) in unrelated 
subjects. Covering all the genome with such a huge density of markers offers the possibility of 
finding previously unsuspected associations with physiological systems. The new high-
throughput microarrays can contain up to more than 1 million markers across the genome, not 
only SNPs, but also other polymorphisms such as copy number variation (CNV). The GWAS 
have been shown to be useful for some complex diseases such as types 1 and 2 diabetes, 
bipolar disorder or coronary heart disease, but in HTN the initial results were negatives.88-91. 
Although a combination of different strategies can reap benefits from the advantages of each 
of them and help refine the studies, there are several problems common to all genetic studies. 
Sample size, marker density, genotype quality and phenotype selection need to be adequately 
identified to minimize the risk of false associations.  
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Among the phenotypes of renal disease in HTN, Renal insufficiency (RI), assessed by plasma 
creatinine values or estimated GFR (eGFR), and ESRD are easy to appraise, although ESRD 
takes a long time to develop and its incidence is rare. Nephroangiosclerosis, the renal damage 
induced mainly by HTN, is a misleading trait because its diagnosis using clinical criteria can be 
erroneous in the absence of renal biopsy. Consequently, UAE has been the most widely used 
marker of renal damage in HTN. Proteinuria as a qualitative trait has been used, but its 
incidence and prevalence are low in HTN. Microalbuminuria, a small amount of UAE, is much 
more frequent and has been used as either a quantitative trait or a qualitative one when UAE 
is within the range 30-300 mg/day. Whether using the quantitative or the qualitative approach, 
the within individual variability needs to be taken into account so more than one sample is 
necessary to achieve accuracy in the assessment. Quantification of UAE in a twenty-four hour 
urine sample, nocturnal timed-urine collection or albumin/creatinine ratio in spot morning urine 
is used. Assessing the temporal trend of UAE, in order to gain precision at the time of 
qualifying the trait, has also been used in a few studies. 
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3.4. Genetic bases of microalbuminuria and related traits in essential 
hypertension  and general population 
 
3.4.1. Candidate gene studies 
The candidate genes analyzed in association studies with renal traits in HTN have 
pertained to those codifying proteins or peptides of the renin-angiotensin-aldosterone system 
(RAAS), natriuretic peptides, the adrenergic system, inflammation, oxidative stress, 
intracellular signalling, lipid metabolism, regulation of the extracellular matrix, fibrinolysis 
among others. 
A resume of some of the candidate gene studies for renal traits in essential hypertension is 
shown in table 3.1 (I,II,III). 
 
3.4.1.1. RAAS genes  
The genes of the RAAS are among the most studied. This physiological pathway regulates 
the plasma and tissue levels of angiotensin II, a peptide which is involved not only in 
glomerular, but also vascular damage, and therefore in the development of HTN-induced 
nephroangioesclerosis92-94. Moreover, drugs blocking either the generation of angiotensin II or 
the binding to the AT1- receptor are able to reduce UAE beyond the BP lowering effect and, 
therefore, protect the kidney 95-99 .       
The Insertion/Deletion polymorphism (I/D) of the angiotensin converting enzyme (ACE) gene, 
M235T of the angiotensinogen (AGT) gene, A1166C in the angiotensin II type 1 receptor 
(AT1R) gene, and T344C of the aldosterone synthase (CYP11B2) are among the gene 
variants which have been associated with renal traits. 
The D allele of the I/D polymorphism in ACE seems to increase the risk of 
nephroangioesclerosis independent of BP levels. One retrospective study found a significantly 
higher prevalence of the DD genotypes in patients with nephroangioesclerosis diagnosed by 
biopsy compared with hypertensive patients without renal damage74, a finding replicated in an 
independent Italian cohort of hypertensive patients with or without renal damage100 . 
The risk of RI in one cross-sectional study in an Italian population found an increase of risk of 
having renal failure (Cr>1.5 mg/dl) for carriers of various genotypes: DD in I/D of ACE, TT in 
M235T of AGT, CC in A1166C of AT1R, and CC in C344T of CYP11B2101 . The strongest risk 
was for the TT genotype of the M235T polymorphism in the AGT gene101. The study also found 
certain epistatic effects among these variants. Moreover, the combination of the opposite 
alleles showed a protective role for renal damage101. 
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Concerning the association with microalbuminuria, in one cross-sectional study carried out in a 
subset of never before treated young hypertensives, there was a trend to present higher levels 
of UAE in carriers of the DD genotype of I/D in the ACE gene than for the other genotypes102. 
Furthermore, the UAE in these patients showed a stronger relationship with BP levels than it 
did for the other genotypes 102. In a prospective study, patients with the DD genotype showed a 
significant positive correlation between the slopes of SBP and UAE (r=0.60) over time75. This 
correlation was not present in carriers of the I allele. Some findings75, 102 suggest that this 
polymorphism can modulate the impact of the blood pressure in kidney damage.  
Two polymorphisms of the AT1R gene (A1166C and C573T) were also tested in a subset of 
183 hypertensive patients less than 50 years old103. The TT genotype of  C573T had 
significantly lower levels of UAE than did the other genotypes103. A similar and significant result 
was found for the AA genotype of A1166C, as this allele A is closely linked with the allele T of 
the C573T polymorphism103.  
In the AGT gene, the M235T and another polymorphism in strong linkage disequilibrium, A-6G, 
located in the promoter region in a prospective study in  young hypertensives have also been 
studied 104. Although no significant differences in genotypes for either polymorphism was 
observed between patients with or without microalbuminuria, the A-6G polymorphism seems to 
influence the risk of new onset microalbuminuria in a three year follow-up study104. In this case, 
the development of microalbuminuria was linked to the changes in fasting glucose and 
weight104, 105, a previously described association with M235T.  
In the study performed by Pontremoli et all106, patients carrying the allele D in ECA, T in AGT 
and C in AT1R have higher early organ damage as compared to carriers of the other alleles of 
the polymorphisms studied. These were not only associated with the greatest UAE, but also 
with left ventricular hypertrophy and increased intima media thickness (IMT). 
 
3.4.1.2. Natriuretic peptides and alpha-adducin genes 
The human atrial natriuretic peptide (ANP) plays a key role in the volume handling, and 
interaction with the RAAS system influences renal haemodynamics107-109. The ANP gene has 
been associated with microalbuminuria and renal impairment. The mutant allele A1 of the 
2238T>C polymorphism, also called the ScaI110 polymorphism, which is a restriction fragment 
length polymorphism (RFLP), seems to be less frequent in microalbuminuric hypertensive 
patients with diabetes according to one Italian study111. This allele A1 causes a break in the 
stop codon, which results in an ANP with two more arginine molecules, and could protect 
against renal damage. The functional hypothesis is that this variant reduces the blood levels of 
ANP and, therefore, the renal damage induced by hyperfiltration. In the same study, another 
mutant allele, T, of the 708C>T (rs5064) polymorphism was less frequent in subjects with 
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microalbuminuria111.  In a partial replication only the Scal polymorphism, but not the T allele in 
diabetics, was observed in a Mexican population112.  
Also related to sodium handling is the Alpha-Adducin (ADD1) gene. The Gly460Trp 
polymorphism of this gene has been related to salt sensitivity and several renal traits113, 114. 
Regarding microalbuminuria, one Italian study failed to find an individual association, although 
an epistatic interaction with the I/D polymorphism in the ECA gene was associated with 
increased risk of microalbuminuria115. Homozygotes DD for the I/D polymorphism in ECA and 
460Gly of the ADD1 gene had greater prevalence of microalbuminuria than carriers of the I 
allele did. A controversial result was observed in another study in which the allele 460Try in the 
ADD1 gene seems to interact with the D allele of the I/D polymorphism in ECA gene to 
increase the risk of mild renal dysfunction116. 
 
3.4.1.3. Adrenergic system and adrenomedulin genes 
The adrenergic system plays an important role in the development of hypertension, 
obesity, insulin resistance and, therefore, with hypertension-induce organ damage117-119. 
Overactivity of the sympathetic nervous system (SNS) may be one of the contributing factors 
to the development of UAE and renal impairment120, 121 . 
Masuo et all122, in a 5 year follow-up study including nonobese normotensive patients with 
normal renal function, found a relationship between high levels of norepinephrine at the 
beginning of the follow up, the allele Gly16 of the Arg16Gly in the beta/adrenergic receptor 
type 2 gen (ADRBR2) and the decrease of  renal function over time. Polymorphisms of the 
ADRBR2 have also been related with left ventricular remodelling and its regression after 
hypertensive treatment 123. Among the three polymorphisms studied, Gly16Arg, Gln27Glu, and 
Thr164Ile, only the allele 27Glu of the Gln27Glu was associated with a larger cardiac size at 
baseline and with a better response to the enalapril treatment than those carrying the other 
allele Gln27123. Interestingly, the associated SNP was in strong linkage disequilibrium with 
Gly16Arg which has shown a relationship with renal impairment over time in nonobese 
normotensive patients122.  
Related to the adrenergic system is the gene which codifies adrenomedulin. Patients with 
cardiovascular disease may have an increase in their blood levels of adrenomedulin124, a 
hormone which is mainly secreted by endothelial cells and has important functions in the 
cardiovascular system including diuresis, vasodilatation, aldosterone inhibition and cardiac 
output regulation125-127.  Kobayashi Y et al128  analyzed several polymorphisms and haplotypes 
of the adrenomedulin gene in a Japanese hypertensive population. They were unable to find 
an association with HTN, but some haplotypes, including allele 19 for the number of repeats in 
Genetic bases of microalbuminuria and related traits in essential hypertension 
 
 27 
the microsatellite, the A allele of the SNP rs4399321 and the G allele of the SNP rs7944706128 
were associated with microalbuminuria128.  
 
3.4.1.4. Oxidative stress 
The endothelial nitric oxide synthase (eNOS) is another gene that studies have tried to 
associate with renal impairment and microalbuminuria in HTN. The results are conflicting. One 
of these studies, carried out in an Italian population with HTN, did not find an association 
between eNOS polymorphisms and either microalbuminuria or endothelial dysfunction129. 
Another study tried to relate two polymorphisms of the eNOS gene with ESRD of several 
etiologies. Although the study only included a small number of ESRD due to HTN, the tandem 
repeat polymorphism seems to influence the ESRD in non-diabetic subjects, whereas the 
Glu298Asp polymorphism could be related to ESRD of any etiology130. 
 
3.4.1.5. Kallikreins 
Genes which codify kallikreins can also be related to hypertension-induced renal damage. 
Urinary excretion of kallikreins may have a genetic component and have been previously 
associated with renal impairment and HTN131, 132. The tissular form of kallikrein depends on 
genes which are located in cytoband q13.3 of chromosome 9 whereas the plasmatic form is 
codified by genes on chromosome 4q34-35133, 134.  
Polymorphisms in the promoter region of the kallikrein 1 gene were studied in order to assess 
the possible association with ESRD in African-American subjects135  The allele 12G of the -
130(G)N polymorphism was associated with ESRD, but only in the subgroup of hypertensive 
patients135. There was no association in the group of diabetics nor was there when diabetics 
and hypertensives were compared jointly against the control group135. 
 
3.4.1.6. Other genes 
Another interesting gene is the non-muscle myosin heavy chain 9 gene (MYH9) which has 
been associated with segmental and focal glomerulosclerosis (FSGS)136, 137. It seems also to 
be associated with renal damage associated with hypertension, at least in African-American 
populations. Within the HyperGen study population, several SNPs of the MYH9 were 
associated with the albumin/creatinine ratio after adjusting for confounding factors, both in 
unrelated African-Americans, as well as within African-American families. In contrast, there 
was no association within European-American families138. Moreover, one polymorphism and 
one haplotype of this gene showed an stronger association with ESRD due to HTN than that 
for albumin/creatinine ratio 139. The fact that this gene is expressed in podocytes and involved 
in segmental or global glomerulosclerosis seems to give credit to its role as a candidate gene 
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for hypertension-related glomerulosclerosis. What is not clear is if the hypertension is due to 
the renal disease or vice versa.  
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3.4.2. Linkage studies  
Several linkage studies have been published to date. The HyperGen study found a heritability 
rate for the creatinine clearance of 0.17 and 0.18 in African-Americans and in Caucasian-American 
families of essential hypertension, respectively 140.  This study found a significant logarithmic of 
odds score (LOD) values on chromosome 3 (specially in African-American subjects (LOD=3.61, to 
214.6 centimorgans, 3q27) according to the scale of Lander and Kruglyak in an adjusted model 141. 
There are two candidate genes in this region of chromosome 3, the 3-hydroxyl-coA dehydrogenase 
gene and the apolipoprotein D gene.  The former can facilitate the accumulation of long chain fatty 
acid in the tubular cells of the kidney, and the second might produce atherosclerosis in renal 
vessels140. Using the albumin/creatinine ratio within the same HyperGen population, the previous 
results were not be replicated by Freedman et al142. In the Freedman study, the albumin/creatinine 
ratio heritability after adjusting for confounding factors was 0.49, and the susceptibility loci were 
located on chromosomes 12 and 19 (maximum LOD=2.40 , to 9cM on chromosome 19)142 . The 
low density lipoprotein (LDL) receptor gene is located in this chromosomal region (19p13). 
Therefore, those genes which are linked to atherosclerosis seem to play a role in the renal damage 
associated with HTN. This can be due to the endothelial damage and atherosclerosis of the small 
and large vessels142. 
It is noteworthy to mention some efforts to identify in humans the major loci related with 
albuminuria and renal failure in the Fawn Hooded Rats143. These genes, called Rf-1 and Rf-2, are 
located on chromosome 1 which corresponds to the human chromosome 10.  One linkage study in 
this chromosome found a significant linkage peak in 10p for the ESRD in African-Americans, but 
failed to find an association in the human homologue of Rf-1144. The same group, in 356 African-
American sib-pairs concordant for ESRD, including a large number of sib-pairs with hypertensive 
ESRD, found significant evidence for linkage for one marker close to the Rf-1 gene (LOD score 
3.4, p=0.0004)145. The association of ESRD with the marker D10S677 was present in the whole 
group, in type 2 diabetic ESRD and in the non-diabetic ESRD group145. The study was also able to 
replicate the previous linkage peak on chromosome 10p in the total sample and in the non-diabetic 
group, but not in the type 2 diabetic ESRD or the late onset ESRD145. The linkage peak in the long 
arm of chromosome 10 was also replicated in another study in 49 Utah Caucasian-Americans 
selected by premature cardiovascular disease146.  In this case the association was with creatinine 
clearance in three visits during 10 years of follow-up (LOD score for D10S677, 1.4 in the first 
visit)146. The best peak of association for creatinine clearance was in examination 3 (D10S2470, 
LOD score 2.09)146. Interestingly, this peak is close to the one found in examination 1 and in the 
previously described African-Americans145, 146.  The heritability for creatinine clearance increased 
from 0.33 in the first to 0.53 in the third examination. They also found a heritability of 0.20 for the 
change in creatinine clearance between the first two visits and 0.40 for the change in creatinine 
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clearance between the first and the last measurement146.  These studies suggest that there is a 
susceptibility loci for renal failure on chromosome 10 at least in hypertensives with RI 144-146.  These 
loci, however, seem to be different in regards to the etiology of renal failure. 
In the general population, one linkage study within the Framingham Heart Study suggests a high 
heritability component for serum creatinine, glomerular filtrate rate (GFR) and creatinine clearance 
(0.29, 0.33 and 0.46 for each phenotype, respectively)147 . The association loci for these traits were 
located in different chromosomes: 3q,4q and 11p (maximum LOD=2.28 , 176 cM in the long arm of 
chromosome 4 for serum creatinine)147 . Within the associated chromosomal regions, there are 
several candidate genes, such as: activated factor for the TNF receptor gene, interleukin 8 gene 
(IL-8), albumin gene and vascular endothelial growth factor (VEGF) gene147 . The authors 
hypothesize that the interaction between those genes would produce glomeruli inflammation and 
renal damage147.  In a later work with the same population of Framingham, the heritability for 
microalbuminuria was 0.16 and a suggestive LOD score for the association was found on 
chromosome 8 (LOD=2.22 , to 135 cM)148. This result was replicated in a subanalysis in 
hypertensive families148. The hialuron synthase gene falls in that region of chromosome 8. This 
gene is expressed in the tubular cells of the kidney and has been related with acute and chronic 
renal cortex scarring149.  
The Strong Heart Family Study150 included a large cohort of American-Indian individuals enriched 
by cardiovascular risk factors. Within this cohort, a linkage study for GFR revealed a significant 
QTL on chromosome 12p (LOD 3.5 and 4.6 after removing those individuals after hypertensive 
therapy)150. Interestingly, a similar peak on chromosome 12 had been previously described in 
African-American type 2 diabetics151. Although not the objective of the study, the authors also 
analyzed the linkage for ACR, finding no evidence for linkage. It is noteworthy that within that 
region there lies a possible candidate gene which codifies the glomerular epithelial protein 1 
(GLEPP1)152. 
 
A resume of the main linkage studies for renal traits in essential hypertension is shown in table 3.2 
(I,II).
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3.4.3. Whole genome association studies and combined strategies  
Urinary albumin excretion in hypertension was assessed within the British Genetics of 
Hypertension (BRIGHT) study153. EUA was measured in 24-hour urine samples.  More than a half 
million of SNPs were evaluated in order to assess the association with blood and urine biomarkers. 
Between them, two SNPs, on chromosomes 3 and 12, showed an association with urine albumin, 
but none of them was selected for replication in others populations153. 
In general populations, there is one example of a family-based association study within the 
“NHLBI´s Framingham Heart Study”. The authors assessed several markers of the renal function, 
including UAE. Two statistical analyses, the family-based association test (FBAT) and the 
generalized estimating equations (GEE), were performed to evaluate the strength of the 
association with the traits154.  Several SNPs in different chromosomes were associated with 
UAE154.  One of the associated SNPs, rs2113379, is located in an intronic region within the 
ADAM23 which belongs to the metalloprotease gene family. They also identified another possible 
candidate gene, PCDH9, which belongs to the cadherin gene family154. The main weakness of this 
study, due to the variability and circadian pattern of the UAE, was that it used an isolated urine 
sample instead of 24-hour urine sample to determine it154.  An attempt was made to replicate the 
SNPs most associated with renal damage, within the participants of the Atherosclerosis in 
Communities study (ARIC study)155. Unfortunately none of the SNPs associated with the UAE were 
selected for replication. In this study, one intronic SNP within the methenyltetrahydrofolate 
synthetase (MTHFS) seems to be associated with CKD, and the allele C seems to increase the 
risk of kidney disease progression in Caucasian-Americans, but not in an African-American 
population155. Again these results must be cautiously considered because the replication was only 
for CKD, but not for the estimated GFR or serum cystatin C and in only one of the successive 
visits. 
As an example of combined strategies, there is one running Italian study which is evaluating the 
genetic influence in the response to losartan treatment in a cohort of untreated hypertensive 
patients156. Several variants in different genes previously described are being evaluated, including 
genes of the RAAS, adrenergic system, kinin-kallikrein, sodium handling and drug metabolism. 
Half of the population is also being used to perform a GWAS, with more then 1 million SNPs. 
Although it is not the main objective of the study, the genetic association with intermediate 
phenotypes will be tested. Among the intermediate phenotypes to be analyzed is microalbuminuria 
based on several 24-hour urine collections during follow up. Perhaps this study can discover new 
variants in different genes or clarify the role of the previously described variants. 
 
A resume of the main genome wide association studies for renal traits in essential hypertension is 
shown in table 3.3.
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3.4.4. Summary of genetics of microalbuminuria in HTN and general population 
Despite the great efforts that have been made in the field, knowledge about the major genetic 
variants causing the susceptibility to develop renal damage in HTN is scarce.  
In general, candidate gene strategy has led to conflicting results. Although there are associations 
with some variants which have been replicated, the majority was not or showed an association only 
in certain subgroups of patients. The RAAS system is probably the principal system involved not 
only in the HTN-induced renal damage association, but also in the risk for HTN itself. One should 
take into account, however, that this system is the most studied one, and that there is a bias to 
publish only positive results. The bias for positive results and the heterogeneity of the different 
studies, put in doubt the results of the meta-analysis. The greatest degree of evidence is for the D 
allele of the I/D  polymorphism in the ECA gene. This allele has been related to the blood levels of 
ECA157 which increases the possibility of a functional role for this variant.  Although there are some 
conflicting results, cross-sectional and follow-up studies give credit to its role as a susceptible 
variant for several renal traits in HTN. Supporting the potential role of the D allele in renal damage 
are the results obtained in type 1 diabetes. A large case control study in three different European 
type 1 diabetic populations demonstrated that the D allele alone or in haplotypes with others was 
associated with the risk to develop albuminuria158.  The evidence for other variants of the RAAS  is 
less clear, although there are several studies which support the interaction between different 
genetic variants on the system101, 106.   
The appearance of new candidate genes, such as the non-muscle myosin heavy chain 9 gene 
(MYH9) is remarkable. This gene is a strong candidate gene for renal failure associated with 
hypertension in the African-American population138, 139. We still do not know what the exact 
contribution of these genes to the renal damage is nor if their influence varies among populations.   
Linkage studies have given credit to some of the previously described candidate genes and have 
also identified others. The high heritability for different renal traits in this kind of study supports the 
potential role of genetic factors in interaction with environmental factors142, 147, 148. This heritability 
seems to be higher for the quantitative trait albumin/creatinine ratio than the heritability for 
qualitative microalbuminuria142, 148.  
Some of the linkage peaks deserve special attention. For example, the linkage peak on 
chromosome 3q for creatinine clearance which was found in both African-Americans within the 
HyperGen study  as well as in Caucasian-Americans of European descent within the Framingham 
Heart study140, 147 contains several interesting genes such as Hydroxyl-CoA-dehydrogenase and 
apolipoprotein D gene. Another linkage peak for GFR on chromosome 12p, which was found in 
both Native Americans within the Strong Heart family Study, as well as in African-American type 2 
diabetics150, 151, contains the gene protein tyrosine phosphatase receptor type O (PTPR0), a gene 
which codifies an epithelial protein expressed in the glomeruli152. Likewise, the human homologue 
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region for the Rf-1 gene in rats on chromosome 10, is another potential loci for renal failure in 
hypertension according to several linkage studies144-146. It is noteworthy that some of the linkage 
peaks contain genes of lipid metabolism140, 142 which are thought to be related to the development 
of atherosclerosis accelerated by HTN 142. 
The genome wide association studies (GWAS)  have also helped to identify new candidate genes, 
such as the metalloprotease, ADAM23, and the methenyltetrahydrofolate synthetase (MTHFS) 
gene154, 155. The association of variants in MTHFS with CKD was replicated, although with certain 
limitations and, therefore, further studies are needed to assess its possible role. 
Over the next few years, there will probably be an increasing number of GWAS related to 
microalbuminuria in hypertension.  As far as we know, no large studies of this class have been 
made with microalbuminuria as the main endpoint.  
In summary, the genetic studies for albumin excretion and renal damage have identified several 
variants in candidate genes and different regions of the genome which may influence the 
appearance of HTN-induced organ damage. These results have to be taken into cautious 
consideration because most of them have not been clearly replicated or the results have been 
controversial. Well-designed, large-scale future GWAS and replication studies with large cohorts 
can help to clarify the genetic bases of renal damage in HTN.   
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3.5. Genetic bases of microalbuminuria and related traits in type 1 and type 2 
diabetes 
 
3.5.1. Overview 
Microalbuminuria also increases both morbidity and mortality in type 1 and type 2 diabetes 3-11, 
159
. For this reason it is also important to know which factors lead to its development in diabetic 
patients. It is clear that the grade of glycemic control and the time of evolution of the disease are 
between the main factors for the development of microalbuminuria in DM160, 161. These factors 
usually coexist with high blood pressure levels and insulin resistance which have been related with 
renal damage especially in non diabetics subjects36-39 . In contrast to retinopathy which appears in 
almost all the subjects with more than 20 years of evolution of DM, renal damage only appears in a 
third of patients 162-167. That’s means that there must be another factors, mainly genetics, which 
contribute to the development of renal damage in type 1 and type 2 diabetes165.  This genetic 
susceptibility, in combination with the other factors, may ease the development of microalbuminuria 
and renal damage in diabetic patients. Although the genetics of microalbuminuria in DM have been 
widely explored in the last few years, the information in the majority of the cases is confusing.  
Epidemiological and family studies strongly support the genetic contribution for microalbuminuria 
and renal damage in DM. In this way, it has been demonstrated that relatives of patients with DM2 
are prone to develop microalbuminuria even if they were not diabetics themselves and this 
microalbuminuria can finally drive to the end stage renal disease (ESRD)76, 77.  Also the ESRD itself 
have a strong family clustering in diabetes and HTN77, 83. The genetic susceptibility for 
microalbuminuria is also supported by the high heritability for the ACR, ranging from 0.30 to 0.44, 
in families enriched for subjects with type 2 diabetes77, 168-170, and also for the differences in renal 
disease between ethnics171. For example, Afro-Americans or Hispano-Americans78-80 are prone to 
develop albuminuria and renal disease. It seems that the differences between ethnics are more 
due to different genetic backgrounds than related to environmental factors such as different 
lifestyle or inequalities in the availability of the treatments 81. 
Although genetic factors play an important role for the development of renal damage in DM, what 
are the main genomic variants involved it is not as clear. The next pages resume some of the 
studies which have tried to unravel the genetic susceptibility variants for diabetes associated 
nephropathy. 
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3.5.2. Candidate gene studies 
Some of the systems or physiological pathways which have been investigated are: renin-
angiotensin-aldosterone system (RAAS), fibrinolysis, oxidative stress, lipid metabolism, growth 
factors and glucose metabolism.  
A resume of some of the candidate gene studies for renal traits in type 1 and type 2 diabetes is 
shown in table 3.4 (I-IV).    
 
3.5.2.1. RAAS genes 
The I/D  polymorphism has been widely explored in diabetes patients. Although there are some 
positive studies for the association of the D allele with DN, not all the studies support this 
association172, 173 . Besides the meta-analysis174, 175  to analyze the relationship of this 
polymorphism of ACE with diabetes nephropathy are inconclusive due to the heterogeneity of the 
studies. However, one large case control study in three different European populations has given 
credit to the role of the D allele, alone or in haplotypes with others alleles, in the development of 
albuminuria in type 1 diabetes158. Another study in this case in type 2 diabetes with advanced 
nephropathy failed to find positive association with individual variants of ACE gene but not with 
haplotypes176. 
The TT genotype of the polymorphism p.M235T, in the AGT gene,  as well, have been related to 
the risk of diabetic nephropathy individually or in association with other polymorphisms in the 
RAAS system genes177-179. One consideration to take into account is that this association seems to 
be strongly influenced by gender177-179.  
 
3.5.2.2. Fibrinolysis   
The activated plasminogen inhibitor (PAI-1) because of its functions in the intravascular 
fibrinolysis, tissue healing and remodelling, might also be involved in the glomerular lesions180. One 
common single-base-pair guanine I/D  polymorphism in the promoter region of the PAI-1 gen (PAI-
1 4G/5G I/D) could regulate the blood levels of PAI-1181, 182. One study carried on Caucasian 
population aimed to detect association between this PAI polymorphism and renal impairment in 
type 1 diabetics180. None differences in genotypes were found between people with or without 
renal damage180 .  However subjects with microalbuminuria had a trend to present higher blood 
PAI-1 levels than those without it180.   Similar non conclusive results were obtained in an Austrian 
population of subjects with type 2 diabetes regarding to the UAE183. Nevertheless this study found 
a positive association with proliferative diabetic retinopathy183. Genotype 4G/4G might be more 
frequent in subjects with albuminuria although that was only a trend without statistical 
significance183 . 
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3.5.2.3. Oxidative stress 
The p. V16A polymorphism in the Manganese Superoxide dismutase gene (MnSOD) has been 
widely explored in diabetes. This polymorphism was associated with different stages of UAE in a 
Korean population of subjects with type 2 diabetes184.  The A allele seems to be protective against 
the development of microalbuminuria184. The endothelial nitric oxide synthase (eNOS) gene has 
been also associated with renal impairment and microalbuminuria in diabetics. Both the allele C of 
the 786 T>C polymorphism and the deletion allele of the I/D  polymorphism of eNOS, increase the 
risk of advanced DN in Caucasian subjects with type 1 diabetes185.  Mainly in Asian diabetic 
populations, other polymorphisms of this gene such as tamden repeats and the missense mutation 
(p. Glu298Asp) in exon 7, were related to the risk of ESRD130. There is not agreement for the 
association between all the studies. For example, in a British population of type 1 diabetics, Rippin 
et all186 were not able to find association with nephropathy.  
Other genes implicated are the paraoxonase 1(PON-1) and 2(PON-2) which codify enzymes 
involved in the protection against the oxidative stress. Unsurprisingly, several of the studied 
polymorphisms (p.Gln192Arg in PON1, p.Ala148Gly and Cys311Ser in PON2) did not show 
association with nephropathy in a Russian population of type 1 diabetics187. 
 
3.5.2.4. Lipid metabolism  
It is noteworthy that the previous authors187, who failed to find association with oxidative stress 
genes, in the same population of type 1 diabetics, did find association with polymorphisms in 
another kind of genes belonging to the lipid metabolism. Special attention deserves the allele 
epsilon 2 of one multiallelic polymorphism which codifies three isoforms (epsilon 2/epsilon 
3/epsilon 4) in the Apolipoprotein E (apo-E) gene. This isoform, ε2, has been related with DN in 
several papers188-192. Besides this polymorphism showed to be independently associated with 
microalbuminuria in both type 1 and type 2 diabetics193. However this result is not supported by all 
the studies. One Russian study found relationship between the allele ε3 and the risk of DN and 
albuminuria (≥300 mg/day)194 . In this study other allele, D, of the I/D  polymorphism in 
Apolipoprotein B (apo-B) gene showed to be protective against the presence of DN and 
albuminuria194.   One case-control study in Chinese population of type 1 diabetics did not find 
association between the S447X in the Lipoprotein Lipase (LPL) gene, the 455T>C SNP in the 
apoC3 gene and the ε2,ε3, and ε4 isoforms in the ApoE and the risk of DN, individually195. 
Nevertheless some combination of genotypes for the previous SNPs may have a protective role 
against DN195 .  
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3.5.2.5. Growth factors  
Between them, transforming growth factor beta (TGF-β) gene is one of the most important 
ones because of its profibrogenic properties. This gene is involved in the regeneration of the tissue 
and fibrosis which occurs after an injury in several organs including the kidney196. 
Animal models of DN showed an increase in the messenger ribonucleic acid (RNA) TGF- β1 in the 
glomeruli, tubule, and interstitium197. Also in animals there is an upregulation in TGF- β receptors in 
those with glomerulosclerosis198, 199. Taking into account these facts, several polymorphisms in this 
gene TGF- β or in the receptors genes (TGFβR1 and TGFβR2) tried to be linked with DN and 
microalbuminuria with inconclusive results. Patel et all200 found a significant association between 
the Leu10 allele of the SNP p.Leu10Pro (rs1982073) of the TGF-β1 gene and the risk of DN. 
Interestingly this study included a large number of subjects with micro or macroalbuminuria 
(35.7%)200. However not all the studies support this association201, 202. 
 
3.5.2.6. Glucose metabolism 
One of these genes codify the aldolase reductase (ADLR1) which is the key enzyme in the 
poliols pathway that reduces the nicotiamide-adenin dinucleotide phosphate (NADPH) depends on 
glucose to sorbitol203. It is remarkable that this way is only activated in presence of hyperglucemia 
203
. Two are the main factors contributing to the organ damage associated with hyperglucemia: the 
accumulation of sorbitol due to its osmotic effects and the decrease in the NADPH levels affecting 
the oxidative-reduction status of the cell203, 204 . Neamat’Allah et all205, in several populations of type 
1 and type 2 diabetics, found an association between the allele T of the 106C>T SNP and 
nephropathy in 3 out of the 4 studied populations. These authors also made a meta-analysis for 
another previously associated polymorphism  in a microsatellite sequence ((CA) n)206, 207. This 
meta-analysis showed no association in type 2 diabetics whereas in type 1 diabetics the 
association is doubtful 205.  Another gene involve in the glucose metabolism codify the receptor of 
advanced glycation end products “RAGE”.  The glycation products are responsible for many 
adverse effects including the vascular damage208. It has been demonstrated in animal models that 
by blocking the receptor for the glycation products we can prevent the development of 
atherosclerosis209, 210. Moreover there is an over-expression of the receptor in animals with 
vascular disease211. Two polymorphism in the promoter (-429T>C, and -374T>A) and one 
missense mutation (p.Gly82Ser) have been the most studied ones.  The relationship between 
these polymorphisms and renal damage was investigated in a Finnish population with type 1 
diabetics212. The prevalence of microalbuminuria was significant less for the genotype AA of the -
374T>A polymorphism but only in the group with poor glycemic control (HbA1c > 9.5)212. The 
authors of this study suggest an interaction between the genetic variants and the environmental 
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factors212. Several variants in different “RAGE” genes were evaluated in Caucasians type 1 
diabetics subjects213 but none of them were clearly associated (only one variant, C-1152A, showed 
a weak association)213.  
The ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) gene has been associated 
with insulin resistance and it is expressed in the kidney tubules 214, 215, therefore is a strong 
candidate gene for DN. This gene was related with DN in type 1 and type 2 diabetes, but it is not 
clear if this association is due to the diabetes status itself or to the presence of DN216-218. In favour 
of the association with DN, a recently published large collaborative study in type 2 diabetes, 
showed association between the allele 121Q of the K121Q polymorphism of the ENPP1 gene and 
a decrease in the GFR at least in two of the three studied populations and in the whole sample219.
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3.5.3. Linkage studies  
Urine albumin: Krolewski et al170 studying families with multiple relatives enriched for type 2 
diabetes and most of them of Caucasian origin, found an heritability rate for the ACR running from 
0.20 in the whole family to 0.39 in the group of relatives without diabetes170.  Three quantitative trait 
loci were identified: One peak placed 36 cM in the long arm of chromosome 22, another peak to 69 
cM in the q arm of chromosome 5 and the last peak to 169 cM in the q arm of chromosome 7170. 
Besides another additional peak was found in the p arm of chromosome 21 but only in the diabetic 
subgroup170. Maximum LOD score of 3.7 corresponded to the 22q loci170 . Only in the 7q loci there 
was a strong candidate gene, the eNOS gene, that was previously associated with the risk of 
nephropathy by the same and another different research groups170, 185, 220. 
       eGFR: In a Mexican-American population including diabetics and no diabetics patients and 
near 20% of hypertensives, Puppala et al221 found a high heritability for the GFR estimated by 
Cockcroft-Gault or by Modification of Diet in Renal disease (MDRD) formula (0.40 and 0.36, 
respectively).  They found suggestive association for eGFR by standard linkage analysis on 
chromosome 9q and another significant peak on chromosome 2q37.1 (LOD score 3.3) but only 
when using a genotype x diabetes interaction model221. These results reinforce the hypothesis of 
the genetic and environmental factors interaction. 
The same group of Krowleski and colleagues222 also studied the linkage with eGFR in 63 families 
with type 2 diabetes , the majority of them of European-American origin. They found a high 
heritability for the estimated GFR by different formulas (Cystatin C, MDRD, Cockcroft-Gault) 
especially in the group of diabetic subjects222. They found different linkage peaks than that 
observed for UAE. Maximum LOD score was found on chromosome 2q in diabetic relatives pairs 
(LOD score of 4.1) and 7p (LOD score 4.0) in all relatives pairs222. Additionally, another two linkage 
peaks, 10q, 18p, showed suggestive association in diabetic relatives pairs and other two, 3q and 
11p, in nondiabetic relative pairs222. Within the 7p region lies the interleukine-6 gene and the 
neuropeptide Y (hNPY) which are known candidate genes for DN. The region 2q and 10q did not 
contain any candidate gene.  
Taking into account these two studies, there might be an interaction between  the diabetic 
environment and the presence of DN221, 222. It is not clear if the peak on chromosome 2q detected 
in both studies correspond to the same QTL for eGFR, although the two LOD score peaks are 
separated by 23 cM. 
       Diabetes nephropathy: As I mentioned before, it is important to remark the criteria to 
considerer DN in order to compare different studies as well the study population. The majority of 
the studies considerer as DN those subjects with both albuminuria-proteinuria and with ESRD.  
In the study of Imperatori et al84 using the albumin creatinine ratio (ACR) to define DN in type 2 
diabetics Pima Indians, association peaks were found on chromosomes 7q, 3q, 9q and 20q. The 
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7q linkage peak contains a strong candidate gene, eNOS, and has been replicated latterly by 
another authors170. 
One of the most robust results were found in one linkage study for DN in type 2 diabetes 
performed in 18 Turkish families223. Cases included subjects with either proteinuria and ESRD223. A 
significant peak (LOD score 6.1) placed on chromosome 18q22.2-23223 . Interestingly when they 
included patients with microalbuminuria as cases the magnitude of association increases from a 
LOD score of 6.1 to 6.6223. Moreover the authors were able to confirm the results in the previous 
described Pima Indian cohort84, 224 although the association on chromosome 18 was not present in 
the initial analysis. Within this linkage peak lies the Carnosine Dipeptidase 1 gene (CNDP1) which 
has been associated with DN in several populations225. Moreover one variant of this gene seems to 
be of protection against DN225, 226. In contrast, one large case-control and follow-up study, trying to 
replicate the findings in Caucasians type 1 diabetics, did not find relationship between 
polymorphism of the CNDP1 gene and different stages of DN227. 
Another linkage study in an Afro-American population with type 2 diabetes only find modest 
association even after performed a multi-locus linkage analysis151. The highest LOD score belong 
to the 7p (LOD 1.43) for the single locus analysis and 16p for the multi-locus analysis (LOD 1.63). 
After performed an ordered subsets analysis (OSA) by age at diagnosis of ESRD, age at diagnosis 
of diabetes and duration of diabetes several peaks on chromosomes 3q, 7p and 18q increased the 
LOD score values and had a significant LOD score higher than 3151.  Some of the associations are 
in concordance with other previous linkage studies84, 223, 228. Within the 3q peak is the ATR1 gene 
which is a strong candidate gene for DN, but it seemed not to be the responsible of the 3q linkage 
peak according to one study in Caucasian families with type 1 diabetes228. Adiponectin is another 
interesting candidate gene including in that linkage peak. One large study in African-American with 
type 2 diabetes including 851 with DN and 871 controls, found a significant association between 
the SNP rs182052 in intron1 of the Adiponectin gene and type 2 diabetes and also with DN229. 
They did not detect association with the polymorphism in the promoter region described by Vionnet 
and colleagues230.  
Using 100 discordant sib-pairs (DSP)231 from 83 families , Rogus et al232 found a linkage peak not 
previously described on chromosome 19q (maximum likelihood score (MLS), 3.1) and another 
peak (MLS, 2.1) on chromosome 2q that overlapped one of the linkage peak for UAE found within 
the FIND study233. When considering separately proteinuria and ESRD, they found another four 
linkage peaks (1q (MLS=1.8), 20p (MLS=2.8), 3q (MLS=1.5 for proteinuria and MLS=1.1 for 
ESRD)233. These finding suggest that some of the susceptibility loci for UAE can be different than 
those for ESRD233. 
A resume of some of the main linkage studies for renal traits in type 1 and type 2 diabetes mellitus 
is shown in table 3.5 (I-VI).
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3.5.4. Whole genome association studies and combined strategies  
The genetics of kidney in Diabetes (GoKind) study is a large study using different strategies in 
order to unravel the genetic of nephropathy in type 1 diabetes234. Within this project are included 
several study design based on case-control and family trios234. Cases include patients with 
macroalbuminuria, proteinuria or ESRD and the controls are all normoalbuminurics after more than 
10 years of follow up234. One first genome wide scan with a low density panel of markers did not 
reveal associated SNPs after correcting for multiple testing. Two of the most associated SNPs 
were located in the pleckstrin homology domain containing, family H (PLEKHH2) gene which is 
expressed in the podocytes of the glomeruli and therefore is an interesting candidate gene. Using 
Tag-SNPs and the same GoKind cohort235, several SNPs in the PLEKHH2 were analyzed235. 
Between all the selected SNPs, the allele T of one SNP in the promoter region (rs11886047) 
showed association with DN by transmission disequilibrium test (TDT)235. The fact that there were 
a higher frequency of heterozygotes CT in cases than in controls seems to reinforce the results235. 
1177 type 1 diabetes from this GoKind population and 850 African-American  with type 2 diabetes 
were used to assess the association of a new candidate gene, the transient receptor potential 
cation channel subfamily C, member 1 (TRPC1), identify in one of the linkage peak (3q22-24) in 
both type 1 and type 2 diabetes236. There were not association between SNPs of the TRPC1 gene 
and DN, but the expression of this gene seems to be reduced in animals with DN236. The authors 
suggest that the alterations in the TRPC1 expression can be a late phenomenon in DN236. 
Ewens et al237 evaluated the association of variants in 115 candidate genes with DN by TDT in  72 
families with type 1 diabetes of European ancestry. They found association with genes involve in 
the kidney function such as AGTR1, Aquaporin1 (AQP1), LPL, genes coding extra-cellular matrix 
components, transcription factors and growth factors237.  Probably many of the association are 
false positive because of the lack of power of the study. The most associated SNPs were within the 
B-cell leukaemia/lymphoma 2 (bcl-2) gene (p-value=0.001) and within the Collagen type 4 Alpha 1 
(COL4A1) gene (p-value=0.0002)237. The former gene lies close to a region identify by linkage 
studies223 and the second one was previously associated to DN with contradictories results238, 239. 
Regarding the type 2 diabetes, the Family Investigation of Nephropathy in Diabetes (FIND)240 study 
is another multicenter study which is using different strategies to discover susceptibility variants for 
DN in type 1 and type 2 diabetes. Four ethnics groups are included: European-American, African-
American, Mexican-American, and American-Indian. Three are the main used strategies: genome 
wide linkage study241, mapping by admixture linkage disequilibrium (MALD)242 and test to detect 
the association between alleles and disease within the population. Cases also includes subjects 
with macroalbuminuria, proteinuria or ESRD240. One initial linkage study within these populations 
revealed four linkage peaks for DN: 7q21.3, 10p15.3, 14q23.1, 18q22.3 after pooling all the p-
values in the four populations by Fisher´s method233. The linkage peaks on chromosome 7q is 
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mainly due to the African-American subpopulation, the 10p and 14q are mainly due to the 
American-Indian and the 18q peak mainly due to the European-American subpopulation233. The 
quantitative trait linkage analysis for ACR showed a linkage peak in 2q14.1 in American-Indian, 
7q21.1 in European-American and 15q26.3 in African-American families233.   The linkage study for 
eGFR as a quantitative trait by the MDRD equation, revealed several suggestive peaks, using 
multipoint IBD, on chromosomes 1q43, 7q36.1, 8q13.3, 11p15.1, 18q13-21, and 20p12.2,  after 
adjusted by diabetes duration and ACE inhibitor/ARB use. In the Mexican-American cohort which 
compromises the majority of the families, the 8q and 18q peaks reached the Langer-Kruglyak141 
significance for linkage 243. 
A GWAS with around 100000 SNPs was performed in Japanese population with type 2 diabetes244. 
The study included 94 type 2 diabetic cases with DN and retinopathy and 94 controls with 
retinopathy but without nephropathy.  A great number of loci were identified and were selected for 
further evaluation in a large number of subjects245. There was a strong association between DN 
and SNPs in the following genes: Solute carrier family 12, member 3 (SLC12A3), Engulfment and 
cell motility 1 (ELMO1) and neurocalcin D (NCALD). Although the authors performed several in 
vitro studies246-248 to asses the role of these gene in the pathogenesis of DN, the mechanisms for 
renal damage associated with variants in these genes is unknown.  
As I said before, the most associated SNPs (p-value <0.01) were selected to be replicated in a 
larger sample that the previous one including 466 cases and 266 controls246. One SNP within an 
intronic region of the ELMO1 gene was associated with DN in that Japanese population246. To 
asses the role of that gene in the development of DN, they study the gene expression in normal 
and diabetic mice246. That expression was mainly observed in glomerular and tubular epithelial 
cells and was increased in the kidney of diabetic mice246. They also demonstrated high mRNA 
gene expression in cell cultures under high glucose conditions and an increase on the expression 
of extracellular matrix protein genes such as TGF-β1 in cells overexpressing ELMO1246. 
Hanson et al249 in a pooling based genome wide scan250, 251 for ESRD in type 2 diabetes Pima-
Indian found association with markers in 8q24.21249. This region contains the plasmocytoma 
variant translocation gene (PVT1) a new candidate gene for DN. This gene is highly expressed in 
the kidney252 and could easy the proliferation of the mesangial cells which usually occurs in the 
DN. 
A resume of the great scale candidate gene study of Ewens et al237 and some of the main genome 
wide association studies for renal traits in type 1 and type 2 diabetes is shown in table 3.6 (I,II,III).
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3.5.5. Summary of genetics of microalbuminuria in diabetes mellitus 
Familial aggregation, epidemiological and animal studies support the genetic contribution for 
kidney damage in type 1 and type 2 diabetes76, 77, 83, 85, 86.  
As I said in the case of hypertensive nephropathy, great efforts have been made in this field but we 
still are far away to know which major genetic variants are causing the susceptibility to develop 
nephropathy in diabetes.  
In general, candidate gene strategy has given contradictory information. Although there are some 
variants which have been replicated, the majority of them were not or only showed association in 
certain subgroup of patients selected by intrinsic or extrinsic factors.  Between the different 
physiological pathways that have been explored, the RAAS system as in the case of HTN, is 
probably involved. We can not forget that this system has been largely studied and that there is a 
bias to publish only positive results. These bias for positive results and the difficulties to compare 
different studies, make doubtful the results of the two meta-analysis for the I/D  polymorphism in 
ECA gene174, 175. The D allele of this polymorphism has been related with the blood levels of 
ECA157 what increase the possibility of a functional role for this variant.  Although the meta-analysis 
are not concluding, one large case control study in three different European type 1 diabetic 
populations has given credit to the role of the D allele, alone or in haplotypes with others alleles, in 
the development of albuminuria  158.  The evidence for other variants of the RAAS genes is less 
clear although there are several papers which support the interaction between different variants of 
this system176-179. 
Linkage studies have given credit to some of the previously described candidate genes and have 
also identified some others genes. The high heritability for ACR in this kind of studies suggest an 
interaction between genetic and environmental factors77, 168-170.  
Some of the linkage peaks deserve special attention because their replication in different studies 
and their association with different renal traits. This is the case of the chromosomal region 3q. This 
region has been associated with DN especially in Caucasian type 1 diabetes228, 237, 253.  In type 2 
diabetes there has been association with DN defined by ACR in Pima Indian84 and with eGFR in 
African-American 151. Initially it was though that the AGTR1 gene was the responsible for this 
peak84 , but ulterior studies have rule out this hypothesis228. It seems that the adiponectin gene 
may be the responsible for this peak according to the study of Vionnet N  et al230.  Adiponectin is 
though to be involved in the atherosclerosis process and therefore in the glomerular damage. This 
adipocytokine can blocked several mechanism involve in the atherogenesis254. It is supposed to 
reduce the adhesion of molecules to endothelial cells, the oxidative stress by stimulation of eNOS 
and the vascular smooth cells proliferation255.  Also in 3q is the TRCP1, but this gene seems not to 
be involved at least in the initial phases of DN236. 
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Chromosome 7 also has been repeatedly associated with DN especially in type 2 diabetes. The 
region 7q was associated with DN in type 2 diabetic Pima-Indian84 and with DN and GFR, 
especially in Mexican-American, within the FIND study233, 243. The fact that this chromosomal 
region contains interesting candidate genes reinforces its possible role in the pathogenesis of DN 
at least in type 2 diabetes. Within these genes are the ALDR1 and eNOS which have shown 
association with nephropathy in candidate genes studies130, 185, 186, 205. The short arm of 
chromosome 7 have also been linked with eGFR in Caucasian type 2 diabetics222 and with ESRD 
in African-American type 2 diabetes151. Within the genes which can be responsible for these peaks 
are the Il-6 and neuropeptide Y (hNPY)256, 257. Also in 7p lies the ELMO1 gene which were linked 
with DN in Japanese with type 2 diabetes according to the GWAS performed by Shimazaki A and 
colleagues246.  Their posterior functional analysis seemed to confirm that results246. Probably, the 
most strong association for DN correspond to the 18q locus if we take into account the Lander and 
Kruglyak scale141. This locus was firstly described in Turkish families with  type 2 diabetes223 and 
replicated in Pima-Indian also with DM284, 224. A similar peak was found for the association with 
both DN in different populations mainly European-American and with eGFR in Mexican-American 
within the Find study233, 240.  CNDP1 gene which codifies the enzyme carnosinase could be the 
responsible for this linkage peak225, 226. This enzyme degrades the dipeptide carnosine which can 
act as an ACR inhibitor258, 259, natural reactive oxygen species scavenger260 and advanced 
glycation end products (AGEs) breaker, therefore can protect the kidney in diabetic subjects. 
Although it is a plausible candidate gene at least in type 2 diabetes, a recently published paper in 
type 1 diabetes failed to find association between this gene and nephropathy227.  
The GWAS have also been useful to discover new potential genes associated with DN. Between 
these genes are the PLEKHH2234, 235. The protein coding by this gene has been demonstrated to 
be expressed  in the glomerular podocytes261 and therefore it constitutes an interesting research 
pathway to follow.  
Another three interesting genes such as ELMO1, SLC12A3, NCALD, and PVT1 have been identify 
in Japanese population and Pima-Indian with type 2 diabetes244-246, 249. These genes could be 
involved in the mesangial proliferation and fibrosis associated with DN247  Further in vitro and 
replication studies could clarify in the future if they are or not susceptibility genes for DN.  
In this last part I have tried to make a brief summary of some of the most important papers 
published in this field in diabetes. In spite of the research which has been made what are the 
variants and genes mainly implicate in the susceptibility for DN is not clearly defined.   
As I said before, probably well design multicenter studies using different strategies in very large 
populations can help to clarify the current information in this topic.
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4. HYPOTHESIS AND OBJECTIVES 
 
4.1. Hypothesis 
Some evidences exist about the heritability of renal dysfunction independent in part of the 
traditional risk factors involved in the production of renal damage, high blood pressure and 
abnormalities of the glucose metabolism among others. The most used surrogate marker for renal 
dysfunction is the increment in urinary albumin excretion. Mainly candidate gene and linkage 
analysis has been used to identify the potential genetic factors associated with the urinary albumin 
excretion with variable success.  
 
Our hypothesis is that if there is a genetic basis for increment of urinary albumin excretion in 
essential hypertension subjects, the genome wide association strategy, by means of high-density 
microarrays with hundreds of thousands SNPs, can help us to know what regions are involved and 
what candidate genes fall in those regions. 
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4.2. Objectives 
 
4.2.1. Primary 
• Identify significantly different genotype or allele frequencies between hypertensives with or 
without persistent microalbuminuria by means of a dense panel of SNPs all across the 
genome. 
• Identify in the whole genome possible quantitative trait loci for UAE. 
 
4.2.2. Secondary 
• Identify haplotypes of risk of microalbuminuria in the associated regions. 
• Identify which haplotypes can act as a QTL for UAE. 
• Identify candidate genes for albuminuria and microalbuminuria in HTN within the associated 
chromosomal regions.  
• Assemble our results with those previously published in the literature to construct a SNPs 
panel for assessment the risk to develop an increment in urinary albumin excretion. 
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5. METHODOLOGY 
5.1. Study design 
The study design is a nested case-control study. Both cases and controls belong to a 
hypertensive cohort which was previously used to identify what clinical factors influence the 
development of microalbuminuria in HTN in a prospective way18. The patient recruitment was made 
between the years 1988 and 2000 in the hypertension unit of two hospitals: Clinical Hospital of 
Valencia and the Sagunto’s hospital. 
 
5.1.1. Inclusion criteria 
The inclusion criteria at the beginning of the follow-up were:   
1. Caucasian race 
2. Age within 25 and 50 years old 
3. Blood pressure levels within the normal-high or grade 1 hypertension according to the 
European societies of hypertension and cardiology. This is a systolic blood pressure (SBP) 
within the range 130-159 mmHg and diastolic blood pressure (DBP) within the range 85-99 
mmHg in at least three visits which were spaced by one month among them and after ruling 
out secondary hypertension. 
4. Normal urinary albumin excretion (UAE) (< 15 mg/day)  
5. Never treated with hypertensive drugs 
6. Informed consent  
 
5.1.2. Exclusion criteria 
Main exclusion criteria were: 
1. Secondary hypertension 
2. Nephropathy or diabetes mellitus  
3. Urinary tract infection when UAE was determined 
4. Lack of reproducibility among different UAE measurement 
5. Blood pressure levels outside the pre-specified range of values  
 
After the recruitment the patients were controlled yearly in the outpatient department. UAE was 
assessed in each one of the visit during the follow-up.  Patients were withdrawn from the study if 
they developed microalbuminuria (UAE within the range 30-300 mg/day). 
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All the patients were treated with lifestyle modifications and antihypertensive drug treatment when 
needed. Therapeutic actions included: physical exercise, low sodium and saturated fats intake and 
antihypertensive drugs in case the previous actions failed. Within the antihypertensive drugs we 
used whichever of the following: ß o α –blockers, angiotensin converting enzyme (ACE) inhibitors, 
angiotensin II receptor antagonist (ARA II) and calcium channel blockers. Diuretics such as 
hydrochlorothiazide or other drugs were added if BP levels remained uncontrolled. Yearly the 
following actions were performed: blood pressure levels, 24 hour UAE, and biochemical profile. 
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5.2. Phenotyping 
For the present study cases and controls have been selected from the above described cohort 
according to the UAE during the follow-up: 
 
5.2.1. Controls 
      Subjects with a mean for the 24 hour UAE less than 30 mg/day (normoalbuminurics). 
5.2.2. Cases   
Subjects with a mean for the 24 hour UAE ≥ 30 mg/day and < 300 mg/day (microalbuminurics) 
or >300 mg/day (albuminurics). 
 
As I mentioned above, the study subjects were divided into two groups: normoalbuminurics, if the 
UAE is less than 30 mg/day and microalbuminurics, if the UAE is ≥30 mg/day and < 300 mg/day. 
We also included 16 patients with UAE ≥ 300 mg/day in order to increase our sample size and our 
statistical power. The patients were extracted of a hypertensive cohort with similar characteristics at 
the time of recruitment: age, blood pressure levels and naïve regarding to the treatment. In this way 
we can see in a prospective way which are the factors influencing the development of 
microalbuminuria in HTN. 
Among all the patients, some of them developed microalbuminuria (cases) whereas others did not 
develop it (controls). This design enables to reduce the misclassification bias. Besides, the fact that 
we have used the mean of two 24 hour urinary samples for each subject reduces the possibility of 
false positive or negative regarding to the 24 hour variability and circadian rhythm of the UAE. We 
even considerer a third sample when the differences in UAE between the two samples were greater 
than 25% or if the sample was not well picked up. The right classification of the subjects in cases 
and controls is a key factor in an association genetic study. Another thing to take into account is 
that the majority of our controls (>80%) remained stable regarding to the UAE with very low levels 
(< 15 mg/day) so they can be considerer as hyper-controls. The use of hyper-controls is a way to 
reduce the misclassification because they probably will not developed microalbuminuria in the 
future. 
The basis principle of our study is that the genetic susceptibility threshold is different in cases than 
it is in controls. The well-known factors: age, BP levels, glucose profile and time of evolution of 
hypertension, would result in renal damage depending on the individual genetic susceptibility. 
After the selection according to the case-control status (2 controls for each case), peripheral blood 
was extracted in order to get the deoxyribonucleic acid (DNA) for the genotyping. The genotyping 
included more than 250000 markers spaced along the whole genome. 
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5.3. Sample size 
In this kind of studies, this is, genetic association studies with high-throughput platforms and 
thousand or millions of SNPs, it is quite difficult to determine the minimum sample size to detect 
true associations. In general the bigger it is the sample size the greater the possibility to find true 
significant associations. Small sample sizes can generate multiple false signals across the entire 
genome. That is not always the case. For example, one study with the Gene-Chip Human Mapping 
500K with 50 samples, found a very strong association with one genomic area which disappeared 
when the sample size was increased. 
The sample size that it needs to detect association between a genetic variant and a trait or disease, 
depends on: variant frequency, the risk associated with that variant and the linkage disequilibrium 
(LD) between that variant and a close marker. If we considerer that the LD magnitude between the 
marker an the variant is  d2, then the sample size to detect association with that marker is 
approximately N/ d2  262 . These theoretical principles explain why it is so difficult to calculate the 
minimum sample size, because we do not know a priori the factors to determine it. So we have to 
speculate and calculate it under different scenarios.  Huge sample sizes, which are difficult to 
obtain in clinical studies, can be avoided if the density of the SNPs along the genome is as high as 
500000 SNPs with a mean space between them of 6 kb across the genome. This is based on the 
estimation made by Kruglyak and cols262. The mean space between SNPs in the genotyping 
platform “GeneChip® Human Mapping 500K Array Set” is 5,6 kb. 
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5.4. Clinical and laboratory procedures 
 
5.4.1. Blood pressure measurements (BP) 
It was assessed in a quite place after 5 minutes resting and according to the guidelines of the 
British Society of hypertension (http://www.bhsoc.org/bp_monitors/BLOOD_PRESSURE_1784b). 
Systolic and diastolic blood pressure are the phases I and V of Korotkoff, respectively. 
 
5.4.2. General analytics 
Blood samples were extracted early in the morning after 8 hours fasting. Serum biochemistry 
was assessed by mean of a multichannel auto-analyzer SMAC (Technicon Instruments Cor, 
Tarrytown, New York USA). Plasma glucose was assessed by the glucose oxidase method 
(Beckman Glucose Analyzer, Beckman Instruments, Fullerton, Ca, USA). Total cholesterol and 
triglycerides were assessed by an enzymatic method (Roche Diagnostics). Blood for the 
genotyping was taken into tubes 15% of ethylenediaminetetraacetic acid (EDTA) and was kept at  
4ºC to process in 5 days time Those samples which were not processed in five days after the 
extraction were frozen at  -80ºC. 
 
5.4.3. Urinary albumin excretion (UAE) 
For each individual we collected two consecutives 24 hour samples spaced no longer than one 
week between them.  UAE was assessed by immunonephelometry (Behring Institute)263 . Urine 
samples were stored at 4 ºC in glass tubes and they were processed within the following next 7 
days. We considerer as real value the mean of UAE of the two samples.  If the difference between 
the values for the two samples was greater than 25% or if the highest value of creatinine excretion 
was below than the expected value according to age and body surface area (BSA), then a third  
sample was picked up. 
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5.5. Genotyping procedure 
DNA was extracted of peripheral leukocytes using Chemagic System (Chemagen, Arnold-
sommerfeld-ring2, 52499, Baesweiler, Germany). The extracted DNA met the general 
requirements: 
• Double stranded 
• Free of PCR inhibitors 
• Not contaminated with other human DNAs or DNA from other organisms 
• Not highly degradated 
 
Steps: 
1- Reagent preparation and storage 
2- Restriction enzyme digestion 
3- Ligation 
4- PCR 
5- PCR purification and elution  
6- Quantification of purified PCR product 
7- Fragmentation 
8- Labelling 
9- Target hybridization 
A resume of this steps for the GeneChip® Mapping Assay - Nsp I is shown in figure 5.1. 
Figure 5. 1. Outline of the assay steps for the mapping assay Nsp-I 
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5.5.1. Reagent preparation and storage 
Before to start, all the pipettes were calibrated to ± 5%. DNA sample was prepared by: 
determining the concentration of each sample, diluting each sample to 50 ng/µL using reduced 
EDTA TE buffer and Aliquoting 5 µL of each sample to a 96-well plate (one sample per well). 
AccuGENE® water was used as molecular biology-grade water.  All reagents (except enzymes) 
were kept on ice in a cooling chamber that was chilled to 4ºC. Enzymes were stored at -20ºC until 
they were added to the master mixes.  When enzymes were removed from the freeze, they were 
kept in a cooling chamber that was chilled to -20ºC and placed in ice. All the reagents used for the 
restriction digestion, ligation and PCR steps were stored in a Pre-PCR clean area. The final DNA 
concentration was 250 ng (5 µL, each µL contained 50 ng of DNA). 
 
5.5.2. Restriction enzyme digestion 
The restriction enzyme used was the Nsp I. The reagents used were: 1 vial BSA (100X; 10 
mg/mL), 1 vial NE Buffer 2, 1 vial Nsp I (10 U/µL; NEB) and 2.0 mL of AccuGENE® Water. In this 
step the reference Genomic DNA 103 (Nsp 100 Rxn Kit P/N 900753) was used as a positive control. 
The digestion master mix was prepared as follow:  
To the 2.0 mL Eppendorf tube the appropriate volumes of AccuGENE® Water, NE Buffer and BSA 
were added based on figure 5.2. 
Reagent 1 Sample 96 Samples 
(15% extra) 
Figure 5. 2. Nsp I digestion master mix. 
The Nsp enzyme was removed from the freeze and immediately was placed in a cooler. The 
enzyme was spinned for 3 seconds before added to the master mix. After that, the master mix was 
vortexed three times, one second each time. It was spinned for three second and it was placed in 
the cooling chamber. 135 µL of Digestion Master Mix were aliquoted to each tube of the strip tubes 
labelled Dig. 14.75 µL of Digestion Master Mix were added to each DNA sample in the cooling 
chamber on ice. The total volume in each well must be 19.75 µL. 
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Figure 5. 3. Total volume for each well. 
 
After that the plate was sealed with adhesive film. The centre of the plate was vortexed for 3 second 
and spinned down at 2000 rpm 30 seconds. Then the plate was loaded into the thermal cycler and 
the digestion program was run (Figure 5.4). 
Figure 5. 4. 500K digest program. 
 
When the program was finished it was spinned down again at 2000 rpm during 30 seconds before to 
the next step. 
 
5.5.3. Ligation 
Firstly, the following reagents were thawed: adaptor Nsp I and T4 DNA Ligase Buffer (10X) on 
ice during 20 minutes. Then the ligation master mix was prepared as follow: 
To the 2.0 mL Eppendorf tube, the appropriate volumes of the following reagents were added: 
adaptor Nsp I and T4 DNA Ligase Buffer (10X), based on figure 5.5. 
Materials and methods 
 
 
 79 
Figure 5. 5. Nsp I ligation master ix. 
 
After removed the T4 DNA ligase, it was immediately placed in a cooling chamber on ice. Before 
add to the mater mix it was pulse spinned for 3 second. After the addition of the T4 DNA ligase to 
the master mix, it was vortexed at high speed 3 times, 1 second each time and then pulse spinned 
3 seconds. Then the master mix was placed on ice before to add to the reactions. 48 µL of Ligation 
Master Mix were aliquoted to each tube of the strip tubes on ice. Then 5.25 µL of Ligation Master 
Mix were added to each reaction on the Digestion Stage Plate. The volumes are shown in figure 
5.6.  
Figure 5. 6. Resume of the volumes. 
 
Then the plate was tightly sealed, the centre of the plate was vortexed for 3 seconds and was 
spinned down at 2000 rpm during 30 seconds. The plate was loaded into the thermal cycle and the 
ligate program was run (Figure 5.7). 
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Figure 5. 7. 500K ligate program. 
 
After that, the samples were diluted using the AccuGENE® Water which was placed on ice 20 
minutes prior to use it. When the plate was removed from the thermal cycler it was spinned down at 
2000 rpm 30 seconds and was placed on the cooling chamber. To make the dilution 10 ml of 
AccuGENE® Water were poured into the solution basin. 75 µL of the water were added to each 
reaction. The total volume was 100 µL (Figure 5.8). 
Figure 5. 8. Resume of the volumes. 
 
Again the plate was tightly sealed with adhesive film, vortexed during 3 seconds, and spinned down 
at 2000 rpm for 30 seconds. The plate was stored in a cooling chamber on ice prior to the next 
step. 
5.5.4. PCR 
Firstly, the following reagents were thawed on ice: TITANIUM Taq PCR Buffer, dNTPs, PCR 
Primer 002. Then 10 µL of sample from each well of the ligation plate were transferred to the 
corresponded well of the reaction plate according to figure 5.9.  
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Figure 5. 9. Transferring equal aliquots of diluted, ligated samples to three reaction plates. 
 
Then the plates were sealed with adhesive film and placed in cooling chambers on ice. To prepare 
the PCR master mix the following steps were performed:  
To the 50 ml Falcon tube in the cooling chamber the reagents were added in order: The TITANIUM 
Taq DNA polymerase was removed from the freeze and immediately placed in a cooler. The Taq 
DNA polymerase was pulse spinned for 3 seconds before to add it to the master mix. The master 
mix was vortexed at high speed three times, 1 second each time. The mix was poured on the 
solution basin and placed on ice. The composition of the PCR master mix is shown in figure 5.10. 
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Figure 5. 10. PCR master mix. 
 
Then in the PCR staging area, 90 µL of the PCR master mix were added to each sample to a final 
volume of 100 µL. The reaction plates were tightly sealed with adhesive film and the centre of each 
reaction plate was vortexed at high speed for 3 seconds. Then, the plates were spinned down at 
2000 rpm during 30 seconds and were kept in cooling chambers on ice until placed into the thermal 
cycler. After loaded the plate in the thermal cycler the PCR program was run according to figure 
5.11. 
Figure 5. 11. 500K PCR thermal cycler program for the GeneAmp® PCR System 9700. 
 
The gels were run to ensure the consistency of the results. After the plates were removed from the 
thermal cycler, they were spinned down at 2000 rpm during 30 seconds. The plates were placed in 
the cooling chamber on ice. Then 3 µL of 2X Gel Loading Dye were aliquoted to each well of the 
three gel plates and  3 µL of each PCR product were transferred into the corresponded well of each 
gel plates. The plates were sealed with adhesive film and the centre was vortexed and spinned 
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down at 2000 rpm during 30 seconds. The 6 µL of each plate were loaded onto 2% TBE gels. The 
gels were run at 120V for 40 minutes to 1 hour to verify that the lengths of the fragments were 
between 250 bp and 1100 bp. Figure 5.12 shows a correct distribution of the fragments. 
Figure 5. 12. Example of PCR products runs on 2% TBE agarose gel at 120V for 1 hour. 
 
 
5.5.5. PCR product purification and elution 
Firstly the PCR products plate was thawed to a room temperature and the centre of each plate 
was vortexed during 3 seconds and spinned down at 2000 rpm during 30 seconds. The EDTA 
solution was prepared to achieve a final concentration of 0.1 M.  
The manifold and collector were connected to a suitable vacuum source able to maintain 600 mbar. 
The waste tray was placed in the base of the manifold. 
3 µL of the diluted EDTA were added to the solution basin.  8 µL of the diluted EDTA were added to 
each well of the PCR products plate. Then the plate was tightly sealed and vortexed at high speed 
for 3 seconds and spinned down at 2000 rpm during 30 seconds.  Then the plate was putted in a 
plate holder. 
The next step was to prepare the clean-up plate which was labelled to indicate its orientation. 
Then the samples were transferred and pooled from the same row and well of each PCR product 
plate to the corresponding row and well of the Clean-Up Plate. This step is represented in figure 
5.13. 
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Figure 5. 13. Pooling PCR products onto the Clean-Up Plate. 
        
The pipette tips were change between each of the three pooled samples. After the procedure it was 
checked that each well of the PCR product plate was empty.  The final volume of the clean-up plate 
was around 320 µL. 
The next step was to purify the PCR products.  For this, the clean-up plate with the samples was 
loaded onto the manifold. To protect the samples of environmental contaminants, the clean-up 
plate with the samples was covered with the lid of a pipette tips box. The vacuum was turned on 
and brought up slowly to 600 mbar. The vacuum was checked by trying to lid the middle section of 
the manifold off the base. It took between 1.5 and 2 hour until all of the wells were dried.  Then, the 
PCR products were washed three times. For this 75 mL AccuGENE® Water were added to a 
solution basin and 50 µL of water were added to each well. Then the wells were dried during 15-20 
minutes. This procedure as a mentioned before was performed three times. After the third wash the 
manifold was tapped firmly on the bench to get the drops from the side walls went to the bottom. 
The samples were dried completely for about 45 to 60 minutes and it was checked that the top and 
the bottom rows were completely dry. 
The following step was to elute the PCR products. After turned off the vacuum, the plate was 
removed from the manifold and then the bottom of the plate was blotted on a thick stack of clean 
absorbent paper to remove any remaining liquid. Then the bottom of each well was dried with an 
absorbent wipe. Five millilitres of the RB buffer were aliquoted to the solution basin. 45 µL RB 
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buffer were added to each well of the plate. The plate was tightly sealed and was shaken at 1000 
rpm for 10 minutes at room temperature. Forty five microlitres were transferred of the eluted sample 
to the correspondent well of a fresh 96 well-plate following the user guide recommendations. That 
is that the plate was tilted 45ºC and it was pipetted up and down 3-4 times before removing and 
transferring to the fresh 69 well-plate. 
 
5.5.6. Quantitation and normalization 
A 96 well-plate fragment was labelled and was placed in a cooling chamber. The optical plates 
were also labelled: OP1, OP2, OP3 and OP4. The RB buffer and the eluted PCR products plate 
were vortexed at high speed for 3 seconds and spinned down at 2000 rpm for 30 seconds. Then, 
three diluted aliquots of the purified samples were prepared. Seventy five millilitres of room 
temperature AccuGENE® water were poured into the solution basin. One hundred ninety eight 
microlitres of water were aliquoted to each well of OP1, OP2, and OP3 and the first four rows of 
OP4. After that, 2 µL of each purified PCR product were transferred from the purified sample plate 
to the corresponded well of optical plates.  This transference is shown in figure 5.14. 
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Figure 5. 14. Loading optical plates with purified sample. 
 
To ensure that all product was dispensed it was pippeted several times and 2 µL of each purified 
PCR product were transferred from row H to the correspondent well of the OP4.  
A tend fold dilution was obtained as a result. The well containing only water was used as a blank. 
Then the samples were mixed with a pipette set to 180 µL by pipetting up and down. Then three 
plates of diluted PCR products were prepared to test. 
Next step was to quantify the PCR products with a UV spectrophotometer plate reader.  For this, 
the OD at 260, 280 and 320 nm was measured. Three OD readings were taken for each sample 
and the average of the three readings was calculated.  The undiluted sample concentration was 
calculated with the following formula: 
Sample concentration in µg/µL = Average Sample OD x (0.05 µg/µL) x 100. 
The average OD was between 0.5-0.7. The final PCR product concentration was of 2.5 to 3.5 µg/µL 
and the ratio OD280/OD260 was between 1.8 and 2.0 for the majority of the samples. The OD320 
was around zero. 
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The volume of RB Buffer required to normalize the samples was calculated according to the 
following formula: 
X µL RB Buffer = 45 µL − (Y µL purified PCR product) 
Where: 
Y = the volume of purified PCR product that contains 90 µg 
The value of Y is calculated as: 
Y µL purified PCR product = (90 µg) / (Z µg/µL) 
Z = the concentration of purified PCR product in µg/µL 
The calculated volume of the RB buffer was added to each well of a new 96-well reaction plate. 
Then the calculated volume (Y) of the purified PCR product was added to the correspondent well 
with RB buffer. The final volume of each well was 45 µL containing 90 µg of purified PCR product. 
The plate was sealed with adhesive film and the centre of the plate was vortexed for 3 seconds, 
spinned down at 2000 rpm for 30 seconds and placed in a cooling chamber. 
 
5.5.7. Fragmentation 
Firstly, 50 µL of 10X Fragmentation Buffer were aliquoted to each tube of the 12-tube labelled 
buffer. Immediately 5 µL of Fragmentation Buffer were added to each sample of the 96-well 
reaction plate to a final volume of 50 µL. The fragmentation reagent was diluted according to figure 
5.15 to a final concentration of 0.05 U/µL. 
Figure 5. 15. Dilution recipes for fragmentation reagent concentrations of 2 and 3 U/µL. 
 
For this step the AccuGENE® water and the fragmentation Buffer were added to a 1.5 mL 
Eppendorf tube on ice and were let to cool on ice. After that the fragmentation reagent was 
removed from the freeze and was spinned for 3 seconds and placed in a cooler. Then it was added 
to the 1.5 mL Eppendorf tube. This tube with the diluted fragmentation reagent was vortexed at 
high speed three times, 1 second each time and spinned 3 seconds. Immediately this diluted 
fragmentation reagent was added to the samples. For this step 50 µL of diluted Fragmentation 
Materials and methods 
 
 
 88 
Reagent were aliquoted to each tube of the 12-tube strip labelled FR. From this 5 µL of diluted 
Fragmentation Reagent were added to each sample to a final volume of 55 µL. The plate was 
sealed with adhesive film, the centre of the plate was vortexed for 3 seconds and then was placed 
in a chilled plastic plate holder to spin it down at 4 °C at 2000 rpm for 30 sec.  After that the plate 
was loaded into the thermal cycler and the fragmentation program was run (Figure 5.16). 
Figure 5. 16. 500K fragment program. 
 
To check that the fragmentation was right, 4 µL of each fragmented PCR product were used. This 
volume was diluted with 4 µL gel loading dye. It was run on 4% TBE gel with the BioNexus All 
Purpose Hi-Lo ladder at 120V for 30 minutes to 1 hour. The gel was checked according to figure 
5.17. 
Figure 5. 17. Typical example of fragmented PCR products runs on 4% TBE agarose gel at 120V. 
 
 
5.5.8. Labelling 
After thawed the reagents on ice, the labelling master mix was prepared.  For this, the volumes 
of figure 5.18 were added to a 15 mL centrifuge tube on ice. 
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Figure 5. 18. Labelling master mix. 
 
The TdT enzyme was removed from the freeze and immediately placed in the cooler. The enzyme 
was spinned for 3 seconds before to add it to the master mix. This master mix was vortexed at high 
speed for 3 seconds and spinned another 3 seconds. To add the labelling master mix to the 
samples the following steps were done. One hundred seventy eight microlitres of the labelling 
master mix were aliquoted to each tube of the strip tubes. Then, 19.5 µL of the labelling master mix 
were aliquoted to each sample to a final volume of 70 µL. To ensure that all the mix was added to 
our samples, it was pipetted up and down several times. The plate was tightly sealed. The centre of 
the plate was vortexed at high speed for 3 seconds and spinned down at 2000 rpm during 30 
seconds. Then the plate was loaded into the thermal cycle to run the label program (Figure 5.19). 
Figure 5. 19. 500K label program. 
 
After removed from the thermal cycle it was spinned down at 2000 rpm during 30 seconds.  
 
5.5.9. Target Hybridization 
Firstly, the oven was preheated at 49 ºC before to load the samples. Then the hybridation 
master mix was prepared as follow. To the 50 ml centrifuge tube the reagents were added 
according to figure 5.20. 
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Figure 5. 20. Hybridization master mix. 
 
It was ensured that all the components mixed well. Then 20.9 mL of the Hybridization Master Mix 
were poured into a solution basin. Then 190 µL of Hybridization Master Mix were added to each 
sample of the label plate to a final volume of 260 µL. Then the plate was tightly sealed and vortexed 
for 3 minutes. The plate was cut into 4 strips and each strip of 24 samples was putted into a plate 
holder. This was spinned down at 2000 rpm for 30 seconds and was placed into the thermal cycler 
to run the Hybridation program (Figure 5.21). 
Figure 5. 21. 500K Hyb program. 
 
Each set of 24 wells was placed separately. The set which was not in the thermal cycler was placed 
into the cooling chamber on ice. 
Next step was loaded the sample onto arrays. When the plate was at 49ºC, it was removed from 
the thermal cycler. Then 200 µL of denatured sample were pipetted from each well and were 
injected into the array one by one. Another operator was ready to cover the septa on each array 
with a Tough-Spot according to figure 5.22. 
Materials and methods 
 
 
 91 
Figure 5. 22. Applying Tough-Spots® to the array cartridge. 
 
When 4 arrays were loaded, the septa were covered and loaded into an oven tray evenly spaced. 
Immediately the tray was placed into the oven and it was ensured that they rotated at 60 rpm at all 
times. The arrays were let to rotate at 49 °C, 60 rpm for 16 to 18 hours. 
 
5.5.10. Washing, staining, and scanning Arrays 
Firstly the reagents for this stage were prepared according to tables 5.1-5.3. 
 
Table 5. 1. Non stringent and stringent wash buffer. 
Wash A: Non-Stringent Wash Buffer Wash B: Stringent Wash Buffer 
(6X SSPE, 0.01% Tween 20) (0.6X SSPE, 0.01% Tween 20) 
For 1000 mL: For 1000 mL: 
300 mL of 20X SSPE 30 mL of 20X SSPE 
1.0 mL of 10% Tween-20 1.0 mL of 10% Tween-20 
699 mL of water 969 mL of water 
Filter through a 0.2 µm filter Filter through a 0.2 µm filter 
Store at room temperature Store at room temperature 
 The pH should be 8 
 
Table 5. 2. Anti-streptavidin antibody. 
0.5 mg/mL Anti-Streptavidin Antibody 
Resuspend 0.5 mg in 1 mL of water 
Store at 4°C 
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Table 5. 3. MES stock buffer and array holding buffer. 
12X MES Stock Buffer 1X Array Holding Buffer 
(1.25 M MES, 0.89 M [Na+]) (Final 1X concentration is 100 mM MES, 
1M [Na+], 0.01% Tween-20) 
For 1,000 mL: For 100 mL: 
70.4g of MES hydrate 8.3 mL of 12X MES Stock Buffer 
193.3g of MES Sodium Salt 18.5 mL of 5 M NaCl 
800 mL of Molecular Biology Grade Water 0.1 mL of 10% Tween-20 
Mix and adjust volume to 1,000 mL 73.1 mL of water 
The pH should be between 6.5 and 6.7 Store at 2°C to 8°C, and shield from light 
Filter through a 0.2 µm filter  
 
At this time, a new experiment in the GeneChip® Operating Software (GCOS) 1.4 client was 
opened  
The Fluidics Station 450 was used to wash and stain the probe arrays and GCOS was use to 
operate it. To prime the fluidics station, Prime_450 was chosen in the protocol drop-down list. 
The intake buffer reservoir A was changed to Non-Stringent Wash Buffer, and intake buffer 
reservoir B to Stringent Wash Buffer. The priming was done according to the instructions on the 
screen. 
The following procedures were done to wash and stain the probe array. After 16-18 hours of 
hybridation, the hybridation cocktail was removed from the probe array and set it aside in a micro 
centrifuge vial. Then the probe array was filled completely with 270 µL of Array Holding Buffer. 
The staining reagents were prepared according to figure 5.23-5.26. 
Figure 5. 23. Stain buffer. 
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Figure 5. 24. SAPE solution mix. 
 
 Figure 5. 25. Antibody solution mix. 
 
Figure 5. 26. Array holding buffer. 
 
Then, 820 µL of Array Holding Buffer were added to each micro centrifuge tube.  
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Figure 5. 27. FS-450 fluidics protocol - Antibody amplification for mapping targets. 
 
Instructions of the Fluidics Station 450 were followed to wash and stain the probe array. After 
staining was finished, the micro centrifuge vials containing stain were removed and replaced with 
three empty micro centrifuge vials as prompted. If bubbles were presented, they were removed 
according to the instructions. 
Next step was to scan the probe array with GeneChip® Scanner 3000 7G. If the scan was not 
performed immediately, the probe arrays were kept at 4ºC in the dark until they were ready for 
scanning. All the scans were performed within 24 hour. The GeneChip® Scanner 3000 7G was 
operated by means of the GCOS Software 1.4 
Before scanning the probe array cartridge, Tough-Spots®, label spots were applied to each of the 
two septa on the probe array cartridge to prevent leaking of fluids from the cartridge during 
scanning. Then it was ensured that the spots did not interfere with the focus. 
After the scanning, the analysis workflow was performed using GeneChip® Operating Software 
(GCOS) 1.4, GeneChip® Genotyping Analysis Software (GTYPE) 4.0 and Genotyping Console 3.0. 
The analysis workflow is shown in figure 5.28. 
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Figure 5. 28. Data analysis workflow for GeneChip® Human Mapping 250K arrays. 
 
MPAM calling algorithm was used in a subset of SNPs to obtain the MCR and MDR metrics. The 
relation between the MCR and MDR parameters obtained after genotyping was used to evaluate 
the possible contamination of the samples. The call rate of the reference genomic DNA 103 sample 
was used as an indicator that all the steps worked properly. The quality control parameters are 
shown in figure 5.29. 
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Figure 5. 29. Dynamic model mapping algorithm report metrics. 
 
To resume all the steps, an overview of the assay is shown in figure 5.30. 
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Figure 5. 30. GeneChip® Mapping 500K assay overview. 
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5.6.  Management of the genotyping microarray data 
The intensity files (.CEL) were obtained by the use of the GCOS (Gene-Chip Operating 
Software). The Affymetrix® Genotyping Console™ 3.0 (AFFYMETRIX, INC. 3420 Central 
Expressway ,Santa Clara, CA 95051 USA) was used to assessed the quality of the intensity files 
using the Dynamic Model (DM) algorithm264. 
Those files with a poor quality control (QC) call rates, QC call rate <93%, were not considering for 
genotyping.  The BRLMM algorithm265 was used to infer the genotypes based on the intensity 
signal of the two alleles A and B. We used the Affymetrix power tool (apt) probeset genotype (apt- 
1.10.2) to convert the CEL files into the genotyping files. As we did not have a great number of 
subjects we were able to run the BRLMM algorithm for all the samples at the same time. We did not 
have to divide them into batches of equal  or different sizes what can affect the results of the 
downstream analysis266. 
The cluster plots for the main associated SNPs were obtained with the Affymetrix software 
Genotyping Console version 3.0.1. 
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5.7. Resume of the genotyping procedure 
The DNA was extracted from leukocytes of peripheral blood (5-10 mm). The DNA was purified 
following standard procedures (Chemagic Magnetic Separation Module I, chemagen Biopolymer-
Technologie AG, Arnold-Sommerfeld-Ring 2 D-52499 Baesweiler Germany ) 267.  
As it had been commented before, we used the Nsp chip of the GeneChip Human Mapping 500K of 
Affymetrix for the genotyping. This chip includes more than 250000 SNPs across the genome. The 
high-density chip has a good coverage of the genome and a good coverage between populations 
(Figure 5.31).  
 
Figure 5. 31. HapMap Phase II coverage of the Mapping 500K array Set. 
The samples were processed following the quality recommendations of the manufacturer 
(https://www.affymetrix.com/support/downloads/manuals/500k_assay_manual.pdf).   
The Nsp enzyme was used as restriction enzyme and the Nsp I adaptor in the ligation stage. DNA 
fragments within the range 200-1100 bp were amplified by PCR with only one primer. For the PCR 
stage we use the DNA TitaniumTM Taq polymerase. For the hybridation stage we used the 
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thermocycler 7900 of Applied Biosystems (Applied Biosystems, 850 Lincoln Centre Drive Foster 
City, CA 94404, USA). The GeneChip® Scanner 3000 7G was used in the fluorescence analysis. 
During all the stages suitable quality control procedures were performed to the accuracy of the 
genotyping268.
Materials and methods 
 
 
 101
5.8. Statistical analysis 
 
5.8.1. General statistics 
Quantitative variables are expressed as mean ± standard deviation (SD). Qualitative variable 
are expressed as entire number and percentage. Treatment is described as a categorical variable 
based on the number of drugs which the individual is taking (less than two drugs or more than two 
drugs). Microalbuminuria and albuminuria will be considered as both qualitative variable (yes or 
not) and quantitative trait according to the UAE values. To assess the association specifically with 
microalbuminuria we discharged those subjects with UAE ≥ 300 mg/day. 
Binomial multivariate logistic regression will be used to analyze what clinical factors explain the 
presence of microalbuminuria including interactions between variables. The introduction method 
will be used to construct the model. Those variables without influence in the presence of 
microalbuminuria will be deleted according to the score value. The best model with the lowest 
number of variables will be selected according to the -2log likelihood and R square values and also 
considering the significance for the Hosmer-Lemeshow test. 
In the same way, multiple linear regression will be used to find those clinical co-variables which 
influence the changes in microalbuminuria as a continuous trait. Again the best model with the 
lowest number of variables will be selected based on the R square and corrected R square values. 
 
5.8.2. Genetic statistics 
 
5.8.2.1. Individual SNPs association with microalbuminuria and albuminuria 
(qualitative traits)  
 
The association analysis between the selected polymorphisms and the phenotype will be 
assessed by comparing the allele frequencies between cases and controls. The basic statistical 
tests that will be used include:  standard allelic test using chi-square test (1df) or the Fisher's exact 
test. 
We will also include the following test to asses the association under different genetic models: 
• Cochran-Armitage trend test  
• Genotypic (2 df) test  
• Dominant gene action (1df) test  
• Recessive gene action (1df) test  
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One advantage of the Cochran-Armitage test is that it does not assume Hardy-Weinberg 
equilibrium, as the individual, not the allele, is the unit of analysis. The genotypic test provides a 
general test of association in the 2-by-3 table of disease (Case-Control)-by-genotype. The 
dominant and recessive models are tests for the minor allele which is the less frequent allele 
according to the data for each polymorphism. If we considerer D as the minor allele and d as the 
major allele then we will assess the following comparisons (Table 5.4).      
Table 5. 4. Diagram of the comparison between different genetic models. 
Allelic D        versus      d 
Dominant (DD, Dd)    versus      dd 
Recessive DD       versus   (Dd, dd) 
Genotypic DD       versus      Dd         versus    dd 
For each of the test described above we will obtain the chi-square test, the degree freedom (DF) 
and the asymptotic p-value. We also performed the adaptive permutations analysis for the main 
association analysis.  In this approach, if after only 10 permutations it is seen that for 9 of these the 
permuted test statistic for a given SNP is larger than the observed test statistic, there is little point 
in carrying on, as this SNP is incredibly unlikely to ever achieve a highly significant result. This 
greatly speeds up the permutation procedure, as most SNPs (that are not highly significant) will 
drop out quite quickly, making it possible to properly evaluate significance for the handful of SNPs 
that require millions of permutations. Naturally, the precision with which one has estimated the 
significance p-value (i.e. relating from the number of permutations performed) will be correlated the 
significance value itself -- but for most purposes, this is precisely what one wants, as it is of little 
interest whether a clearly un-associated SNP really has a p-value of 0.78 or 0.87. Permutation 
procedures provide a computationally intensive approach to generating significance levels 
empirically. Such values have desirable properties: for example, relaxing assumptions about 
normality of continuous phenotypes and Hardy-Weinberg equilibrium (HWE), dealing with rare 
alleles and small sample sizes, providing a framework for correction for multiple testing, and 
controlling for identified substructure or familial relationships by permuting only within cluster. 
5.8.2.2. Individual SNPs association with UAE (quantitative trait) 
The association between individual SNPs and the quantitative trait (microalbuminuria mg/24 
hours) will be perform using either asymptotic (likelihood ratio test and Wald test) or empirical 
significance values. With these test we will obtain the following measurements (Table 5.5).         
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Table 5. 5. Linear regression parameters. 
BETA Regression coefficient 
SE Standard error 
R2 Regression r-squared 
T Wald test (based on t-distribution) 
P Wald test asymptotic p-value 
 
We will also determinate the means for microalbuminuria for each of the genotypes with the SD as 
well as the number and frequency of each genotype for all the SNPs. 
 
5.8.2.3. Individual SNPs association with albuminuria, microalbuminuria and UAE 
(qualitative and quantitative traits) including significant co-variables 
Linear and logistic regression models (quantitative and qualitative traits respectively) will be 
used to include important covariates in the analysis such as age, sex, BMI, SBP, DBP, glucose, 
eGFR and treatment. We will calculate the Beta regression coefficients and the OR with the 
correspondent confident intervals, the coefficient for the t-statistic and the asymptotic p-value for 
that test for all the SNPs.   
 
5.8.2.4. Multiple comparison 
The following test will be used to address the multiple comparison problems (Table 5.6)  
 
Table 5. 6. Test for multiple comparisons. 
BONF Bonferroni single-step adjusted p-values 
HOLM Holm (1979) step-down adjusted p-values 
SIDAK_SS Sidak single-step adjusted p-values 
SIDAK_SD Sidak step-down adjusted p-values 
FDR_BH Benjamini & Hochberg (1995) step-up FDR 
control 
FDR_BY Benjamini & Yekutieli (2001) step-up FDR 
control  
 
Although it is the most stringent one, we used the Bonferroni correction to considerer a results as 
significant.  The more stringent a multiple testing correction, the less false positive genes are 
allowed. The trade-off of a stringent multiple testing correction is that the rate of false negatives 
(genes that are called non-significant when they are) is very high.        
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5.8.2.5. Haplotype analysis 
All tests described above are based on single SNP tests. Haplotypes will be study using the 
proxy association approach taking into account the main associated SNPs in the individual 
analysis. Specifically, given a particular (reference) SNP this approach involves a) finding flanking 
markers and haplotypes (proxies) that are in strong linkage disequilibrium with the reference SNP 
and, b) testing these proxies for association with disease, within a haplotype-based framework.  
With this we will obtain the following benefits: 
• technical validation of single SNP results (by looking for flanking haplotypes involving 
different markers that also show the same result).  
• refining a single SNP association signal (is there a stronger association with a local 
haplotype?).  
• More robust single SNP tests (by framing single SNP tests within an haplotypic framework, 
some degree of control against non-random genotyping failure can be achieved).  
The R-square and the D´statistic (defined as the linkage disequilibrium measure, D, divided by the 
theoretical maximum for the observed allele frequencies) will be used to measure the linkage 
disequilibrium (LD). Haplotypes frequencies will be estimated by the Expectation Maximization 
Algorithm (EM).  
Tag-SNPs, LD and haploblocks were calculated using Haploview version 3.32 269. The haploblocks 
were defined by mean of the confidence intervals (Gabriel et al270). 
 
5.8.2.6. Haplotype-based association tests with generalized linear models (GLM) 
We will also use linear and logistic regression to perform haplotype-based association analysis. 
These will let to include the main co-variables (Age, sex, BMI, SBP, DBP, glucose and eGFR) into 
the haplotype association analysis for those SNPs which showed association in the individual 
analysis with co-variables. 
The individual SNP and haplotype analysis in both case-control (qualitative trait: albuminuria or 
microalbuminuria) and quantitative trait will be performed with the program PLINK v.1.06 
developed by Shaun Purcell (http://pngu.mgh.harvard.edu/purcell/plink/)271. An extended 
information about the statistical tests that are used can be found in the web site. 
 
5.8.2.7. Genetic statistical power  
To see our statistical power we took into consideration some of the graphs which other 
authors272 had developed for GWAS analysis using either Affymetrix or Illumina chips and 
considering the CEU HapMap population. According to these graphs (Figure 5.32 and 5.33), it is 
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quite clear that our study is underpowered to detect OR equal or below 1.5. These graphs assume 
an equal number of cases than controls. 
 
Figure 5. 32. Power for the test of genotypic association as a function of sample size at different 
genotype relative risks (GRR). 
 
These figures 5.32 and 5.33 are for the CEU HapMap population when the number of cases equals 
the number of controls and a multiplicative model is used. 
 
Figure 5. 33. Power for genotypic and allelic tests. 
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Data is shown for a GRR of 1.5 under a multiplicative model, the CEU HapMap population, and the 
specified genotyping system. 
We also used several programs such as the Power for Genetic Association (PGA)273 software, 
developed by Menashe and cols and the free software PAWE-3D274 
(http://linkage.rockefeller.edu/pawe3d/) to calculate the statistical power making different 
assumptions but as I commented before with would need a much bigger sample size to detect OR  
1.5 with an statistical power of 0.8. 
 
5.8.2.8. Quantile-Quantile plots 
Quantile-Quantile (Q-Q) plots are constructed by ranking a set of values of a statistic from 
smallest to largest (the ‘order statistics’) and plotting them against their expected values, given the 
assumption that the values have been sampled from a distribution of known theoretical form (in our 
case, the chi-squared distribution, usually on one degree of freedom—for example, the distribution 
of our trend tests under the null hypothesis). 
Deviations from the line of equality indicate either that the theoretical distribution is incorrect, or 
that the sample is contaminated with values generated in some other manner (for example, by a 
true association). The Q-Q plots for the p-values obtained in the association analysis were made  
with the statistical software R version 2.8.1275.
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6. RESULTS 
6.1. Clinical characteristics of the study population 
The final sample size comprised of 201 controls and 102 cases. Among the cases, 86 (84.3%) 
had an UAE between 30-299 mg/day and 16 patients (15.7%) had UAE values equal or higher 
than 300 mg/day. As expected the cases were older than the controls and also had greater values 
of 24 hour BP, BMI, and fasting glucose. Interestingly there were not differences regarding to the 
office BP levels. The GFR estimated by MDRD was significantly lower in cases than in controls but 
not the CC estimated by Cockcroft-Gault formula. Regarding lipids, the LDL was significantly lower 
in cases than in controls due to the major percentage of individuals under statins treatment. Also 
the number of lowering blood pressure drugs was significantly higher in cases than it was in 
controls as well as the percentage of individuals with metabolic syndrome according to the ATPIII 
criteria276. 
The main characteristics of the study population grouped by the case-control status are shown in 
table 6.1. 
 
Table 6. 1. Main characteristics of the study population. 
 
NORMOALBUMINURICS 
N =201 
ALBUMINURICS 
N=102  
    Microalbuminurics =86 (84.3%) 
    Macroalbuminurics=16 (15.7%) 
 
  
AGE (years) 42.3±10.6 46.3±12.5** 
GENDER (Male/Female) 100(49.8)/101(50.2) 60(58.8)/42(41.2) 
BMI (Kg/m2) 28.3±4.1 29.7±4.6* 
OFFICE SBP 146.6±15.3 147.5±20.3 
OFFICE DBP 91.3±10.5 90.6±15.3 
24 H SBP 132.5±13.5(n=156) 145.4±15.6**(n=58) 
24 H DBP 84.4±9.9(n=156) 93.9±11.2**(n=58) 
FASTING GLUCOSE (mg/dl) 100.2±13.9 107.6±17.5** 
INSULIN 4.59±6.0(n=32) 6.09±12.2(n=38) 
HOMA 1.15±1.5(n=32) 1.93±3.9(n=38) 
UREA (mg/dl) 34.2±8.2 42.4±20.9** 
CREATININE (mg/dl) 0.94±0.23 1.09±0.51** 
GFR (ml/min) (Cockroft-Gault) 104.3±32.5 100.5±36.3 
GFR (ml/min) (MDRD) 83.9±24.5 76.9±21.9* 
UAE (mg/day) 8.3±5.7 292.3±881.2** 
TRIGLYCERIDES (mg/dl) 132.7±74.0 152.8±122.2 
TOTAL CHOLESTEROL (mg/dl) 208.0±37.2 204.7±40.5 
LDL CHOLESTEROL (mg/dl) 131.6±33.7 114.8±39.2** 
HDL CHOLESTEROL (mg/dl) 47.7±11.6 47.9±12.3 
LVM (g) 188.4±83.3(n=87) 204.4±109.2(n=36) 
ANTYHYPERTENSIVE DRUGS: 
Less than 2 drugs (n/%) 
More than 2 drugs (n/%) 
 
151(96.8) 
5 (3.2) 
 
65 (73)** 
24 (27)** 
METABOLIC SYNDROME (n/%) 46 (22.9) 43 (42.2) ** 
* and ** significant differences between the normoalbuminuric and albuminuric group (* p-value<0.05, **p-value<0.005). 
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6.2. Clinical factors associated with albuminuria, microalbuminuria and UAE 
 
6.2.1. Logistic regression model for albuminuria and microalbuminuria 
To analyze the impact of the clinical factors in the presence of albuminuria we constructed 
several logistic regression model by using the enter mode.  Previously we observed the scatter plot 
to see the relationship between the different variables included in the analysis. 
 
Figure 6. 1. Scatter plot for the relationship between pairs of variables. 
 
In the univariate analysis only age, glucose, eGFR by MDRD and the number of drugs were 
significantly associated with albuminuria.  When including all these variables in the logistic 
regression (LR) model,   only glucose and the numbers of drugs were independently associated 
with the risk of albuminuria. Those hypertensive patients receiving 2 or more drugs had an 
increase risk of albuminuria (OR 7.83 (3.61-16.90), p<0.0001). The result of the logistic regression 
model for the clinical variables is shown in table 6.2 
 
 
 
. 
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.Table 6. 2 . Result of the logistic regression for albuminuria. 
 
B S.E. Wald df Sig. OR 95.0% C.I for OR 
        
Lower Upper 
Step 
1(a) 
AGE (years) -0.17 0.17 1.100 1 0.294 0.983 0.951 1.015 
 SEX (male vs female) 0.79 0.320 0.60 1 0.806 1.082 0.577 2.027 
 BMI (Kg/m2) -0.10 0.040 0.059 1 0.808 0.990 0.916 1.071 
 SBP (mmHg) .009 .012 0.526 1 .468 1.009 .985 1.034 
 DBP(mmHg) -0.002 .018 0.007 1 .932 0.998 .964 1.034 
 
GLUCOSE (mg/dl) .025 .011 4.962 1 .026 1.026 1.003 1.049 
 eGFR MDRD (mL/min/1.73 m2) -0.13 0.008 2.468 1 0.116 0.987 0.972 1.003 
 
Nº DRUGS 
(2 or more vs less than 2) 
2.058 .394 27.221 1 .000 7.832 3.615 16.968 
 Constant -2.920 2.339 1.559 1 .212 .054   
 
We obtained similar results when we excluded those patients with macroalbuminuria (UAE≥300 
mg/day). 
6.2.2. Linear regression model for UAE 
The study of clinical factors associated with microalbuminuria was also performed by using a 
multiple regression analysis. Age, sex, BMI, SBP, DBP, glucose, eGFR  by MDRD  and the 
number of drugs explained 14% of the variation in the UAE levels (R square 0.140). In this model 
the most significant variables were the number of drugs (2 or more) and the eGFR. The result of 
the linear regression model is shown in table 6.3. 
 
Table 6. 3. Result of the linear regression analysis for UAE. 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
95% Confidence Interval 
for B 
Model 
  
  
  
B Std. 
Error 
Beta 
t Sig. 
Lower 
Bound 
Upper 
Bound 
1 (Constant) 1021.681 466.608  2.190 .030 102.200 1941.161 
  AGE (years) -2.143 3.331 -.050 -.643 .521 -8.707 4.422 
  SEX (male vs female) -97.001 65.522 -.094 -1.480 .140 -226.115 32.113 
  BMI (Kg/m2) 8.038 8.072 .067 .996 .320 -7.868 23.944 
  SBP (mmHg) -.975 2.613 -.032 -.373 .709 -6.125 4.174 
  DBP (mmHg) -5.663 3.749 -.142 -1.511 .132 -13.050 1.724 
 GLUCOSE (mg/dl) -.759 2.267 -.023 -.335 .738 -5.225 3.708 
 eGFR MDRD (mL/min/1.73 m2) -5.085 1.356 -.257 -3.750 .000 -7.758 -2.413 
 
Nº DRUGS 
(2 or more vs less that 2) 
185.842 81.868 .163 2.270 .024 24.515 347.169 
Adjusted R Square 
.109 
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If we consider only those patients with UAE<300 mg/day, in this case, the variables that were 
independently associated with UAE were: fasting glucose (Beta 0.510 (0.44-0.97), sig 0.032) and 
the number of drugs (Beta 39 (22-56), sig<0.0001). The eGFR by MDRD was no longer 
independently associated after excluding patients with macroalbuminuria (Table 6.4). 
. 
Table 6. 4. Result of the linear regression analysis for UAE excluding macroalbuminurics. 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95% Confidence Interval for B Model 
  
  
  
B Std. 
Error 
Beta   Lower 
Bound 
Upper 
Bound 
1 (Constant) -
16.114 
48.663  -.331 .741 -112.040 79.812 
  AGE (years) -.166 .350 -.036 -.473 .637 -.856 .525 
  SEX (male vs female) -2.007 6.882 -.019 -.292 .771 -15.572 11.559 
  BMI .387 .848 .030 .456 .649 -1.285 2.060 
  SBP (mmHg) .059 .269 .019 .219 .827 -.471 .589 
  DBP (mmHg) -.486 .391 -.114 -1.245 .215 -1.257 .284 
 
GLUCOSE (mg/dl) .510 .236 .145 2.155 .032 .044 .976 
 eGFR MDRD (mL/min/1.73 m2) -.183 .146 -.085 -1.255 .211 -.470 .104 
 
Nº DRUGS 
(2 or more vs less that 2) 
39.146 8.693 .319 4.503 .000 22.011 56.282 
Adjusted R Square 
.150 
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6.3. Genetic analysis 
 
6.3.1. Quality control parameters 
6.3.1.1. Individual Call Rate 
The average call rate for the individuals was 94.8%±0.06%. 213 subjects (70.3%) had a call 
rate higher than 95%, 24(7.9%) between 90 and 95% and 66 (21.8%) had a call rate lower than 
90%. These last 66 subjects with an individual call rate lower than 90% were not included in the 
final analysis. The average call rate after filtering these samples was 98%. 
6.3.1.2. SNP Call Rate 
Of the 262314 SNPs included in the Affymetrix Nsp chip, 150388 (57.3%) had a call rate higher 
than 95%, 83555 (31.9%) had a call rate between 90 and 95%, and 28371 (10.8%) had a call rate 
lower than 90%.12379 (4.7%) markers had less than two alleles and were excluded from the 
analysis.  We decided to use 0.9 (90%) as a threshold for SNP call rate because there were a 
huge amount of SNPs between 90-95% and because this study was planned as a preliminary 
analysis to select SNPs which later on we will try to replicate in a larger sample. We are concerned 
that we are increasing the number of false positive (type I error) but in this way we are reducing the 
number of false negative results (type II error). 
6.3.1.3. Hardy Weinberg Equilibrium 
Using a p-value of 0.0001 as a threshold, 6239 SNPs, failed the HWE in the whole sample and 
therefore they were excluded from the association analysis.  These SNPs which were not in HWE 
were equally distributed along the entire genome with no differences regarding case-control status 
or gender. 
6.3.1.4. Minor allele frequency 
Considering a MAF of 0.1, 78369 SNPs were not included in the association analysis. We 
decided this MAF threshold over other commonly used as 0.05 or 0.01 in order to improve our 
statistical power due to our small sample size. 
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6.3.1.5. Missingness 
One hundred sixty six SNPs with significant missing rates between cases and controls were 
not considerer for the association analysis and also 153 SNPs with different missing rates between 
batches. 
6.3.1.6. Total Filtered 
After applying the above mentioned filters, 169406 SNPs were selected for the further analysis. 
 
The SNP call rate for each chromosome is shown in figure 6.2. 
 
Figure 6. 2. Bars diagram of the SNP call rate for each chromosome. 
 
6.3.1.7. Cryptic relatedness 
This step performs a check on the cryptic relatedness between study participants.  We 
estimated the sharing of genetic information by estimating identity by state (IBS) using the PLINK 
software.  Surprisingly, we detected 5 individuals with an IBS higher than 95% who were excluded 
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from the association analysis.  We also performed the multidimensional scaling plot for the IBS 
pairwise distances according to the case-control status in order to detect individuals quite different 
from the rest and exclude them from the analysis (Figure 6.3) 
 
 Figure 6. 3. Multidimensional scaling plot for the IBS pairwise distances adjusted for the case-
control status. 
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6.3.1.8. Batch effect 
Because we had batches with only cases and batches with only controls we were not able to 
adjust the analysis taking into account the batch which the individual belongs to. This means that 
we can not sure that the associated SNPs were due to differences in the genotyping procedure or 
due to real differences between cases and controls. To solve this problem, we made a database of 
controls and a database of cases and after that we compared the SNPs between batches in cases 
and in controls separately. Those SNPs significantly different between batches of cases and those 
significantly different between batches of controls, were eliminated.  
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We also deleted those SNPs with different missing rates between batches by comparing the SNP 
missing rate between each batch and the rest of batches. 
6.3.1.9. Sample contamination 
As I commented previously, the pairwise clustering based on the Identity by State (IBS) 
revealed 5 individuals with very high value for the IBS proportion which means that those 
individuals could be in fact siblings or even twins or correspond to repeat or contaminated 
samples. One individual of each of these five pairs was excluded for the analysis. 
6.3.1.10. Resume 
After making all the procedures described above, 77 cases and 152 controls were included in 
the final analysis. Regarding to the SNPs, 169406 remained after all the filters. The genotyping call 
rate for these final individuals was 97.9% (range 90.5%-99.6%) and for the SNP was also 97.9% 
(range 90.4%-100%). 
6.3.2. Association analysis for qualitative traits (Unadjusted) 
6.3.2.1. Association analysis for albuminuria 
The genomic inflation factor (based on the median chi-squared) for the basic association 
analysis was 1.07. The median chi-square statistic was 1.06. 
The Quantile-Quantile (Q-Q) plot for the basis association analysis unadjusted and adjusted for 
genomic control are shown in the figure 6.4.                        
Figure 6. 4. Q-Q Plot for the observed and expected p-values. a) Unadjusted and b) Adjusted for 
genomic control. 
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6.3.2.1.1. Individual SNPs analysis 
Between all the selected markers only one SNP [SNP_A-4215311(rs6980941)] on 
chromosome 8, cytoband p22, showed significant association even after Bonferroni correction (p-
value for the basic allelic test, unadjusted 4.23x10-8; Bonferroni p-value 0.007; p-value for the trend 
test 2.21e-007). To assess the consistency of this result, we also performed the adaptative 
permutation analysis. The SNP_A-4215311 remained being the most associated marker with an 
empirical p-value of 1e-006 after 1 million of permutations. The result for this SNP under different 
genotypic model is shown in the table 6.5. 
  
Table 6. 5. Association with the main marker on chromosome 8 under different genotypic models. 
Chr SNP A1 A2 TEST AFFECT UNAFFECT CHISQ DF P-VALUE 
8 SNP_A-4215311 A B ALLELIC 31/101 15/267 30 1 4.2e-008 
8 SNP_A-4215311 A B TREND 31/101 15/267 27 1 2.22e-007 
8 SNP_A-4215311 A B GENO 5/21/40 0/15/126 27 2 1.43e-006 
8 SNP_A-4215311 A B DOM 26/40 15/126 23 1 1.31e-006 
8 SNP_A-4215311 A B REC 5/61 0/141 11 1 0.0009379 
A1: Minor allele; A2: Major allele. 
 
Carriers of the minor allele of this SNP had significantly higher risk of being albuminuric than 
carriers of the other allele (OR 5.46 (2.81-10.55), p-value 1.6e-007) according to the Fisher exact 
test (Table 6.9). 
This polymorphism is located in an intergenic region, approximately 100 Kb of distance of the 
MSR1 (Macrophage acetylated LDL receptor I and II) gene. This gene encodes the class A 
macrophage scavenger receptors, which include three different types (1, 2, 3) generated by 
alternative splicing of this gene. These receptors or isoforms are macrophage-specific trimeric 
integral membrane glycoproteins and have been implicated in many macrophage-associated 
physiological and pathological processes including atherosclerosis. The isoforms type 1 and type 2 
are functional receptors and are able to mediate the endocytosis of modified low density 
lipoproteins (LDLs).  
The other two most associated SNPs were SNP_A-4204317 (rs2154401) on chromosome region 
10q11.21 and SNP_A-1888702 (rs7974380) on chromosome region 12q24.23 although they did 
not reach the statistical significance (p-values for the basic allelic test, 2.69e-006 and 2.89e-006 for 
rs2154401 and rs7974380, respectively). 
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Table 6. 6. Association with the main marker on chromosome 10 under different genotypic models. 
Chr SNP A1 A2 TEST AFFECT UNAFFECT CHISQ DF P-VALUE 
10 SNP_A-4204317 A B ALLELIC 95/53 121/177 22 1 2.52e-006 
10 SNP_A-4204317 A B TREND 95/53 121/177 22 1 2.52e-006 
10 SNP_A-4204317 A B GENO 32/31/11 20/81/48 26 2 2.24e-006 
10 SNP_A-4204317 A B DOM 63/11 101/48 8 1 0.005679 
10 SNP_A-4204317 A B REC 32/42 20/129 25 1 7.09e-007 
A1: Minor allele; A2: Major allele. 
 
Table 6. 7. Association with the main marker on chromosome 12 under different genotypic models. 
Chr SNP A1 A2 TEST AFFECT UNAFFECT CHISQ DF P-VALUE 
12 SNP_A-1888702 A B ALLELIC 44/102 149/127 22 1 2.89e-006 
12 SNP_A-1888702 A B TREND 44/102 149/127 22 1 2.25e-006 
12 SNP_A-1888702 A B GENO 4/36/33 39/71/28 22 2 1.33e-005 
12 SNP_A-1888702 A B DOM 40/33 110/28 14 1 0.0001461 
12 SNP_A-1888702 A B REC 4/69 39/99 15 1 9.31e-005 
A1: Minor allele; A2: Major allele. 
 
For the SNP on chromosome 10, cytoband q11.21, the nearest gene, about 250 kb of distance, 
correspond to the CXCL12 gene. This gene is called "chemokine (C-X-C motif) ligand 12 (stromal 
cell-derived factor 1)" and belongs to the intercrine family. It has a role in the activation of 
leukocytes and it induces by different pro-inflammatory stimuli such as lipopolysaccharide, TNF or 
IL1. 
The SNP on chromosome region 12q24.23 is close to several genes (about 150-200Kb) none of 
them being a suitable candidate gene for albuminuria. 
A graphical representation of the main association analysis is shown in the figure 6.5 
Figure 6. 5. Manhattan plot for the main association analysis with albuminuria and cluster plots of 
the main associated markers. 
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Table 6. 8. Characteristics of the main associated SNPs with albuminuria. 
SNPID Call 
Rate 
%AA %AB %BB MAF H.W. p-
Value 
dbSNP 
rS ID 
Chr Physical 
Position 
Allele 
A 
Allele 
B 
SNP_A-4215311 91.67 5.263 19.736 66.666 0.1650 0.00155 rs6980941 8 16185825 C G 
SNP_A-4204317 98.25 24.56 46.49 27.19 0.4866 0.42858 rs2154401 10 43975281 A G 
SNP_A-1888702 92.54 15.35 47.80 29.38 0.4241 0.40359 rs7974380 12 116877645 A G 
 
Table 6. 9. Fisher test for the main associated SNPs. 
Chr SNP BP A1 FA FU A2 OR UL LL p-val 
8p22 SNP_A-4215311 16185825 A 0.235 0.053 B 5.46 2.81 10.55 1.646e-007 
10q11.21 SNP_A-4204317 43975281 A 0.642 0.406 B 2.62 1.74 3.94 3.297e-006 
12q24.23 SNP_A-1888702 116877645 A 0.301 0.54 B 0.36 0.24 0.56 3.356e-006 
A1: Minor allele; A2: Major allele; FA: Frequency in affected; FU: Frequency in unaffected; UL: Upper limit, LL: Lowe limit. 
 
6.3.2.1.2. Haplotype and LD analysis  
In this region 8p22 we found one haplotype, which included the marker most associated with 
the risk of albuminuria. This haplotype, BAA, include the allele A of the previously associated SNP, 
the allele B for the SNP_A-1802309, which is located -142 kb to the main associated marker, and 
the allele A for the SNP_A-2202211, which is located -101 kb to the main associated SNP. These 
two SNPs are located within intronic regions of the MSR1 gene. 
It is noteworthy that the association with the haplotype is stronger than the association with the 
individual SNP (Table 6.10). 
 
Table 6. 10. Haplotype association analysis for markers in region 8p22. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ OR CHISQ P-VALUE 
SNP_A-1802309 
(rs351562) 
0.237/0.233 0.996 -142 0.0195 1.19 0.591 0.442 
SNP_A-2202211 
(rs614439) 
0.165/0.125 0.991 -101 0.0509 1.23 0.668 0.414 
SNP_A-4215311 
(rs2154401) 
0.111/0.042 0.904 0 * 4.7 26.6 2.47e-007 
 
HAPLOTYPE 
..* 
FREQ OR CHISQ P-VALUE 
BAA 0.0655 6.82 28 1.2e-007 
ABB 0.0732 1.16 0.22 0.639 
AAB 0.119 0.839 0.375 0.54 
BAB 0.647 0.548 6.74 0.00944 
SNP_A-1802309, SNP_A-2202211, SNP_A-4215311 
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Figure 6. 6. Cluster plots for the other two markers which form the haplotype with the most 
associated marker. 
 
Table 6. 11. Main characteristics of the other two markers which form the haplotype with the most 
associated marker. 
SNPID SNP 
Call Rate 
SNP 
%AA 
SNP 
%AB 
SNP 
%BB 
MAF H.W. 
p-Value 
dbSNP 
rs ID 
Chr Physical 
Position 
Allele 
A 
Allele 
B 
SNP_A-1802309 98.68 4.38 35.52 58.77 0.224 0.609 rs351562 8 16043410 A G 
SNP_A-2202211 99.56 72.36 25.43 1.75 0.145 0.670 rs614439 8 16085267 C G 
 
The LD of the associated region on chromosome 8 is shown in figure 6.7. 
 
Figure 6. 7. LD map with haploblocks for the region ± 200kb of the hit on chromosome 8 (LD is 
shown as D'/LOD with the D' values). 
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None of the proxy SNPs to the most associated one (SNP_A-4215311) were in strong linkage 
(R2>0.8) with it. 
As we can see in the figure above, the main associated marker (SNP_A-4215311 (rs6980941) is 
located between two areas of high LD. In contrast the SNP_A-2202211 (rs614439) is a region of 
high LD and is a Tag-SNPs for the following markers: SNP_A-1992440 (rs614794), SNP_A-
4222370 (rs438721), SNP_A-4222828 (rs368773), SNP_A-2089204 (rs414580).       
For the marker on chromosome region 10q11.21, the haplotype association was weaker than that 
for the individual marker (Table 6.12) 
 
Table 6. 12. Haplotype association analysis for markers in region 10q11.21. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ OR CHISQ P-VALUE 
SNP_A-2213753 
(rs1492712) 
0.293/0.258 0.969 -123 0.245 0.563 
 
7.52 
 
0.00611 
SNP_A-2001107 
(rs2639463) 
0.468/0.450 0.956 -89.2 0.64 2.23 15.5 8.1e-005 
SNP_A-4204317 
(rs10810668) 
0.484/0.408 0.974 0 * 2.6 22.7 1.93e-006 
 
HAPLOTYPE 
..* 
FREQ OR CHISQ P-VALUE 
BBA 0.406 2.36 17.6 2.77e-005 
BAA 0.0501 2.01 3.61 0.0573 
AAB 0.264 0.505 9.71 0.00183 
BAB 0.209 0.474 9.09 0.00258 
SNP_A-2213753, SNP_A-2001107, SNP_A-4204317 
 
All the SNP forming the haplotype are in an intergenic region of chromosome 10, cytoband q11.21. 
The LD of that region is shown in the figure 6.8. 
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Figure 6. 8. LD of the associated region on chromosome 10. 
 
The main associated marker in this region is not in high LD (R-sq>0.8) with others markers. 
For the markers on chromosome 12, cytoband q24.23, the haplotype analysis and LD is shown in 
table 6.13 and figure 6.9. 
Table 6. 13. Haplotype association analysis for markers in region 12q24.23. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ OR CHISQ P-VALUE 
SNP_A-4232903 
(rs11068715) 
0.114/0.075 1 -65.3 0.0204 1.16 
 
0.233 
 
0.629 
SNP_A-2269666 
(rs10850931) 
0.122/0.067 1 -52.5 0.0184 1.44 1.68 0.195 
SNP_A-1888702 
(rs7974380) 
0.457/0.425 0.921 0 * 0.394 22.6 2e-006 
 
HAPLOTYPE 
..* 
FREQ OR CHISQ P-VALUE 
ABA 0.413 0.421 20.5 6.08e-006 
BAB 0.06 1.91 3.43 0.0639 
ABB 0.43 1.95 12.7 0.000365 
BAB 0.209 0.474 9.09 0.00258 
SNP_A-4232903, SNP_A-2269666, SNP_A-1888702 
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Figure 6. 9. LD of the associated region on chromosome 12 cytoband q24.23. 
 
Again, there are not other SNPs in high LD with the associated marker in this region. 
6.3.2.2. Association analysis for microalbuminuria 
 The genomic control for this analysis was 1.05 with a mean chi-square statistic of 1.04.  
Figure 6. 10.  Q-Q plot for the observed and expected p-values (unadjusted) for the association 
with microalbuminuria. 
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6.3.2.2.1. Individual SNPs analysis 
After removing 8 patients with macroalbuminuria (EUA≥300mg/day), the most associated SNP 
on chromosome 8 in the individual analysis without remained statistically significant even 
considering Bonferroni correction [SNP_A-4215311(rs6980941), unadjusted p-value 1.74e-007; 
Bonferroni p-value 0.029 for the basic allelic test]. The second and third most associated SNP 
were also the same that in the association analysis for albuminuria, SNP_A-4204317 (rs2154401) 
on chromosome region 10q11.21 and SNP_A-1888702 (rs7974380) on chromosome region 
12q24.23. As it happened before these SNP did not reach the statistical significance (p-value 
unadjusted 1.28e-006 and 6.12e-006, Bonferroni p-value 0.21 and 1, respectively).   
The association with these markers under different genotypic model is shown in tables 6.14-6.16. 
The Manhattan plot for this analysis is shown in figure 6.11. 
 
Table 6. 14. Association with the main marker on chromosome 8 under different genotypic models. 
Chr SNP A1 A2 TEST AFFECT UNAFFECT CHISQ DF P-VALUE 
8 SNP_A-4215311 A B ALLELIC 27/91 15/267 27 1 1.739e-007 
8 SNP_A-4215311 A B TREND 27/91 15/267 25 1 5.966e-007 
8 SNP_A-4215311 A B GENO 4/19/36 0/15/126 25 2 3.61e-006 
8 SNP_A-4215311 A B DOM 23/36 15/126 22 1 3.16e-006 
8 SNP_A-4215311 A B REC 4/55 0/141 10 1 0.001789 
A1: Minor allele; A2: Major allele. 
 
Table 6. 15. Association with the main marker on chromosome 10 under different genotypic 
models. 
Chr SNP A1 A2 TEST AFFECT UNAFFECT CHISQ DF P-VALUE 
10 SNP_A-4204317 A B ALLELIC 87/45 121/177 23 1 1.27e-006 
10 SNP_A-4204317 A B TREND 87/45 121/177 24 1 9.429e-007 
10 SNP_A-4204317 A B GENO 29/29/8 20/81/48 27 2 1.55e-006 
10 SNP_A-4204317 A B DOM 58/8 101/48 10 1 0.001959 
10 SNP_A-4204317 A B REC 29/37 20/129 24 1 8.653e-007 
A1: Minor allele; A2: Major allele. 
 
Table 6. 16. Association with the main marker on chromosome 12 under different genotypic 
models. 
Chr SNP A1 A2 TEST AFFECT UNAFFECT CHISQ DF P-VALUE 
12 SNP_A-1888702 A B ALLELIC 39/91 149/127 20 1 6.12e-006 
12 SNP_A-1888702 A B TREND 39/91 149/127 21 1 5.47e-006 
12 SNP_A-1888702 A B GENO 4/31/30 39/71/28 21 2 3.3e-005 
12 SNP_A-1888702 A B DOM 35/30 110/28 14 1 1.41e-004 
12 SNP_A-1888702 A B REC 4/61 39/99 13 1 3.23e-004 
A1: Minor allele; A2: Major allele. 
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Figure 6. 11. Manhattan plot for the association analysis with microalbuminuria. 
 
6.3.2.2.2. Haplotype and LD analysis 
The association with the three SNPs haplotype "BAA" on chromosome region 8p22 remained 
but it was a little bit weaker than the previously described for albuminuria as you can see in table 
6.17. 
 
Table 6. 17. Haplotype association analysis for the markers on chromosome region 8p22. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ OR CHISQ P-VALUE 
SNP_A-1802309 
(rs351562) 
0.239/0.233 0.995 -142 0.0212 1.24 0.889 0.346 
SNP_A-2202211 
(rs614439) 
0.168/0.125 0.995 -101 0.0526 1.29 0.956 0.328 
SNP_A-4215311 
(rs6980941) 
0.105/0.042 0.905 0 * 4.54 24.4 7.97e-007 
 
HAPLOTYPE 
..* 
FREQ OR CHISQ P-VALUE 
BAA 0.0597 6.76 24.5 7.51e-007 
ABB 0.0741 1.27 0.49 0.484 
AAB 0.121 0.899 0.128 0.721 
BAB 0.649 0.604 5.34 0.0209 
SNP_A-1802309, SNP_A-2202211, SNP_A-4215311 
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Regarding to the haplotype on chromosome region 10q11.21, the association with the haplotype, 
BBA, although it was weaker than that for the individual SNP, it was stronger than that for 
albuminuria (Table 6.18). 
 
Table 6. 18. Haplotype association analysis for the markers on chromosome region 10q11.21. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ OR CHISQ P-VALUE 
SNP_A-2213753 
(rs1492712) 
0.297/0.258 0.968 -123 0.244 0.576 
 
6.65 
 
0.00989 
SNP_A-2001107 
(rs2639463) 
0.469/0.450 0.955 -89.2 0.653 2.41 17.1 2.61e-005 
SNP_A-4204317 
(rs10810668) 
0.484/0.408 0.973 0 * 2.8 24.6 7.13e-007 
 
 
HAPLOTYPE 
..* 
FREQ OR CHISQ P-VALUE 
BBA 0.407 2.94 23.7 1.13e-006 
AAB 0.267 0.52 8.48 0.00359 
BAB 0.208 0.435 10.3 0.00136 
SNP_A-2213753, SNP_A-2001107, SNP_A-4204317 
 
In contrast the association with the haplotype, ABA, on chromosome 12, cytoband q24.23, was 
weaker than that obtained for albuminuria (Table 6.19). 
 
Table 6. 19. Haplotype association analysis for the markers on chromosome region 12q24.23. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ OR CHISQ P-VALUE 
SNP_A-4232903 
(rs11068715) 
0.115/0.075 1 -65.3 0.0229 1.23 
 
0.465 
 
0.495 
SNP_A-2269666 
(rs10850931) 
0.124/0.067 1 -52.5 0.0206 1.56 2.4 0.122 
SNP_A-1888702 
(rs7974380) 
0.463/0.425 0.919 0 * 0.393 20.9 4.93e-006 
 
HAPLOTYPE 
..* 
FREQ OR CHISQ P-VALUE 
ABA 0.419 0.425 18.3 1.87e-005 
BAB 0.0607 2.05 4.05 0.0441 
ABB 0.421 1.88 10.7 0.00107 
SNP_A-4232903, SNP_A-2269666, SNP_A-1888702 
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6.3.3. Association analysis for qualitative traits adjusted for clinical co-variables 
Before to start the description of these analyses, it is important to say that there were a 
significant number of subjects with missing values for some of the co-variables (around 54 
depending on the model), so the sample size and therefore the statistical power were markedly 
reduced.  
6.3.3.1. Association analysis for albuminuria  
This analysis included only 38 cases and 137 controls.  The genomic controls for these 
analysis was around 1.0 and the mean chi-square statistic was also around 1.0.  
In this case, there was not association for the marker, SNP_A-4215311 (p-value 0.06), which was 
significantly associated with albuminuria without including clinical co-variables neither for the 
haplotype "BAA" of the SNPs: SNP_A-1802309, SNP_A-2202211, SNP_A-4215311 (p-value 
0.07). 
As co-variables we included those clinical variables that seem to increase the risk of albuminuria 
including: age, sex, BMI, SBP, glucose, creatinine clearance (CC) estimated by Cockcroft-Gault 
formula, eGFR by MDRD formula and the number of drugs expressed as a qualitative variable (two 
or more drugs or less than two drugs).  
6.3.3.1.1. Models with number of drugs as co-variable 
6.3.3.1.1.1. Individual SNPs analysis 
For the models which include the NºDrugs plus all the others important co-variables, the first 
and second most associated SNPs were on chromosome 2, cytoband q32.2, but they were very far 
from significance, SNP_A-1844966 (rs6719224), and SNP_A-2024873 (rs2033870), unadjusted p-
value 0.00018 and 0.00019 respectively. One of them is located between the O-sialoglycoprotein 
endopeptidase-like 1 (OSGLPL1) and the ORM1-like1 (ORMDL1) genes and the other within an 
intron of the Ankyrin and armadillo repeat-containing protein (ANKAR) gene.  
The third most associated SNP in this analysis was on chromosome 11, cytoband p12 [SNP_A-
2010350 (rs3552231), unadjusted p-value=0.00019] in an intergenic region without any known 
gene close to it. The fourth most associated marker [SNP_A-2194559 (rs146509), unadjusted p-
value= 0.00021] was on chromosome 16, cytoband q23.1, in an intergenic region of the WW 
domain containing oxidoreductase (WWOX) gene.  
The Manhattan plot for these results is shown in Figure 6.12. 
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Figure 6. 12. Manhattan plot for the association analysis with albuminuria including age, sex, BMI, 
SBP, glucose,  eGFR (MDRD) and number of drugs as co-variables. 
 
6.3.3.1.1.2. Haplotype and LD analysis 
We did not find association with any haplotype including the two associated markers on 
chromosome 2, cytoband q32.2. The most associated haplotype in that region of chromosome 2 is 
shown in table 6.20 and include alleles of two SNP within intronic regions of the ANKAR gene and 
of another  polymorphism close to  asparagine synthetase domain-containing protein 1 (ASNSD1) 
and the solute carrier family 40 (iron-regulated transporter), member 1 (SLC40A1) genes. 
 
Table 6. 20. Haplotype association analysis for the markers on chromosome region 2q32.2. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ OR CHISQ P-VALUE 
SNP_A-2180122 
(rs4667295) 
0.232/0.200 
 
0.987 
 
-130 
 
0.421 
 
0.452 
 
5.77 
 
0.0163 
SNP_A-2291588 
(rs1550388) 
0.199/0.146 1 -30.5 1 0.161 16.4 5.05e-005 
SNP_A-1844966 
(rs6719224) 
0.195/0.225 0.965 0 * 0.161 16.4 5.05e-005 
 
HAPLOTYPE 
..* 
FREQ OR CHISQ P-VALUE 
BAB 0.155 0.148 14.7 1.27e-004 
BBA 0.0766 1.52 1.04 0.307 
ABA 0.725 2.34 6.25 0.0124 
SNP_A-2180122, SNP_A-2291588, SNP_A-1844966 
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The LD of that region on chromosome 2 is shown in figure 6.13. 
 
Figure 6. 13. LD of the associated region on chromosome 2. 
 
As we expected the two most associated markers (SNP_A-2024873 and SNP_A-1844966, first 
and second position) on chromosome region 2q32.2 are in high LD (R-sq=1). 
There is a Tag SNP (SNP_A-2143703) within an intronic region of the ORM1-like 1 (ORMDL1) 
gene which captures two of the SNPs of the above described haplotype. 
 
The strength of association for the proxy haplotype analysis on chromosome region 11p12 was 
very weak (Table 6.21). 
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Table 6. 21. Haplotype association analysis for the markers on chromosome region 11p22. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ OR CHISQ P-VALUE 
SNP_A-1784634 
(rs7929217) 
0.149/0.117 0.965 -103 0.302 2.05 
 
4.25 
 
0.0393 
SNP_A-2010350 
(rs355231) 
0.129/0.083 0.965 0 * 2.63 7.78 0.00529 
SNP_A-2296741 
(rs996262) 
0.281/0.316 0.978 79.1 0.337 1.88 5.56 0.0184 
 
HAPLOTYPE 
.*. 
FREQ OR CHISQ P-VALUE 
BAB 0.0799 2.61 6.11 0.0134 
ABB 0.145 1.36 0.832 0.362 
ABA 0.66 0.519 4.18 0.0409 
SNP_A-1784634, SNP_A-2010350, SNP_A-2296471 
 
The LD of this region on chromosome 11 is shown in figure 6.14. 
 
Figure 6. 14. LD of the associated region on chromosome 11. 
 
 
 
Results 
 
 131
The main associated marker in this region is inside one haploblock but there are not others SNPs 
in high LD with it (R-sq>0.8). As it can see in the figure above there are not genes in that region. 
 
For the marker in region q23.1 of chromosome 16, we did not find any haplotype associated (Table 
6.22). 
Table 6. 22. Haplotype association analysis for the markers on chromosome region 16q23.1. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ OR CHISQ P-VALUE 
SNP_A-2021103 
(rs2738708) 
0.132/0.188 0.996 -22 0.283 1.42 
 
0.899 
 
0.343 
SNP_A-2259917 
(rs11150082) 
0.171/0.172 0.983 -8.65 0.815 1.53 1.74 0.187 
SNP_A-2194559 
(rs1465099) 
0.192/0.186 0.978 0 * 1.93 5.05 0.0246 
SNP_A-1892542 
(rs2738502) 
0.312/0.312 0.987 25.2 0.44 1.39 1.4 0.237 
SNP_A-1945385 
(rs2667648) 
0.201/0.200 1 35.8 0.425 1.23 0.428 0.513 
 
HAPLOTYPE 
..*.. 
FREQ OR CHISQ P-VALUE 
 BBABA 0.0728 1.49 0.816 0.366 
AABBB 0.0741 1.24 0.176 0.675 
ABBAB 0.635 0.703 0.579 0.447 
SNP_A-2021103, SNP_A-2259917, SNP_A-2194559, SNP_A-1892542, SNP_A-1945385 
The LD of that region of the WWOX gene on chromosome 16 is shown in figure 6.15. 
Figure 6. 15. LD of the associated region on chromosome 16. 
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The most associated marker in that region, SNP_A-2194559 is a tag-SNP for SNP_A2259917 (R-
sq=0.808). Other marker within the haplotype (SNP_A-2021103) is also a tag-SNP for other five 
polymorphisms. 
6.3.3.1.2. Models without number of drugs as co-variable 
6.3.3.1.2.1. Individual SNPs analysis 
For the model without NºDrugs as co-variable, the results were different. These results 
remained quite similar it does not matter that we use the CC estimated by the Crockoft-Gault 
formula, the eGFR by MDRD or the DBP instead SBP. The most associated SNP in this case, 
although without statistical significance after multiple comparisons correction was also located in 
the short arm of chromosome 8 (cytoband p21.2) and correspond to the marker SNP_A-1992707 
(rs4872244) (unadjusted p-value 3.219e-005).  The third most associated SNP [SNP_A-1911590 
(rs6557750)] was also in the same location 8p21.2. These two SNPs are in LD with an R-sq 
value=0.641 and D'= 0.836.  These two SNPs on chromosome region 8p21.2 are quite close (less 
than 100kb) to the ADAM7 gene.  This gene belongs to a family of zinc-binding proteins which can 
act either as adhesion proteins or as endopeptidases. Therefore can be involved in multiple 
biological processes including inflammation. 
The second most associated marker, was SNP_A-2307844 (rs11241841), unadjusted p-value 
3.33e-005 which was located on chromosome 5, cytoband q23.2, in an intergenic region without 
genes close to it. The fourth most associated marker was SNP_A-2099344 (rs1721936)  
unadjusted p-value 4.31e-005,  on chromosome 7, cytoband p14.1, close to several genes: 
EPDR1, SFRP4, TXNDC3.   
The Manhattan plot for these results is shown in figure 6.16. 
Figure 6. 16. Manhattan plot for the association analysis with albuminuria including age, sex, BMI, 
SBP, glucose, and eGFR (MDRD) as co-variables. 
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6.3.3.1.2.2. Haplotypes and LD analysis     
For the marker on chromosome region 8p21.2, we also found one haplotype including the two 
previously described markers and the marker [SNP_A-4225817 (rs12551522)] which is located 
within an intronic region of the ADAM7 gene. This SNP is also a Tag-SNP for the marker SNP_A-
2090729 (rs2131227). The association with the haplotype is a little bit stronger than the individual 
SNPs association (Table 6.23). 
 
Table 6. 23. Haplotype association analysis for the markers on chromosome region 8p21.2. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ OR CHISQ P-VALUE 
SNP_A-4225817 
(rs12551522) 
0.382/0.30 
 
0.978 
 
-67.4 
 
0.0769 
 
1.18 
 
0.662 
 
0.416 
SNP_A-1992707 
(rs4872244) 
0.124/0.229 0.969 -3.47 0.639 2.26 8.01 0.00466 
 
SNP_A-1911590 
(rs6557750) 
0.11/0.225 0.991 0 * 2.25 7.95 0.00481 
 
HAPLOTYPE 
.*. 
FREQ OR CHISQ P-VALUE 
ABB 0.0952 1.91 4.43 0.0353 
AAB 0.0159 5.16 4.83 0.028 
ABA 0.0254 3.46 4.8 0.0284 
BAA 0.381 1.18 0.662 0.416 
AAA 0.482 0.527 10.1 0.00148 
SNP_A-4225817, SNP_A-1992707, SNP_A-1911590 
 
The LD of the associated region with the haploblocks is shown in figure 6.17. 
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Figure 6. 17. LD of the associated region on chromosome 8. 
 
For the marker on chromosome 5, the association with one haplotype was stronger than that for 
the individual marker (Table 6.24). 
 
Table 6. 24. Haplotype association analysis for the markers on chromosome region 5q23.2. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ OR CHISQ P-VALUE 
SNP_A-2307844 
(rs11241841) 
0.443/0.325 0.917 0 * 0.232 
 
18.3 
 
1.93e-005 
SNP_A-2026794 
(rs2568395) 
0.359/0.438 0.978 9.83 0.615 0.356 11.1 8.69e-004 
SNP_A-1983351 
(rs326041) 
0.251/0.200 0.974 108 0.262 0.412 5.9 0.0151 
 
HAPLOTYPE 
*.. 
FREQ OR CHISQ P-VALUE 
BAB 0.214 0.387 6.1 0.0135 
BAA 0.128 0.412 4 0.0454 
BBA 0.0843 0.0102 6.8 0.00914 
ABA 0.517 4.54 20.4 6.16e-006 
SNP_A-2307844, SNP_A-2026794, SNP_A-1983351 
These three SNPs are in an intergenic region without any genes close to them (Figure 6.18). 
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Figure 6. 18. LD of the associated region on chromosome 5. 
 
Although we excluded those SNPs which were not in HWE (p-value of filter 0.0001), the main 
associated SNP on chromosome 5, cytoband q23.2, was not in HWE according to the Haploview 
software.  
For the marker on chromosome region 7p14.1, we found one haplotype but the association was a 
little bit weaker than that for the individual marker (Table 6.25). 
 
Table 6. 25. Haplotype association analysis for the markers on chromosome region 7p14.1. 
SNP  MAF(our sample/HapMap-CEU ) GENO KB RSQ OR CHISQ P-VALUE 
SNP_A-2099344 
(rs1721396) 
0.18/0.225 0.996 0 * 3.18 
 
18.2 
 
2.04e-005 
SNP_A-2183960 
(rs1721393) 
0.47/0.479 0.956 5.09 0.246 1.94 6.22 0.0126 
SNP_A-1889781 
(rs1403986) 
0.191/0.254 0.983 40.3 0.916 2.69 13.3 2.67e-004 
 
HAPLOTYPE 
*.. 
FREQ OR CHISQ P-VALUE 
BBA 0.18 3.1 17.5 2.8e-005 
ABB 0.288 0.843 0.395 0.53 
AAB 0.519 0.525 5.88 0.0153 
SNP_A-2099344, SNP_A-2183960, SNP_A-1889781 
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The LD of that region on chromosome 7 is shown in figure 6.19. 
Figure 6. 19. LD of the associated region on chromosome 7. 
 
The main marker in that region, SNP_A-2099344 is between two haploblocks and also is a Tag 
SNP for SNP_A-1889781 (R-sq=0.91). This last SNP was in the position number 62 in this 
association analysis. 
As you can see the three SNPs are in an intergenic region close to several genes.  
6.3.3.2. Association analysis for microalbuminuria  
After including clinical co-variables in the model none of the SNPs reached the significance 
level after adjusting for multiple comparisons. Again there was not association with the marker 
SNP_A-4215311 neither for the haplotype which included this SNP.  
6.3.3.2.1. Models with number of drugs as co-variable 
6.3.3.2.1.1. Individual SNPs analysis 
The genomic control for this analysis was 1.02 with a mean chi-squared statistic of 1.00. For 
the models which included NºDrugs as co-variable, the most associated SNPs were far away from 
significance. The most associated SNPs were on chromosome regions: 11p12 [SNP_A-2010350 
(rs355231)], 5q23.2 [SNP_A-2307844 (rs11241841) and SNP_A-4211251 (rs13180385)], 16q23.1 
[SNP_A-2194559 (rs1465099)], 8p11.21 [SNP_A-2151676 (rs11787055)], 2p16.1 [SNP_A-
1889822 (rs10427222)] and 2q32.2 [SNP_A-2024873 (rs2033870), and SNP_A-1844966 
(rs6719224)], with unadjusted p-values within the range 0.00012 and 0.00030). 
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Many of these polymorphisms as we expected were the most associated with albuminuria 
including co-variables. 
The Manhattan plot for this analysis is shown in figure 6.20. 
 
Figure 6. 20. Manhattan plot for the association analysis with microalbuminuria including age, sex, 
BMI, SBP, glucose, eGFR (MDRD) and number of drugs as clinical co-variables. 
 
 
6.3.3.2.1.2. Haplotype and LD analysis 
The haplotype analysis for markers on chromosome regions 11p12 and 5q23.2 are shown in 
tables 6.26 and 6.27. For the markers on chromosome 16q23.1, 8p11.21 and 2p16.1 we did not 
find any haplotype significantly associated. 
The LD of some of those regions has been previously shown (Figures 6.14, 6.15 and 6.18). 
In figures 6.21 and 6.22 we show the LD of the main associated markers on chromosome regions 
8p11.21 and 2p16.1 respectively.  
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Figure 6. 21. LD of the associated region on chromosome 8. 
 
The most associated marker in this chromosomal region (8p11.21), SNP_A-2151676, is inside one 
haploblock. There are not other SNPs in high LD (R-sq>0.8) with it. 
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Figure 6. 22. LD of the associated region on chromosome 2. 
 
The most associated marker in this region 2p16.1, SNP_A-1889822, belongs to one haploblock 
and it is in high LD wit SNP_A-1829255 which is a tag SNP also for SNP_A-2073456. 
 
The proxy association analysis for the associated markers at locus 11p12 and 5q23.2 is shown in 
table 6.26 and table 6.27. 
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Table 6. 26. Haplotype association analysis for microalbuminuria and markers on chromosome 
region 11p12 including age, sex, BMI, SBP, glucose, eGFR (MDRD) and number of drugs as 
clinical co-variables. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ OR CHISQ P-VALUE 
SNP_A-1784634 
(rs7929217) 
0.15/0.117 0.968 -103 0.304 2.19 5.05 0.0246 
SNP_A-2010350 
(rs355231) 
0.133/0.083 0.973 0 * 2.82 8.78 0.00304 
SNP_A-2296471 
(rs996262) 
0.285/0.316 0.977 79.1 0.339 1.93 5.82 0.0159 
 
HAPLOTYPE 
.*. 
FREQ OR CHISQ P-VALUE 
BAB 0.0811 2.81 7.06 0.00789 
ABB 0.146 1.32 0.632 0.427 
ABA 0.658 0.508 4.25 0.0393 
SNP_A-1784634, SNP_A-2010350,  SNP_A-2296471 
 
Table 6. 27. Haplotype association analysis for microalbuminuria and markers on chromosome 
region 5q23.2 including age, sex, BMI, SBP, glucose, eGFR (MDRD) and number of drugs as 
clinical co-variables. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ OR CHISQ P-VALUE 
SNP_A-2307844 
(rs11241841) 
0.443/0.325 0.914 0 * 0.205 19.6 9.65e-006 
SNP_A-2026794 
(rs2568395) 
0.354/0.438 0.977 9.83 0.612 0.29 14 1.8e-004 
SNP_A-1983351 
(rs326041) 
0.249/0.200 0.982 108 0.254 0.348 7.47 0.00628 
 
HAPLOTYPE 
*.. 
FREQ OR CHISQ P-VALUE 
BAB 0.211 0.304 8.3 0.00396 
BAA 0.127 0.431 3.61 0.0576 
BBA 0.0874 0.00968 6.41 0.0113 
ABA 0.518 5.22 22.2 2.45e-006 
SNP_A-2307844, SNP_A-2026794, SNP_A-1983351 
 
Regarding to the haplotype in region q32.2 of chromosome 2 which I described in the association 
with albuminuria adjusted for age, sex, BMI, SBP, glucose, eGFR (MDRD) and number of drugs, 
Results 
 
 141
for the case of microalbuminuria the association was a little bit weaker than the previous one 
(Table 6.28). 
 
Table 6. 28. Haplotype association analysis for microalbuminuria and markers on chromosome 
region 2q32.2 including age, sex, BMI, SBP, glucose, eGFR (MDRD) and number of drugs as 
clinical co-variables. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ OR CHISQ P-VALUE 
SNP_A-2180122 
(rs4667295) 
0.236/0.200 
 
0.986 
 
-130 
 
0.429 
 
0.481 
 
4.83 
 
0.0279 
SNP_A-2291588 
(rs1550388) 
0.201/0.146 1 -30.5 1 0.17 15.2 9.87e-005 
SNP_A-1844966 
(rs6719224) 
0.197/0.225 0.964 0 * 0.17 15.2 9.87e-005 
 
HAPLOTYPE 
..* 
FREQ OR CHISQ P-VALUE 
BAB 0.159 0.157 13.5 2.34e-004 
BBA 0.0769 1.62 1.37 0.241 
ABA 0.722 2.2 5.28 0.0215 
SNP_A-2180122,  SNP_A-2291588,  SNP_A-1844966 
 
6.3.3.2.2. Models without number of drugs as co-variable 
6.3.3.2.2.1. Individual SNPs analysis 
For the model without including the number of drugs as co-variable, two of the most associated 
SNP, first [SNP_A-2307844 (rs11241841)] and fourth [SNP_A-1983348 (rs327866)] positions, 
were on chromosome 5, cytoband q23.2. The second [SNP_A-2099344 (rs1721396)] and third 
[SNP_A-1989536 (rs7778558)] most associated SNPs were on chromosome region 7p14.1 and 
7p14.2 respectively. Interestingly within the region 7p14.2 is located the ELMO gene which has 
been previously associated with diabetic nephropathy. The most associated marker in the case of 
the association for albuminuria adjusted for clinical covariates excluding NºDrugs on chromosome 
8, cytoband p21.2 (SNP_A-1992707) was in the fifth position (p-value unadjusted 9.62e-005). 
The Manhattan plot for this analysis is shown in figure 6.23. 
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Figure 6. 23. Manhattan plot for the association analysis with microalbuminuria including age, sex, 
BMI, SBP, glucose, and eGFR (MDRD) as clinical co-variables. 
 
 
6.3.3.2.2.2. Haplotype and LD analysis  
As I said before, the LD of some of the associated regions has been previously described 
Regarding to the haplotype analysis we found stronger association with one haplotype which 
include the markers on chromosome 5 than that observed for the individual SNPs (Table 6.29). 
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Table 6. 29. Haplotype association analysis for microalbuminuria and markers on chromosome 
region 5q23.2 including age, sex, BMI, SBP, glucose and eGFR (MDRD) as clinical co-variables. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ OR CHISQ P-VALUE 
SNP_A-2307844 
(rs11241841) 
0.443/0.325 0.914 0 * 0.205 
 
19.7 
 
8.91e-006 
SNP_A-1983348 
(rs327866) 
0.406/0.375 0.991 15.5 0.459 0.33 14.4 1.46e-004 
 
SNP_A-2057221 
(rs7727284) 
0.262/0.208 0.999 75.6 0.415 0.328 9.15 0.00248 
 
HAPLOTYPE 
*.. 
FREQ OR CHISQ P-VALUE 
BBB 0.252 0.346 8.08 0.00447 
BBA 0.0905 0.335 3.48 0.0619 
ABA 0.0575 0.935 0.0188 0.891 
BAA 0.0896 0.0253 5.7 0.017 
AAA 0.5 4.36 22.6 1.96e-006 
SNP_A-2307844,  SNP_A-1983348, SNP_A-2057221 
 
We also found a stronger association with another haplotype including the markers on 
chromosome 7 (Table 6.30). 
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Table 6. 30. Haplotype association analysis for microalbuminuria and markers on chromosome 
region 7p14.1 including age, sex, BMI, SBP, glucose and eGFR (MDRD) as clinical co-variables. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ OR CHISQ P-VALUE 
SNP_A-2266758 
(rs1668349) 
0.409/0.350 0.991 -62.5 0.145 0.578 
 
19.7 
 
0.447 
SNP_A-2099344 
(rs1721396) 
0.173/0.225 0.995 0 * 18.1 14.4 2.05e-005 
SNP_A-1989606 
(rs10280461) 
0.491/0.295 0.995 78.2 0.201 1.13 9.15 0.288 
 
HAPLOTYPE 
.*. 
FREQ OR CHISQ P-VALUE 
AAA 0.363 0.731 1.18 0.278 
BAA 0.127 1.14 0.139 0.709 
BBB 0.174 3.42 20.4 6.34e-006 
BAB 0.291 0.397 6.52 0.0107 
AAA 0.5 4.36 22.6 1.96e-006 
SNP_A-2266758, SNP_A-2099344, SNP_A-1989606 
 
For the marker on chromosome 7, cytoband p14.2, the association with the haplotype was weaker 
than that for the individual analysis (Table 6.31). 
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Table 6. 31. Haplotype association analysis for microalbuminuria and markers on chromosome  
region 7p14.2 including age, sex, BMI, SBP, glucose and eGFR (MDRD) as clinical co-variables. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ OR CHISQ P-VALUE 
SNP_A-2225176 
(rs4723436) 
0.234/0.208 0.995 -101 0.12 1.21 
 
0.423 
 
0.515 
SNP_A-1989536 
(rs7778558) 
0.144/0.125 0.986 0 * 3.41 16.7 4.45e-005 
SNP_A-2037803 
(rs10233082) 
0.326/0.308 0.973 198 0.14 1.75 4.06 0.044 
 
HAPLOTYPE 
.*. 
FREQ OR CHISQ P-VALUE 
BBA 0.0536 1.72 1.81 0.177 
ABA 0.0552 3.19 7.01 0.00809 
AAA 0.212 1.36 1 0.316 
BAB 0.143 0.418 3.56 0.059 
AAB 0.495 0.732 1.25 0.263 
SNP_A-2225176, SNP_A-1989536, SNP_A-2037803 
The LD of that region on chromosome 7 is shown in figure 6.24. 
Figure 6. 24. LD of the associated region on chromosome 7. 
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The main associated marker is not in high LD (R-sq>0.8) with others markers.  
The association with a similar haplotype than that previously described for albuminuria with co-
variables on chromosome region 8p21.2 was stronger for the case of microalbuminuria (Table 
6.32). 
 
Table 6. 32. Haplotype association analysis for microalbuminuria and markers on chromosome 
region 8p21.2 including age, sex, BMI, SBP, glucose and eGFR (MDRD) as clinical co-variables. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ OR CHISQ P-VALUE 
SNP_A-1924618 
(rs9314285) 
0.148/0.258 0.946 -80.8 0.721 2.42 8.19 0.00422 
SNP_A-4225817 
(rs12551522) 
0.385/0.30 
 
0.982 
 
-64 
 
0.0838 
 
0.929 0.0725 
 
0.788 
SNP_A-1992707 
(rs4872244) 
0.119/0.229 0.968 0 * 3.16 11.3 7.78e-004 
 
 
HAPLOTYPE 
..* 
FREQ OR CHISQ P-VALUE 
BAB 0.115 3.14 11.6 6.74e-004 
ABA 0.355 0.941 0.0493 0.824 
AAA 0.493 0.586 4.11 0.0427 
SNP_A-1924618,  SNP_A-4225817, SNP_A-1992707 
 
Also two of the SNP of this haplotype are in intronic region of the ADAM7 gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
 147
6.3.4. Association analysis for quantitative traits (Unadjusted) 
6.3.4.1. Association analysis for UAE 
The genomic control for this analysis was 1.07 with a mean chi-square of 1.02. Below is shown 
the Q-Q plot for this analysis (Figure 6.25) and the graphical representation of the results (Figure 
6.26). 
 
Figure 6. 25. Q-Q plot for the observed and expected p-values (adjusted for GC) for the 
association analysis with UAE. 
 
 
6.3.4.1.1. Individual SNPs analysis 
In the analysis for the quantitative trait, we found two SNPs which reached the statistical 
significance even after Bonferroni correction.  
The most associated one was also located on chromosome 8 and correspond to the marker, 
SNP_A-4205634 (rs41534844) (p-value unadjusted=1.17x10-9, Bonferroni p-value=0.00019). The 
empirical p-value for the adaptative permutation analysis was 7e-006 after one million of 
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permutations. This marker, in contrast to the one associated with the qualitative trait, is located not 
in the short arm but in the long arm of chromosome 8 (cytoband q12.1).  Carriers of the minor 
allele of this SNP had higher levels of UAE than carriers of the major allele (Beta 49.8 (34.6-65.1), 
p-value 1.17x10-9). 
This marker, rs41534844, is very close (less than 100Kb) to a non coding RNA gene (U6 
spliceosomal RNA) and to the inositol monophosphatase domain containing 1 gene (IMPAD1) and 
there were not other SNPs in high LD (R-sq>0.8) with it. 
The other marker which was significantly associated with UAE was on chromosome 2 (cytoband 
p11.2) and corresponded to the marker, SNP_A-2207401 (rs11675985) (p-value 
unadjusted=6.39x10-9, Bonferroni p-value=0.001). The empirical p-value for the adaptative 
permutation analysis was 1.0e-005 after one million of permutations. This SNP is located in an 
intronic region of the Receptor Expression-Enhancing Protein 1 (REEP1) gene and it is not in high 
LD with another markers. 
The third most associated marker although it was not statistically significant was on chromosome 9 
[SNP_A-2169005 (rs1339550) (p-value unadjusted=1.30e-006, Bonferroni p-value=0.220)].  This 
SNP is located in cytoband p22.2, in an intronic region of the basonuclin (BNC2) gene. 
None of the SNP previously associated with the qualitative trait reached the statistical significance. 
 
Figure 6. 26. Manhattan plot for the association analysis with UAE. 
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Table 6. 33. Characteristics of the main associated SNPs with UAE. 
SNPID Call 
Rate 
%AA %AB %BB MAF H.W. p-
Value 
dbSNP 
rs ID 
Chr Physical 
Position 
Allele 
A 
Allele 
B 
SNP_A-4205634 94.74 2.63 18.42 73.68 0.125 0.102 rs41534844 8 57985421 C T 
SNP_A-2207401 99.56 1.75 18.42 79.38 0.110 0.398 rs11675985 2 86412486 G T 
SNP_A-2169005 96.93 75.87 19.73 1.31 0.115 0.969 rs1339550 9 16844839 C T 
. 
Table 6. 34. Linear regression for the main associated SNPs with UAE. 
Chr SNP BP A1 BETA SE UL LL STAT p-value 
8q12.1 SNP_A-4205634 (rs41534844) 57985421 A 49.87 7.78 34.6 65.1 6.41 1.178e-009 
2p11.2 SNP_A-2207401 (rs11675985) 86412486 A 54.9 9.05 37.21 72.56 6.09 6.396e-009 
9p22.2 SNP_A-2169005  (rs1339550) 16844839 B 44.08 8.80 26.83 61.34 5.07 1.301e-006 
A1: minor allele; UL: upper limit; LL: lower limit. 
6.3.4.1.2. Haplotype and LD analysis 
We also found one haplotype including the most associated marker significantly associated 
although the level of association was weaker than that for the individual marker (Table 6.35, Figure 
6.27).  
The same happened for the second most associated SNP on chromosome 2 (Table 6.36, Figure 
6.28).  
 
Table 6. 35. Haplotype association analysis for the markers on chromosome region 8q12.1 and 
UAE. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ BETA STAT P-VALUE 
SNP_A-4194885 
(rs985942) 
0.495/0.460 0.939 -0.62 0.122 13.4 
 
2.43 
 
0.016 
SNP_A-4205634 
(rs41534844) 
0.119/0.100 0.952 0 * 48.7 6.37 1.43e-009 
SNP_A-2235942 
(rs11992681) 
0.321/0. 0.978 155 0.0887 13.5 2.08 0.0384 
 
HAPLOTYPE 
.*. 
FREQ BETA STAT P-VALUE 
AAB 0.0847 62.2 6.05 8.04e-009 
ABB 0.104 -9.4 -0.848 0.397 
BBB 0.134 -9.63 -0.98 0.328 
ABA 0.277 -6.97 -1.06 0.291 
BBA 0.363 -13.9 -2.23 0.0268 
SNP_A-4194885, SNP_A-4205634, SNP_A-2235942 
Results 
 
 150
Figure 6. 27. LD of the associated region on chromosome 8. 
 
As you can see the main associated marker is in LD with SNP_A-4194885 (R-sq = 0.114, D' = 
0.933). 
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Table 6. 36. Haplotype association analysis for the markers on chromosome region 2p11.2 and 
UAE. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ BETA STAT P-VALUE 
SNP_A-2207401 
(rs11675985) 
0.1/0.083 0.999 0 * 54.9 
 
6.09 
 
6.4e-009 
SNP_A-2208736 
(rs1863052) 
0.469/0.429 0.999 0.383 0.0988 -0.911 -0.159 0.874 
SNP_A-1801207 
(rs12714182) 
0.443/0.408 0.999 24.7 0.0725 11.3 2.01 0.0459 
 
HAPLOTYPE 
*.. 
FREQ BETA STAT P-VALUE 
BBA 0.313 -3.81 -0.622 0.535 
AAA 0.0847 57.2 5.92 1.52e-008 
BBB 0.156 4.65 0.587 0.558 
BAB 0.385 -17 -2.89 0.00425 
SNP_A-2207401, SNP_A-2208736, SNP_A-1801207 
 
Two of the markers included in this haplotype are in intronic regions of the REEP1 gene and the 
other is located in a gene which codifies the U8 small nucleolar RNA and therefore can regulate 
the gene expression. 
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Figure 6. 28. LD of the associated region on chromosome 2. 
 
The most associated marker is not in high LD (r-sq>0.8) with others markers. The SNP_A-2208736 
is a Tag SNP for: SNP_A-2191871 and SNP_A-1855476. 
 
For the marker on chromosome 9, the haplotype analysis was not conclusive (Table 6.37). 
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Table 6. 37. Haplotype association analysis for the markers on chromosome region 9p22.2 and 
UAE. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ BETA STAT P-VALUE 
SNP_A-2169005 
(rs1339550) 
0.117/0.150 0.987 0 * 44 
 
5.03 
 
1.13e-006 
SNP_A-2211656 
(rs3927680) 
0.465/0.354 0.991 32.5 0.154 11.6 1.91 0.0571 
SNP_A-1804453 
(rs10810668) 
0.205/0.200 0.991 57.6 0.114 15. 2.02 0.0443 
 
HAPLOTYPE 
*.. 
FREQ BETA STAT P-VALUE 
BAB 0.068 52.1 4.53 1.04e-005 
AAB 0.122 -10.2 -1.03 0.302 
AAA 0.225 -5.17 -0.694 0.489 
ABA 0.521 -12.5 -2.04 0.0426 
SNP_A-2169005, SNP_A-2211656, SNP_A-1804453 
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6.3.4.2. Association analysis for UAE after excluding patients with 
macroalbuminuria 
The genomic control for this analysis was 1.05 with a mean chi-square statistic of 1.01.  
 
Figure 6.29. Q-Q plot for the association analysis with UAE excluding patients with 
macroalbuminuria (UAE≥300mg/day). 
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6.3.4.2.1. Individual SNPs analysis 
In this case the most associated SNP was also on chromosome 8 (cytoband q12.1), SNP_A-
4205634 (rs41534844), but it was not statistically significance after Bonferroni correction 
(unadjusted p-value=1.34e-006, Bonferroni p-value=0.227). There was not association with the 
previously associated marker on chromosome 2, SNP_A-2207401 (rs11675985).  
The second most associated marker, SNP_A-4225953 (rs4859184), was on chromosome region 
3q27.1, in an intronic region of the MCF2 cell line derived transforming sequence-like 2 (MCF2L2) 
gene.  The third marker was on chromosome 12 cytoband p13.2, SNP_A-2260232 (rs17808125), 
in an intronic region of the 12 open reading frame 59 (C12orf59) gene and a few kb from the 
Oxidized low-density lipoprotein receptor 1 (OLR1) gene. The fourth marker was on chromosome 
4q13.1in an intronic region of the EPH receptor A5 (EPHA5) gene which belongs to the protein- 
tyrosine kinase family and it is involved in the intracellular signalling. 
The Manhattan plot for this analysis is shown in figure 6.30. 
 
Figure 6.30. Manhattan plot for the association analysis with UAE excluding subjects with 
macroalbuminuria (UAE≥300mg/day). 
 
6.3.4.2.2. Haplotype and LD analysis 
Interestingly the association with the haplotype, AAB, on chromosome 8 which was previously 
described in the association analysis for UAE including also macroalbuminurics was significantly 
stronger than the association with the individual marker (SNP_A-4205634) (Table 6.38). 
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Table 6. 38. Haplotype association analysis for the markers on chromosome region  8q12.1 and 
UAE after excluding patients with UAE≥300mg/day. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ BETA STAT P-VALUE 
SNP_A-4194885 
(rs985942) 
0.495/0.460 0.941 -0.627 0.116 5.42 
 
1.58 
 
0.116 
SNP_A-4205634 
(rs41534844) 
0.113/0.100 0.959 0 * 25.1 4.95 1.69e-006 
SNP_A-2235942 
(rs11992681) 
0.319/0. 0.977 155 0.0861 9.13 2.31 0.0218 
 
HAPLOTYPE 
.*. 
FREQ BETA STAT P-VALUE 
AAB 0.0811 34.7 5.76 3.49e-008 
ABB 0.108 -4.72 -0.702 0.468 
BBB 0.132 -2.82 -0.468 0.641 
ABA 0.276 -4.73 -1.17 0.242 
BBA 0.368 -5.93 -1.53 0.127 
SNP_A-4194885,  SNP_A-4205634, SNP_A-2235942 
 
For the marker on chromosome 3, there were not other SNPs in high LD with it and the association 
with haplotypes was weaker than that for the individual analysis (Table 6.39). 
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Table 6. 39. Haplotype association analysis for the markers on chromosome region 3q27.1 and 
UAE after excluding patients with UAE≥300mg/day. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ BETA STAT P-VALUE 
SNP_A-4225953 
(rs4859184) 
0.201/0.167 0.955 0 * 20.8 
 
4.89 
 
2.22e-006 
SNP_A-1845324 
(rs6808204) 
0.181/0.143 0.986 33 0.0474 -2.86 -0.634 0.527 
SNP_A-2116091 
(rs1911979) 
0.48/0.479 1 56.8 0.0689 -6.29 -1.85 0.0661 
 
HAPLOTYPE 
*.. 
FREQ BETA STAT P-VALUE 
BBB 0.436 -8.32 -2.36 0.0193 
BAA 0.178 -2.84 -0.629 0.53 
ABA 0.157 21.5 4.65 6.25e-006 
BBA 0.185 -5.27 -1.1 0.272 
SNP_A-4225953,  SNP_A-1845324,  SNP_A-2116091 
The LD of that region on chromosome 3 is shown in figure 6.31. 
Figure 6. 31. LD of the associated region on chromosome 3. 
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For the markers on chromosome region 12p13.2 and chromosome region 4q13.1 we did not find 
haplotypes clearly associated.   
On chromosome 12, the most associated haplotype, BBB, of the following SNPs: SNP_A-2106676, 
SNP_A-2260232, SNP_A-4231220, had a p-value= 0.000375.   
The LD of that region of chromosome 12 is shown in figure 6.32. 
 
Figure 6. 32. LD of the associated region on chromosome 12. 
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On chromosome 4, the most associated haplotype forming with alleles BBB, of the following SNPs: 
SNP_A-2132603, SNP_A-4203758,  SNP_A-4198862, had a p-value= 0.000318. The LD of that 
region on chromosome 4 is shown in figure 6.33. 
 
Figure 6. 33. LD of the associated region on chromosome 4. 
 
 
6.3.5. Association analysis for quantitative traits adjusted for clinical co-variables 
6.3.5.1. Association analysis for UAE 
The genomic control for these models was around 1.02 with a mean chi-square of around 1.00 
and included 175 individuals with no missing co-variables. 
6.3.5.1.1. Models with number of drugs as co-variable 
6.3.5.1.1.1. Individual SNPs analysis 
If we include in the model the number of anti-hypertensive drugs, the marker on chromosome 8 
(SNP_A-4205634) remained significantly associated (second position with a p-value=1.10e-007 , 
Bonferroni p-value=0.01, for the model including age, sex, BMI, SBP, glucose, eGFR by MDRD 
and treatment). In this case the most associated marker was in the chromosome 18, SNP_A-
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4206809 (rs1876021) (p-value unadjusted=5.49x10-8 , Bonferroni p-value=0.0093). This SNP 
appeared in the sixth position in the model which did not include the treatment as co-variable but it 
was not significantly associated (unadjusted p-value=2.59e-006, Bonferroni p-value=0.43). This 
marker is in the region 18q23 and there are not genes close to this marker. There are not SNP in 
high LD with this SNP (R-sq >0.8). 
A third marker also reached the statistical significance even when considering Bonferroni 
correction for multiple comparisons. This marker, SNP_A-2169005 (rs1339550) (unadjusted p-
value=1.92e-007, Bonferroni p-value=0.032), is located in the chromosome region 9p22.2 in an 
intron of the basonuclin (BNC2) gene. This marker was the third associated SNP for UAE although 
did not reach the statistical significance neither for the haplotype (unadjusted p-value =1.3e-006, 
Bonferroni p-value=0.220). In the model which did not include the treatment as clinical co-variable, 
this SNPs was also in the third position but was not statistically significance (unadjusted p-value 
=6.2e-007, Bonferroni p-value=0.10). 
There were also several SNPs on chromosome 12, cytoband p13.2, but they were not statistically 
significant. Those SNPs are in intronic regions of one gene which belongs to the killer cell lectin-
like receptor subfamily K. These genes are expressed in the natural killer cells and therefore are 
involved in the immune response. 
The Manhattan plot for this analysis is shown in figure 6.34. 
 
Figure 6. 34. Manhattan plot for the association analysis for UAE adjusted for age, sex, BMI, SBP, 
glucose, eGFR (MDRD) and number of drugs. 
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6.3.5.1.1.2. Haplotype and LD analysis 
On chromosome 18 we found one haplotype with similar association to the one obtained for the 
individual marker (Table 6.40). As you can see in figure 6.35 the marker on chromosome 18 is 
located between two blocks of high LD. 
 
Figure 6. 35. LD of the associated region on chromosome 18. 
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Table 6. 40. Association between one haplotype which include the most associated marker on 
chromosome region 18q23 with UAE including age, sex, BMI, SBP, glucose, eGFR by MDRD and 
number of drugs as co-variables. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ BETA STAT P-VALUE 
SNP_A-1806724 
(rs1039609) 
0.408/0.383 0.978 -5.83 0.196 14.4 
 
2.53 
 
0.0121 
SNP_A-4206809 
(rs1876021) 
0.129/0.104 0.996 0 * 42.7 4.87 2.42e-006 
SNP_A-1901562 
(rs1039611) 
0.196/0.208 0.983 12.5 0.528 21.8 3.08 0.00243 
 
HAPLOTYPE 
.*. 
FREQ BETA STAT P-VALUE 
BBB 0.122 42.8 4.88 2.34e-006 
AAB 0.0703 -12.1 -1.02 0.31 
BAA 0.282 -2.67 -0.418 0.677 
AAA 0.515 -11 -1.97 0.0499 
SNP_A-1806724, SNP_A-4206809, SNP_A-1901562 
 
The association with the haplotype which include the significantly associated marker on 
chromosome 8 remained without changes after including the number of drugs as co-variable. 
The haplotype association analysis for the hit on chromosome 9 and the LD of the associated 
region is shown in table 6.41 and figure 6.36. 
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Figure 6. 36. LD of the associated region on chromosome 9. 
 
As you can see the SNP_A-2169005 is inside one haploblock in LD with others SNPs, although 
there are not other SNPs with R-sq >0.8 with it. The marker SNP_A-2211656 is in high LD with 
SNP_A-4198891 which is a Tag-SNP for SNP_A-4117339 and SNP_A-2151046. 
 
Table 6. 41. Association between one haplotype which include the significantly associated marker 
on chromosome region  9p22.2 with UAE including age, sex, BMI, SBP, glucose, eGFR by MDRD 
and treatment as co-variables. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ BETA STAT P-VALUE 
SNP_A-2169005 
(rs1339550) 
0.117/0.150 0.987 0 * 46.2 
 
5.19 
 
5.61e-007 
SNP_A-2211656 
(rs3927680) 
0.465/0.354 0.991 32.5 0.154 11.6 1.89 0.0608 
SNP_A-1804453 
(rs10810668) 
0.205/0.200 0.991 57.6 0.114 15.1 2.01 0.0462 
 
HAPLOTYPE 
*.. 
FREQ BETA STAT P-VALUE 
BAB 0.068 54.4 4.63 7.04e-006 
AAB 0.122 -10.7 -1.07 0.287 
AAA 0.225 -5.66 -0.75 0.454 
ABA 0.521 -12.5 -2.01 0.0458 
SNP_A-2169005, SNP_A-2211656, SNP_A-1804453 
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For the associated SNPs on chromosome 12, the haplotype analysis did not increase significantly 
the strength of the individual association (Table 6.42). The LD of the region on chromosome 12 
cytoband p13.2 is shown in figure 6.37. 
 
Figure 6. 37. LD of the associated region on chromosome 12. 
 
As we expected for the association of several SNPs in the same region, they are all in high LD 
between them (R-sq>0.8). 
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Table 6. 42. Association between one haplotype which include the associated marker on 
chromosome region 12p13.2 with UAE including age, sex, BMI, SBP, glucose, eGFR (MDRD) and 
number of drugs as co-variables. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ BETA STAT P-VALUE 
SNP_A-2224125 
(rs1351113) 
0.28/0.305 0.943 -17.7 0.528 16.8 
 
2.52 
 
0.0125 
SNP_A-2032113 
(rs1382264) 
0.176/0.167 0.978 0 * 34.2 4.28 3.01e-005 
SNP_A-2002522 
(rs2733840) 
0.174/0.167 0.965 2.59 0.985 34.2 4.28 3.01e-005 
 
HAPLOTYPE 
.*. 
FREQ BETA STAT P-VALUE 
BBA 0.178 35.8 4.37 2.06e-005 
BAB 0.108 -12 -1.2 0.233 
AAB 0.708 -16.5 -2.51 0.0129 
SNP_A-2224125,  SNP_A-2032113,  SNP_A-2002522 
 
All of these SNPs on chromosome 12 are in the killer cell lectin-like receptor subfamily K, member 
1 (KLRK1) gene: two of them in introns and another in the 3'UTR extreme of the gene. As I said 
before, this gene is expressed in the natural killer cells and therefore has a role in the immune 
response system. 
 
6.3.5.1.2. Models without number of drugs as co-variable 
6.3.5.1.2.1. Individual SNPs analysis 
The results obtained in the unadjusted analysis were consistent and remained without change 
after including the following clinical co-variables in the model: age, sex, BMI, SBP, glucose and 
eGFR by MDRD. The results did not change when considering CC by the Crockoft-Gault formula, 
DBP instead of SBP or model with less number of co-variables. The first most associated marker 
was SNP_A-4205634 (rs41534844) on chromosome 8 (p-value unadjusted=2.08x10-9, Bonferroni 
p-value=0.00035, for the model including age, sex, BMI, SBP, glucose and eGFR by the MDRD 
formula) and the second, SNP_A-2207401 (rs11675985) on chromosome 2 (p-value 
unadjusted=8.0x10-9, Bonferroni p-value=0.0013, for the model including age, sex, BMI, SBP, 
glucose and eGFR by the MDRD formula).  
The Manhattan plot for this analysis is shown in figure 6.38. 
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Figure 6. 38. Manhattan plot for the association analysis with UAE including age, sex, BMI, SBP, 
glucose and eGFR (MDRD) as co-variables. 
 
6.3.5.1.2.2. Haplotype and LD analysis 
The association with the previously described haplotypes also remained being even a little bit 
stronger than the previous one without including clinical co-variables (Tables 6.43 and 6.44). 
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Table 6. 43. Association between the haplotype which include the most associated marker on 
chromosome region  8q12.1 with UAE including age, sex, BMI, SBP, glucose and eGFR (MDRD) 
as clinical co-variables. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ BETA STAT P-VALUE 
SNP_A-4194885 
(rs985942) 
0.495/0.460 0.939 -0.627 0.122 13.4 
 
2.41 
 
0.0167 
SNP_A-4205634 
(rs41534844) 
0.119/0.100 0.952 0 * 49.7 6.42 1.13e-009 
SNP_A-2235942 
(rs11992681) 
0.321/0. 0.978 155 0.0887 13.5 2.06 0.041 
 
HAPLOTYPE 
.*. 
FREQ BETA STAT P-VALUE 
AAB 0.0847 64 6.13 5.32e-009 
ABB 0.104 -9.85 -0.88 0.38 
BBB 0.134 -10 -1.01 0.313 
ABA 0.277 -7.01 -1.05 0.294 
BBA 0.363 -13.8 -2.2 0.0294 
SNP_A-4194885, SNP_A-4205634, SNP_A-2235942 
 
Table 6. 44. Association between the haplotype which include the most associated marker on 
chromosome region 2p11.2 with UAE including age, sex, BMI, SBP, glucose and eGFR (MDRD) 
as clinical co-variables. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ BETA STAT P-VALUE 
SNP_A-2207401 
(rs11675985) 
0.1/0.083 0.999 0 * 54.8 
 
6.02 
 
9.55e-009 
SNP_A-2208736 
(rs1863052) 
0.469/0.429 0.999 0.383 0.0988 -1.31 -0.223 0.823 
SNP_A-1801207 
(rs12714182) 
0.443/0.408 0.999 24.7 0.0725 11.2 1.96 0.0512 
 
HAPLOTYPE 
*.. 
FREQ BETA STAT P-VALUE 
BBA 0.313 -4.29 -0.691 0.49 
AAA 0.0847 57.1 5.85 2.23e-008 
BBB 0.156 4.71 0.586 0.558 
BAB 0.385 -17 -2.85 0.00494 
SNP_A-2207401, SNP_A-2208736, SNP_A-1801207 
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6.3.5.2. Association analysis for UAE after excluding patients with 
macroalbuminuria  
6.3.5.2.1. Models with number of drugs as co-variable 
6.3.5.2.1.1. Individual SNPs analysis 
For the models which include the number of drugs as co-variable, the most associated SNP 
was located on chromosome 10, cytoband p11.22, SNP_A-1999800 (rs10827234) although was 
not significant after correction for multiple comparisons (unadjusted p-value 3.46e-006, Bonferroni 
p-value 0.5). This marker is located in an intronic region of the neuropilin (NRP1) gene. 
Interestingly this gene is a membrane bound co-receptor to a tyrosine kinase receptor for both 
vascular endothelial growth factor (VEGF) and semaphorin and could play a role in angiogenesis 
and cell survival process. 
In this case, the second associated marker was, SNP_A-4205634, on chromosome 8, cytoband 
q12.1 which was significantly associated with UAE without including clinical co-variables, but in this 
case did not reach the statistical significance (unadjusted p-value 6.02e-006, Bonferroni p-value 1). 
The Manhattan plot for this analysis is shown in figure 6.39. 
 
Figure 6. 39. Manhattan plot for the association analysis with UAE excluding subjects with 
macroalbuminuria (UAE≥300 mg/day) adjusted for age, sex, BMI, SBP, glucose, eGFR (MDRD) 
and NDRUGS. 
 
 
As you can see in the plot another peak was on chromosome region 15q26.2, SNP_A-2114547 
(rs8029354), close to the multiple C2 and transmembrane domain-containing protein 2 (MCTP2) 
gene and there were several SNPs in the same cytoband of chromosome 4 (q28.3) in a region 
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without known genes. As I commented before these markers are far away from statistical 
significance. 
6.3.5.2.1.2. Haplotype and LD analysis 
The haplotype analysis including the associated SNPs did not find any haplotype with equal or 
higher strength of association than that for the individual marker, except for the region on 
chromosome 4 in the model which include age, sex, BMI, SBP, glucose, eGFR (MDRD) and 
NºDrugs  as co-variables (Table 6.45). 
 
Table 6. 45. Haplotype for the markers on chromosome region 4q28.3 and UAE after excluding 
subjects with macroalbuminuria (UAE≥300mg/day)  adjusted for age, sex, BMI, SBP, glucose, 
eGFR (MDRD) and NºDrugs  as co-variables. 
SNP MAF(our sample/HapMap-CEU ) GENO KB RSQ BETA STAT P-VALUE 
SNP_A-1799773 
(rs4533822) 
0.242/0.242 0.991 -34.8 0.931 13.2 
 
3.27 
 
0.0013 
SNP_A-2044426 
(rs7678041) 
0.22/0.242 0.928 0 * 13.8 3.43 0.00076 
SNP_A-1979014 
(rs13435210) 
0.258/0.258 0.973 59.3 0.276 1.86 0.465 0.642 
 
HAPLOTYPE 
.*. 
FREQ BETA STAT P-VALUE 
BBA 0.155 3.14 0.645 0.52 
AAA 0.0973 -0.522 -0.0803 0.936 
BBB 0.0742 33.4 5.03 1.18e-006 
AAB 0.661 -11 -2.94 0.00368 
SNP_A-1799773, SNP_A-2044426, SNP_A-1979014 
 
6.3.5.2.2. Models without number of drugs as co-variable 
6.3.5.2.2.1. Individual SNPs analysis 
The genomic inflation factor of this model was 1 with a mean chi-square statistic of 0.98. None 
of the SNPs was significantly associated with UAE after excluding those subjects with UAE≥300 
mg/day and when including clinical co-variables in the linear regression model. The only SNP 
which got a p-value of minus seven was, SNP_A-4198239 (p-value 6.79e-007, Bonferroni p-value 
0.1), in a model which included age, sex, BMI, DBP, glucose and eGFR by the MDRD formula. 
That polymorphism is located on chromosome 16, cytoband q21, and there is one gene, cadherin 
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11 precursor (CDH11), within a distance of 150kb upstream. This gene codifies one integral 
membrane protein which mediates calcium dependent cell-cell adhesion and has been associated 
with the bone development. 
In this model the hit on chromosome 8, SNP_A-4205634, was in the eleventh position of the 
association analysis but it was not significantly associated after correction for multiple testing.  
In figure 6.40 you can see the Manhattan plot for this analysis 
 
Figure 6. 40. Manhattan plot for the association analysis with UAE excluding subjects with 
macroalbuminuria (UAE≥300mg/day) adjusted for age, sex, BMI, DBP, glucose and eGFR 
(MDRD). 
 
 
6.3.6. Tables of the main results 
6.3.6.1. Table 6.46. Main associated SNPs sorted by chromosome 
This table summarizes the results for each one of the individual SNPs which have been 
described in previous pages for the qualitative and quantitative traits, unadjusted and adjusted for 
clinical co-variables. The statistically significant results are highlighted. 
6.3.6.2. Table 6.47. Main associated haplotypes sorted by chromosome 
This table summarizes the results for each one of the haplotypes which have been described in 
previous pages for the qualitative and quantitative traits, unadjusted and adjusted for clinical co-
variables. The statistically significant results are highlighted. 
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7. DISCUSSION   
The main results of our study are summarized in tables 6.46 and 6.47. 
A few polymorphisms have resulted in an association with the presence of an increment in UAE 
expressed as a qualitative or as a quantitative trait in our cohort of young hypertensive patients. 
These SNPs are: rs6980941 in cytoband p22 of chromosome 8, rs41534844 in cytoband q12.1 of 
chromosome 8, rs11675985 in cytoband p11.2 of chromosome 2, rs1339550 in cytoband p22.2 of 
chromosome 9 and rs1876021 in cytoband q23 of chromosome 18. 
There was another group of SNPs which did not reach the statistical significance but they seemed 
to stand out from the rest of SNPs. It is possible that some of them were false negative because of 
the lack of statistical power. However they were also considered as potential candidates because 
they were previously linked with renal damage.
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7.1. Method 
We have performed a genome wide scan in 302 young hypertensive patients selected from a 
cohort with a long follow-up to assess the main factors associated with the development of 
microalbuminuria.  
GWAS is a challenging task because there are a great number of potential factors which can affect 
the final result including: subjects (phenotyping), genotyping and statistical analysis.  In the 
following paragraphs I will discuss some of these issues in detail. 
 
7.1.1. Subjects 
A correct definition of phenotype, sample size and homogeneity of the sample are among the 
main factors which can influence the results in GWAS. 
First, the sample size which is difficult to establish and has to be calculated based on factors that 
we do not know a priori including: a) the genome coverage of the chip which has to include a 
marker in linkage disequilibrium (LD) with the susceptibility variant; b) the magnitude of the LD 
value between the susceptibility variant and the marker; c) the MAF for both the marker and the 
susceptibility allele, d) the OR associated to the susceptibility variant and e) the disease frequency. 
Although we had a small sample size after exclusion of low quality samples, while the study can be 
made underpowered a priori, the accuracy of the phenotype can minimize this problem. By using 
only markers with a MAF higher than 0.1 and also analyzing also the urinary albumin excretion as 
a quantitative trait we tried to improve the power of the study.  
Secondly, the ethnical homogeneity of the sample. A different genetic background between cases 
and controls introduces bias. Statistical analyses have to be done in order to detect subjects with 
different origins. The genomic control, the multidimensional scaling plot for the IBS pairwise 
distances and the Eigenstrat analysis are the most commonly used. In our case, all subjects 
included were of Caucasian origin and belong to the same geographical area. After applying the 
filters and excluding those samples with very high IBS or those individuals who did not cluster as 
the rest in the multidimensional scaling plot for the IBS pairwise distance, our genomic control was 
close to 1.0. This genomic inflation factor did not reveal evidence of any kind of stratification so we 
can be sure that we do not have bias due to population stratification in our results.  
Thirdly, a correct definition of the study phenotype in order to avoid the misclassification bias. This 
is one of the strengths of our study because our patients were selected from a cohort study in 
young hypertensive patients with a tight follow-up which significantly reduced misclassification 
bias. In addition, the UAE was assessed in 24 hour urine sample and on more than one visit. 
Moreover in those cases in which there were discrepancies between measurements, a third 
determination was made. 
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Although we are quite confident that our patients were correctly classified at the time of inclusion 
we cannot assure that controls will not develop micro or macroalbuminuria or that some of the 
microalbuminurics patients will not develop macroalbuminuria in the future. This can be especially 
important for those patients with UAE levels close to the microalbuminuria threshold (30 mg/dl) or 
to the macroalbuminuria threshold (300 mg/day). This problem can be solved by selecting 
hypercontrols with no UAE at all and cases not too close to the upper limit. In our case the majority 
of the controls, 169 (84.1%) had an UAE ≤ 15 mg/day and the majority of the cases, 77 (75.5%), 
had an UAE ≥30 mg/day and ≤ 161 mg/day.  Because we included 8 individuals with 
macroalbuminuria (UAE≥ 300mg/day) we performed the analysis with and without those subjects 
and the results were slightly different. We do not know if the susceptibility loci for micro and 
macroalbuminuria are or not the same or not but the inclusion of the macroalbuminuric patients 
ensured that some but not all the signals for microalbuminuria reached the statistical significance. 
Finally, other factors related with the patient status regarding hypertension and glucose 
metabolism need to be considered.  
One of them is regarding to the blood pressure (BP) levels. Although we only included 
hypertensive patients with BP levels within the range 135-160 of SBP and 85-100 mmHg of DBP to 
try to reduce the mechanical influence of BP in the renal damage, the ANOVA test revealed 
significant differences for 24 hour blood pressure levels and also for glucose being significantly 
higher in cases than in controls. These factors along with the time of evolution of high BP and with 
differences in treatment are among the factors that can explain the development of renal damage 
and might have interfered with the results. The long term of observation of the patients minimizes 
this problem as well as the fact that the kind of drugs did not influence UAE at long term. 
 
7.1.2. Genotyping 
In GWAS, problems affecting the genotyping procedure can have a great impact on the final 
results.  Quality of the DNA samples, management of the samples in the laboratory following the 
instruction of the manufacturer with a pre-PCR and a post-PCR room to avoid the sample 
contamination, size and composition of the batches and algorithms to transform the intensity files 
into the genotypes are all potential sources of problems. Nowadays we usually trust in 
experimented centres to have the genotyping done. It is important to have a tight contact with the 
genotyping centre and to obtain from them all the quality parameters to find out the source of 
possible problems affecting the downstream analysis. 
Although microarray is a high throughput technology, our results faced the traditional problems of 
this technique. A DNA problem was observed with some of the samples, although the amount of 
DNA and the ratio 260/280 were within the optimal range. The fact that the call rate of some of the 
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repeated samples were similar, makes us to think that in those samples the DNA integrity was 
corrupted. We excluded those samples with DNA problem. 
Another source of problems is due to the algorithm to transform the intensity files into the 
genotypes. The accuracy of these algorithms is very high when the call rate of the sample is close 
to 100% but not for those samples with a call rate far from 100%. In this last case some individuals 
can be assigned a wrong genotype or a missing genotype.  As we selected 90% for individuals and 
SNPs call rate due to our screening purposes, there is a group of SNPs (especially those under 
95% of call rate) with some individuals wrongly assigned to one genotype instead of the right one 
as seen in some of the cluster plots. Ideally all the SNPs should be reviewed manually, but this is 
costly and time consuming. The replication of the associated SNP with a different genotyping 
technology will confirm or negate our results.  
 
7.1.3. Statistical analysis 
One of the main problems in GWAS is the possibility of false positive results. This is due to not 
only to the multiple comparisons but also to problems affecting the genotyping or the phenotyping 
which can influence all the downstream analysis.  It is extremely important to be sure before 
starting the statistical analysis that the possible differences in genotypes are due to differences in 
the main phenotype and not to other reasons such as batch effect, population stratification, 
misclassification, etc. To address with the multiple comparison problem there are several statistical 
methods, Bonferroni and the false discovery rate (FDR) being the most commonly used. We 
decided to use the Bonferroni criteria to considerer one SNP as statistically significant although this 
method is the most stringent one. Due to our low statistical power, especially in the analysis which 
included covariables, and the possibility of false negative for some of the results close to the 
significance level we did not discard a group of SNPs which although they did not reach the 
statistical significance after Bonferroni correction they clearly stood out from the rest. 
The most important thing in genetics in order to assess if one result is a false positive or not, is its 
replication in an independent cohort. Until the replication analysis does confirm these associations 
we cannot assume that the associated genome areas are involved. 
There are not pre-specified thresholds to filter SNPs and individuals in GWAS and they vary 
according to the particular characteristics of the study.  In our case we decided to use 90% for the 
individual and SNP call rate because of the microarray platform used and the distribution of call 
rates. As I commented on before we used 0.1 as a threshold for MAF in order to gain statistical 
power. 
There are some points that I would like to remark on regarding to the interpretation of the results. 
Some of them raise the hypothesis of a false positive result: 
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1- There were significant differences for the call rate of the main associated marker for albuminuria 
and microalbuminuria between cases and controls.  Then, there were significantly more missing 
values in controls than in cases although the average call rate for the SNP was above the 
threshold (0.90).  
2- In some of the associated areas there was only one single polymorphism associated. This can 
be easily explained because there were not other SNP in high LD with the most associated one 
and also because the Nsp chip does not cover that region extensively. 
3- The quality of some of the main hits as it has been shown in the cluster plots is poor, with a 
great number of missing individuals (call rate 90%) and misclassification.  
4- The main association for albuminuria-microalbuminuria in the whole genome disappeared when 
we included in the model those factors mainly involved in the development of albuminuria. This 
was not the case for the quantitative trait in which the main hit remained after the inclusion of 
clinical co-variables. 
5- Although we used a high-density chip with more than 250000 markers with a good coverage of 
the genome according to the provider, not all the genomic common variants are included and 
neither are the rare variants. It is possible that the coverage of the main associated areas were not 
good enough. If this is the case, then we can not narrowly define the area of study which makes 
the search for candidate genes more difficult. 
6 -Another point to take into account is that the results for the UAE in the whole genome showed 
peaks in other areas of the genome. It is known that the loci that can be related to the presence of 
one disease and those associated with the levels of the quantitative variable (QTL) might not be 
exactly the same. For instance it can be possible that the variants related with the presence of 
renal damage and the variants which regulate the UAE were in different chromosomes. 
 
All these facts raise the hypothesis of a possible false positive, but as we commented on before, 
this study planned to be the first stage of a two stage design study. We have selected the most 
significantly associated markers in order to be replicated with another genotyping technology in a 
larger sample. 
Nevertheless, there are other points that are in favour of our results: 
1- The association analysis using haplotypes instead of individual markers make the results more 
consistent although we have to consider that in our case, the number of patients for every 
haplotype is quite small. For this reason we only considered those haplotypes with a minor 
haplotype frequency of at least 5% in order again to increase the statistical power. 
2- Although after the inclusion of clinical co-variables the statistical power was significantly 
reduced, in the case of the quantitative trait, the main association remained which reinforces the 
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results. For albuminuria and microalbuminuria it is possible that the lack of statistical power after 
including clinical co-variables was responsible for the disappearance of the main associated areas. 
3- Some of the associated markers are located within possible candidate genes or close to them 
such as: MSR1, ADAM7, CXCL12, PEBP1, LOX1, Neuropilin 1, BNC2, CDH11, ELMO1, ELMO3, 
etc. Moreover some of these areas have been previously described in the literature by different 
authors and by using different strategies.  
4- Based on our results, we have been able to select an interesting panel of SNPs for replication in 
a larger sample.
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7.2. Results 
The main analysis discovered a region on chromosome 8 that could be related to the presence 
of albuminuria and microalbuminuria in hypertensive patients. One SNP (rs6980941) and one 
haplotype, in the cytoband p22 of chromosome 8 showed a significant association with the risk of 
albuminuria and microalbuminuria even after Bonferroni correction or after running the adaptative 
permutation analysis.  We also found another two markers, one on chromosome 10 cytoband 
q11.21 (rs2154401) and another on chromosome 12 cytoband q24.23 (rs7974380) which also 
might be related to albuminuria and microalbuminuria but they were not statistically significant after 
the correction for multiple comparisons.  Three haplotypes containing the main hits were also 
associated with albuminuria and microalbuminuria. The analysis including covariates did not reveal 
any marker significantly associated using Bonferroni correction but some of these areas could be 
important as much as they have been reported in the literature. 
Regarding to the association with UAE as a continuous trait two markers reached the statistical 
significance. One of them, rs41534844, was also on chromosome 8 although in this case not in the 
short but in the long arm of the chromosome (8q12.1) and another, rs11675985, on chromosome 2 
cytoband p11.2. Also there was an association with two haplotypes containing these SNPs. After 
excluding those subjects with UAE>300mg/day, the association with the marker on chromosome 
region 8q12.1 remained especially when considering the haplotype analysis but not with the 
marker on chromosome 2p11.2. 
If we include clinical co-variables in the analysis, the marker in 8q12.1 remained significantly 
associated even after Bonferroni correction whatever model we considered and also the 
association with the haplotype. The marker on chromosome 2p11.2 and also the haplotype 
including this SNP remained significantly associated but only in those models which did not include 
the number of drugs as co-variable. If we considered the number of drugs as co-variable, another 
two markers also reached the statistical significance, one on chromosome 18 cytoband q23 
(rs1876021) and the other on chromosome 9 cytoband p22.2 (rs1339550). This last marker was 
the third most associated with UAE without including co-variables although in this case it was not 
statistically significance. 
The macrophage acetylated LDL receptor I and II (MSR1) lies quite close to the main hit for 
albuminuria and microalbuminuria in locus 8p22 and it is an interesting candidate gene because it 
can be involved in the atherosclerosis process. This gene encodes integral membrane 
glycoproteins that can mediate the endocytosis of the modified LDL which is a crucial step in the 
development of the atherosclerosis plaque. It is known that the characteristic histological changes 
of the renal damage associated to hypertension (glomerulosclerosis) are quite similar to those 
observed in the atherosclerosis process277, 278. Glomeruli inflammation has a key role in the 
development of albuminuria and MSR1 could be involved in this process. Moreover, one study in 
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rat models of diabetic nephropathy demonstrated a lack of progression of the typical lesions which 
appeared in DN  including UACR in those rats which lacked  the MSR1 gene279.  Besides as it has 
been described in the introduction those genes related to the lipid metabolism are thought to be 
related with the damage due to the atherosclerosis and therefore might be associated with the 
development of micro or macroalbuminuria in HTN142. These kinds of genes have also been 
previously identified by linkage studies as associated to renal disease 140, 142.  
In one of those linkage studies for non diabetic ESRD in blacks, the authors also found a linkage 
peak on chromosome region 8p22 (D8S1106) especially in those pedigrees with the largest BMI 
(LOD score  3.4)280.  The associated marker in locus 8p22 in that study, however, was far away 
from our peak. In this study they also found one marker in region 8p21.2 (D8S1771) and another in 
region 2q32.1 (D2S1391) associated with ESRD considering the interaction with age at the 
diagnosis of ESRD. Two of the most associated markers with albuminuria when we co-variate the 
analysis by age, sex, BMI, SBP, glucose, and eGFR (MDRD) were also in 8p21.2 (rs4872244, and 
rs6557750) although they were not statistically significant. Our markers are approximately 500kb of 
distance for the associated marker in that linkage study280. These markers are quite close to the 
several genes of the ADAM family, including ADAM7, ADAMDEC1 and ADAM28. The association 
with one haplotype, which includes one SNP inside ADAM7 gene, was stronger than that for the 
individual markers. These genes are desintegrin and metallopeptidases which belong to the gene 
family of membrane-anchored and secreted proteins that have proteolytic and/or adhesive 
properties and therefore can be involved in multiple biological and pathological processes including 
glomeruloesclerosis281 and inflammation282. In the literature one SNP within the ADAM23 gene in 
chromosomal region 2q33 was associated with UAE in a family-based association study using the 
“NHLBI´s Framingham Heart Study” population154. 
When including the number of drugs as a co-variable, two of the most associated markers were on 
chromosome region 2q32.2, although the p values were again far away from significance and they 
were too far from the linkage peak of Freedman et al280. 
The second most associated SNP with albuminuria and microalbuminuria is located on 
chromosome 10 cytoband q11.21 although it did not reach the statistical significance threshold. In 
this region, the chemokine (C-X-C motif) ligand 12 (CXCL12) is located although it is around 250kb 
from the main hit in that region. Inflammatory cytokines seem to play a role in the development of 
renal damage especially in the development of diabetic nephropathy.  Rat models of diabetic 
nephropathy demonstrated over-expression of interferon gamma (INFγ) and tumor necrosis factor 
alpha (TNF- α) both in the early and late stages of the diabetes nephropathy283 . Besides in 
subjects with type I diabetes, pro-inflammatory cytokines such as: interleukin 6 (IL-6), interleukin 8 
(IL-8), monocyte chemoattractant protein-1 (MCP-1), interferon-gamma-inducible protein (IP-10), 
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and macrophage inflammatory protein-1delta (MIP-1δ), measured in urine samples, were 
associated with the decline in the renal function284 .  
The third most associated marker for albuminuria and microalbuminuria (rs7974380) was located 
on chromosome 12, cytoband q24.23, close to several genes (RFC5, WSB2, PEBP1, TAOK3, 
KSR2). Between them, the phosphatidylethanolamine binding protein 1 (PEBP1) gene through its 
role in PKC signalling can have a role in the development of diabetes nephropathy285. Protein 
Kinase C (PK-C) belongs to a multigene family which is involved in different signalling pathways 
and especially in the response to different growth factors. Several polymorphisms of the PK-C beta 
gene might ease the development of renal impairment in Japanese diabetics286. Besides the 
overexpression of PKC is a potential target to treat the DN286-289. 
Another interesting result for the association with microalbuminuria including co-variables is the 
finding of one polymorphism in the cytoband p14.2 of the chromosome 7.  In this region the ELMO 
gene is located which was associated with the risk of DN in a GWAS performed in a Japanese 
population of type 2 diabetes245, 246. This gene through its role in the regulation of extracellular 
matrix proteins seems to be involved in the development of DN247. However our peak is far away 
from the ELMO gene (about 1500 kb) and as I said before, none of this polymorphism reached the 
statistical significance when including co-variables in the LR model. 
Regarding the association analysis with UAE as a continuous trait, we found another two 
polymorphisms which reached the statistical significance even when Bonferroni correction was 
applied and also when important clinical co-variables such as age, sex, BMI, SBP, DBP, glucose or 
eGFR were included in the linear regression model. The most associated marker was located, as 
in the case of albuminuria and macroalbuminuria, on chromosome 8 but not in the short but in the 
long arm (8q12.1) (rs41534844, Bonferroni p-value 0.00019). This SNP was also the most 
associated one with UAE after excluding those patients with an UAE≥300mg/day but in this case it 
did not achieve the statistical significance after adjusting for multiple comparison (unadjusted p-
value=1.34x10-6, Bonferroni p-value=0.227), although the haplotype analysis which includes the 
allele B of this SNP was quite consistent (p-value 3.49x10-8).  The minor allele of this SNP 
significantly increased the levels of UAE (Beta 49.8, CI (34.6-65.1)). The inositol 
monophosphatase domain containing 1 (IMPAD1) gene is very close to the main associated 
marker. It is not clear what the exact function of this gene is and it has not been reported to be 
associated with UAE or nephropathy.  Another SNP in that region 8q12.1, rs10504244, showed an 
association with cystatin C but not with UACR within the Framingham Heart Study in an American 
general population of European descent 154. Those authors also did not find a suitable candidate 
gene in that region. The distance between that marker and our marker was around 1200kb.  
Another marker significantly associated with UAE was on chromosome 2 cytoband p11.2 and it is 
in an intronic region of the Receptor Expression-Enhancing Protein 1 (REEP1) gene. Mutations in 
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this gene have been related to autosomal dominant hereditary spastic paraplegia but as in the 
other gene it has not been related with renal damage until now.  
The third most associated SNP for UAE although it was not significant is on chromosome 9 
cytoband p22.2. Interestingly, this SNP, rs1339550, reached the statistical significance when we 
included the Nº of drugs as a clinical co-variable (Bonferroni p-value 0.032). This polymorphism is 
located in an intronic region of the basonuclin 2 (BNC2) gene. Functional studies demonstrated a 
different expression profile for the BNC1 gene between smooth muscle cells obtained from human 
coronary artery or from saphenous veins exposed to an oxidized LDL  or platelet-derived growth 
factor290. BCN2 in contrast to BCN1 is widely expressed in different tissues including the kidney. It 
is expressed in the nuclei so it is thought to influence the mRNA. We do not know if the BCN2 
might also be involved in the atherosclerosis process and in the renal damage associated to HTN. 
Polymorphisms within a near region on chromosome 9 (9p21.3)  have been found to be associated 
with coronary heart disease in GWAS and these results have been widely replicated88, 291, 292. 
Among the genes that could be responsible for this association are the cyclin-dependent kinase 
inhibitor 2A and 2B (CDKN2A and CDKN2B). These genes are thought to be implicated in cell 
proliferation and apoptosis which usually occurs in the atherogenesis process. Besides CDKN2A 
and CDKN2B, in 9p21.3, it is the family of the type I interferon genes which include IFNAs, IFNB1 
and IFNW1. These groups of cytokines have pro-inflammatory, antiviral and immunoregulatory 
properties and therefore are widely used for the treatment of several chronic inflammatory 
diseases. They have also been related with several autoimmune diseases in animal models 
including systemic lupus erythemathosus (SLE) and type I diabetes and related traits but not all the 
studies support that association293-296. Although the relationship between type I interferons and 
renal damage have not been described we can speculate that these group of cytokines  might also  
be involved in the pathogenesis of microalbuminuria not only in diabetes but also in hypertension 
as a result of the immune response to the endothelial injury  in the renal glomeruli.  This region 
9p21.2 reached the maximum LOD score for hypertensive ESRD in the linkage study performed in 
Black American families as reported by Freedman et al280 (D9S1121, LOD score 2.03). 
Another interesting gene in the short arm of chromosome 9 (9p24.1) is the interleukin 33 (IL-33) 
gene. This gene was first called “Nuclear factor from High Endothelial Venules”297 . The IL-33 
seems to play a role in trauma, infections and chronic inflammatory diseases by means of the 
interleukin 1 (IL-1) receptor related protein ST2 and might be involved in the immune response297. 
Within its functions are the drive of the production of pro-inflammatory cytokines especially in the 
mast cells and lymphocytes T2 and the chemotaxis of Th2 cell298-300 . The endothelial cells of 
chronically inflamed tissues seem to be a major source of IL-33 in several diseases such as 
rheumatoid arthritis and Crohn’s disease 148. Besides rodents studies have shown that IL-33 is 
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expressed by cardiac fibroblast after mechanical stress and by endothelial cells during 
atherosclerosis 301, 302. 
Moussion et al303 demonstrated that IL-33 has a constitutive and widespread expression in the 
nucleus of endothelium cells along the vascular tree of normal tissues including the peritubular 
capillaries of the kidney. Surprisingly these authors were not able to detect IL-33 in the kidney 
glomeruli303 . The fact that IL-33 could be detected in fibroblast with myofibroblast characteristics 
suggests that this protein might also be involved in tissue fibrosis and these authors suggest that 
IL-33 might be particularly important in the injury during cardiovascular diseases303 . All of these 
studies indicate that the IL-33 may act as an endogen alarming signal for the immune system after 
epithelial or endothelial damage.  
All of these studies indicate that genes in the short arm of chromosome 9 might be important in the 
atherosclerosis process and maybe with the vascular glomerular damage induced by hypertension. 
In those chromosomal regions there are large areas of high LD so we cannot be sure if the 
associated SNP is the risk variant or a marker in LD with it. 
After excluding subjects with UAE≥300 mg/day, the main associated SNP for UAE was the same 
on chromosome region 8q12.1 (rs41534844). In this case the second most associated for UAE 
was not on chromosome 2 but in an intronic region of the MCF2L2 gene on chromosome 3 
cytoband q27.1. It is noteworthy that other authors also found three SNPs in this gene (rs684846, 
rs35069869 and rs35368790) associated with nephropathy in type 2 diabetic subjects304. They did 
not find an association for known candidate genes in that region such as ADIPOQ and IGF2BP2 
genes304. This region in the long arm on chromosome 3 has been previously detected by linkage 
studies84, 151, 228. Vionnet et al230 searching for the possible candidate gene in this region in 
European population of type 1 diabetes found a strong association with a SNP in the promoter 
region of the ADIPOQ gene. 
Another interesting region for the association analysis with UAE after excluding patients with 
UAE≥300mg/day was 12p13.2. Our SNP is inside the C12orf59 gene but it is quite close to the 
oxidized LDL receptor 1 (ORL) gene. As I said genes involved in lipid metabolism might be related 
with hypertensive glomerulosclerosis. Studies in rats demonstrated an up-regulation of the oxidized 
LDL receptor in the kidney of Dahl salt-sensitive rats  which exhibit glomeruloesclerotic changes 
305
. This up-regulation runs in parallel with the glomeruloesclerotic changes and with the decline in 
renal function in these animals305. Other studies in rats support the role of the ORL gene, also 
called LOX1, in the development of DN306. Moreover the blockage of this receptor may reverse the 
pathological glomeruloesclerotic changes307. Moreover polymorphisms of this gene were tried to be 
associated with type 2 DN but the selected SNPs in this gene were not among the most associated 
ones308.  Taking into account these facts these kinds of genes which codify receptors for oxidized 
LDL such as MSR1 and ORL may be related with hypertensive glomerulosclerosis process. 
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The fourth marker most associated with UAE after excluding macroalbuminurics was in an intronic 
region of the EPHA5 gene on chromosome 4q13.1. A linkage peak in this region was previously 
associated with hypertensive ESRD in Black Americans (LOD score 3.44 for the case of late onset 
hypertension)280. 
When we included co-variables in the analysis for UAE, another marker (rs1876021) on 
chromosome 18 cytoband q23 was also significantly associated if we included the Nº of drugs as a 
covariable (Bonferroni p-value=0.0093). There are no genes in that specific region, however, our 
marker is located between the two flanking markers for a linkage peak associated with eGFR (LOD 
score 2.10 in Mexican-Americans) within the Family Investigation of Nephropathy in Diabetes 
(FIND) study243, which is a multicenter study aim to discover susceptibility variants for DN in 
different ethnics of type 2 diabetics. Previously, other authors had found in that region 18q22.2-23 
a very significant linkage peak for DN according to the Lander and Kruglyak scale141 . This study 
performed by Vardali et al223 in 18 large Turkish families of type 2 diabetes found a LOD score of 
6.1 on chromosome 18q22.3-23 between the markers D18S469 and D18S58. Moreover this peak 
was also replicated in type 2 diabetes Pima indian84, 224. The CNDP1 gene which codifies the 
enzyme carnosinase is thought to be responsible for this linkage peak225, 226. This enzyme 
degrades the dipeptide carnosine which can act as an ACE inhibitor258, 259, natural reactive oxygen 
species scavenger260 and advanced glycation end products (AGEs) breaker, therefore it can 
protect the kidney in diabetic subjects. Although it is a plausible candidate gene at least in type 2 
diabetes, a recently published paper in type 1 diabetes failed to find an association between this 
gene and nephropathy227.  Our marker is around 4000 kb of distance from that gene so we can not 
assume that it is the same peak. Anyway in the light of the previous and our results this region 
(18q22.3-23) deserves special attention. 
In the association analysis for UAE adjusted for age, sex, BMI, DBP, glucose and eGFR (MDRD), 
the most associated marker was on chromosome 16 cytoband q21 although again it was not 
statistically significant (unadjusted p-value 6.79x10-7, Bonferroni p-value 0.1). Near this marker the 
Cadherin-11 Precursor (CDH11) gene is located. This gene has been especially related with the 
bone metabolism but because its role in cellular adhesion and calcium ion binding may be 
implicated in other processes. One gene expression study demonstrated a down-regulation of this 
gene in the heart of a streptozotocin-induced diabetic rat 309. This gene is moderately expressed in 
the glomeruli and vascular smooth muscle cells310 (http://www.proteinatlas.org/)  and it may be 
involved in atherosclerosis by means of extracellular matrix proliferation.  In this region other 
members of the Cadherin family (CDH8 and CDH5) are also located. 
The linkage study of Freedman et al280 for hypertensive ESRD in  Black American families  also 
found a peak on chromosome region 16q21 when considering the interaction with age at diagnosis 
of hypertension (D16S1385 (P =0.0084). In the long arm of chromosome 16 there are some 
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identified candidate genes for DN such as Cholesterol Ester Transfer protein Precursor (CETP) 
gene and Solute carrier family 12 member 3 (SLC12A3) gene and also there is a gene of the 
ELMO family (ELMO3). 
Another marker on chromosome 10 (10p11.22), rs10827234, was the most associated one with 
UAE after excluding patients with UAE≥300mg/day and after adjusting for different clinical co-
variables including the number of drugs. This SNP is in an intronic region of the neuropilin (NRP1) 
gene which, as I said in the results, is a membrane co-receptor to a tyrosine kinase receptor for 
both vascular endothelial growth factor (VEGF) and semaphorine. For this reason it might be 
involved in angiogenesis and cell survival process. A recent study reported a decrease in the 
NRP1 expression in cell cultures of mouse podocytes exposed to advanced glycation end (AGE) 
products311. These authors also showed that the expression of this gene in the glomeruli is 
decreased in diabetic db/db mice as compared to their non diabetic littermates311. This also occurs 
in biopsies of DN as compared to the kidney samples of transplant donors311. The down-regulation 
of the NRP1 gene inhibits the migration of podocytes in the same way as the AGE products does. 
This can ease the adhesion of the glomerular basement membrane to the Bowman’s capsule and 
lead to the development of focal glomerulosclerosis311. Another study demonstrated that NRP1 
gene can have a key role in the endothelial cell apoptosis process, which usually occurs in 
hypertension and atherosclerosis312. Iyengar et al313 in one linkage study performed in sibpairs of 
Caucasian origin with type 2 diabetes found a linkage between one marker in an intronic region of 
the NRP1 (D10S1654) and DN. Later on seven SNPs in this gene were evaluated by TDT by other 
researchers within a study of 115 candidate genes for DN237. Two of them, rs869636 and 
rs2804495, were nominally significant (p-value =0.047 and 0.027, respectively)237. Our SNP, 
rs10827234, is close to the rs2804495 in intron 2 (only one SNP between them) and it is in LD with 
it (R-sq = 0.312, D' = 1.000). Besides these association studies, neuropilin antagonist are claimed 
to be useful for the treatment of hypertensive nephrosclerosis 
(http://www.faqs.org/patents/app/20080213268). 
Other chromosome regions associated with UAE after excluding macroalbuminurics adjusted for 
age, sex, BMI, SBP, glucose, and eGFR (MDRD), were locus 15q26.2 close to the multiple C2 
domains, transmembrane 2 (MCTP2) gene and locus 4q28.3. As I said, these regions were far 
from significance. MCTP2 gene has not been reported to be associated with renal damage, 
although it is expressed in the kidney and it is involved in the calcium-mediated intracellular 
signalling. Within the FIND study233, there was a suggestive linkage for ACR in African-American 
families in 15q26.3 (flanking markers D15S657-D15S642). The physical distance between that 
linkage peak and our marker is about 1650 kb. In that region 15q26.3 is the Insulin Growth Factor 
1 receptor (IGF1R) gene which is a strong candidate gene for DN237. In the 4q28.3 region, there 
were no genes close to the associated markers. The closest genes belong to the protocadherin 
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family (PCDH10 and PCDH18) which seem to play a role in the cell-cell connections in the brain.  
This region has not been associated with renal damage, but one marker  (D4S2286) showed an 
association with hypertension in one linkage study performed  in Anglo-Celtic Australian sibpairs 
314
. This marker is around 4000 kb of our associated markers in that region. 
As I described extensively in the introduction, candidate gene, linkage and GWAS have identified 
different regions of the genome which may be influencing the appearance of albuminuria and 
microalbuminuria but only a few loci were replicated. These studies reinforce the hypothesis that 
the organ damage induced by hypertension is a complex process in which several loci plus the 
contribution of environmental factors are possibly involved. 
As far as I know this is one of the first studies of this kind made in hypertensive subjects with or 
without established renal damage based on UAE levels. Our analysis revealed several areas of the 
genome which could be related to the renal damage associated to this condition or which might be 
involved in the regulation of the UAE.  As we do not have the replication of these results we can 
not rule out if the genomic signals are true or in fact they are false positives. All the limitations 
described above must be considered when interpreting the results. 
The genome wide scans have successfully unravelled the genetic susceptibility of certain complex 
diseases but in others such as essential hypertension, they tend to fail due to several reasons: lack 
of power to detect variants with very low associated risk, difficulties regarding to the phenotype, 
lack of complete coverage of all the genome variants, etc. Probably we are faced with the same 
difficulties when studying the target organ damage associated with hypertension. 
The development of new genotyping chips covering more than one million of single nucleotide 
polymorphisms (SNPs) and copy number variation (CNV) altogether with a more accurate 
phenotyping in large scale studies, may be the way to discover the genetic bases of essential  
hypertension and related organ damage. 
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7.3. Conclusions 
1- Several chromosome regions were significantly associated with UAE expressed as a qualitative 
or quantitative trait. 
2- One polymorphism and one haplotype in locus 8p22 were significantly associated with 
microalbuminuria and albuminuria. The associated markers lie close to or inside to the 
macrophage acetylated LDL receptor I and II (MSR1) gene which is a potential candidate for 
microalbuminuria and albuminuria.  Polymorphisms and haplotypes were also significantly 
associated with UAE as a quantitative trait in the following loci: 8q12.1, 2p11.2, 9p22.2 and 18q23. 
The potential possible candidate genes for UAE within those chromosome regions are inositol 
monophosphatase domain containing 1 (IMPAD1), Receptor Expression-Enhancing Protein 1 
(REEP1), basonuclin 2 (BNC2), and Carnosine dipeptidase 1 (CNDP1). 
3- Lesser strength associated loci for microalbuminuria and albuminuria were found in: 10q11.21, 
12q24.23, 2q32.2, 11p12, 16q23.1, 8p21.2, 5q23.2, 7p14.1, 8p11.21, 2p16.1 and 7p14.2. Potential 
candidate genes in these regions for micro and albuminuria are: chemokine (C-X-C motif) ligand 
12 (CXCL12), disintegrin and metalloproteinase domain-containing protein 7 precursor (ADAM7), 
disintegrin and metalloproteinase domain-like protein decysin 1 (ADAMDC1) disintegrin and 
metalloproteinase domain-containing protein 28 precursor, phosphatidylethanolamine-binding 
protein 1 (PEBP1), engulfment and cell motility protein 1 (ELMO1) and engulfment and cell motility 
protein 3 (ELMO3).  For UAE these loci were: 3q27.1, 12p13.2, 4q13.1, 10p11.22, 15q26.2, 
4q28.3, 16q21, 4q32.1 and 16p13.2. Potential candidate genes within these regions for UAE were: 
MCF2-transforming sequence-like protein 2 (MCF2L2), oxidized low-density lipoprotein receptor 1 
(LOX1), ephrin type-A receptor 5 precursor (EPHA5), cadherin-11 precursor (CDH11), neuropilin-1 
precursor (NRP1), multiple C2 and transmembrane domain-containing protein 2 (MCTP2), 
protocadherin-10 precursor (PCDH10) and protocadherin-18 precursor (PCDH18). 
4- These genes are mainly involved in lipid metabolism, inflammation or intracellular signalling 
which are mechanisms than can lead to an increase in UAE in HTN. 
5- GWAS strategy has enabled the replication of some of the previously associated areas with 
renal damage using the same or different strategies such as linkage studies or candidate gene 
study and also to identify new potential susceptibility loci. 
6- A panel of SNPs potentially associated with microalbuminuria and UAE according to our data 
and those reported in the literature has been designed for the replication study.  
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7.4. Future prospects 
Those SNPs which have shown association in the genome wide scan, are now being 
genotyped with another high-throughput technology (SNPlex- Oligonucleotid ligation assay) in a 
larger sample of 800 young hypertensive patients and in a general population of 1500 subjects. We 
should be able to observe if the same loci which were associated, still remain associated and the 
magnitude of the association. 
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